{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 91,
   "id": "501d09d0-d08a-4137-a464-41ed339f41f4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Successfully connected to MongoDB.\n"
     ]
    }
   ],
   "source": [
    "%run ./utils.ipynb"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "id": "7ce7929b-e791-4a9f-91b6-10e9e948a7f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "client = get_mongo_client(uri)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "id": "1e5337b1-430d-4e13-a17e-e8c8cc12eb94",
   "metadata": {},
   "outputs": [],
   "source": [
    "collection = get_collection(client,\"pdf_rag_db\",\"chunks\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "id": "bf01e8d3-1077-4a64-ad93-7ed61a723bb7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "üìÑ PDF: metformin2.pdf, Page: 1, Chunk: 0\n",
      "üìù Text: PRODUCT  MONOGRAPH \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "PrTEVA-METFORMIN \n",
      "(metformin hydrochloride) \n",
      " \n",
      "500 mg and 850 mg Tablets \n",
      " \n",
      "Teva Standard \n",
      " \n",
      " \n",
      "Oral Antihyperglycemic Agent \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "Teva Canada Limited  \n",
      " \n",
      " \n",
      "             ...\n",
      "--------------------------------------------------------------------------------\n",
      "üìÑ PDF: metformin2.pdf, Page: 2, Chunk: 0\n",
      "üìù Text: 2\n",
      "PRODUCT  MONOGRAPH \n",
      " \n",
      " \n",
      " \n",
      "TEVA-METFORMIN \n",
      "(metformin hydrochloride) \n",
      " \n",
      " \n",
      "500 mg and 850 mg Tablets \n",
      " \n",
      " \n",
      " \n",
      "THERAPEUTIC  CLASSIFICATION \n",
      " \n",
      "Oral Antihyperglycemic Agent \n",
      " \n",
      " \n",
      "ACTIONS  AND  CLINICAL  PHA...\n",
      "--------------------------------------------------------------------------------\n",
      "üìÑ PDF: metformin2.pdf, Page: 2, Chunk: 1\n",
      "üìù Text: when there is insulin secretion. Metformin, at therapeutic doses, does not cause hypoglycemia \n",
      "when used alone in man or in the non-diabetic animal, except when using a near lethal dose.  \n",
      "Metformin h...\n",
      "--------------------------------------------------------------------------------\n",
      "üìÑ PDF: metformin2.pdf, Page: 2, Chunk: 2\n",
      "üìù Text: that it might enhance the effect of insulin on the peripheral receptor site. This increased \n",
      "sensitivity seems to follow an increase in the number of insulin receptors on cell surface \n",
      "membranes.\n",
      "Metf...\n",
      "--------------------------------------------------------------------------------\n",
      "üìÑ PDF: metformin2.pdf, Page: 3, Chunk: 0\n",
      "üìù Text: 3\n",
      "in urine at high renal clearance rate of about 450 mL/min. The initial elimination of metformin is \n",
      "rapid with a half-life varying between 1.7 and 3 hours. The terminal elimination phase \n",
      "accounting...\n",
      "--------------------------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "# Preview a few documents from the MongoDB collection\n",
    "for doc in collection.find().limit(5):\n",
    "    print(f\"üìÑ PDF: {doc.get('pdf_name')}, Page: {doc.get('page_number')}, Chunk: {doc.get('chunk_index')}\")\n",
    "    print(f\"üìù Text: {doc.get('chunk_text')[:200]}...\\n{'-'*80}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "82470117-e444-4785-a761-f2adb8b5829b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import chromadb\n",
    "from chromadb.utils import embedding_functions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "2df6fc6a-5e3e-4da0-955a-1f2aa4f7ceda",
   "metadata": {},
   "outputs": [],
   "source": [
    "import chromadb\n",
    "from chromadb.config import Settings\n",
    "\n",
    "def store_embedded_chunks_to_chroma(collection):\n",
    "    \"\"\"\n",
    "    Reads chunks from MongoDB collection, embeds them, and stores them in ChromaDB.\n",
    "    \"\"\"\n",
    "\n",
    "    # 1. Init Chroma client (serverless)\n",
    "    chroma_client = chromadb.Client()\n",
    "\n",
    "    # 2. Create or get Chroma collection\n",
    "    chroma_collection = chroma_client.get_or_create_collection(name=\"pdf_chunks\")\n",
    "\n",
    "    # 3. Prepare data for Chroma\n",
    "    ids = []\n",
    "    documents = []\n",
    "    metadatas = []\n",
    "\n",
    "    for doc in collection.find():\n",
    "        # Unique ID per chunk\n",
    "        chunk_id = f\"{doc['pdf_name']}_{doc['page_number']}_{doc['chunk_index']}\"\n",
    "\n",
    "        # Add data\n",
    "        ids.append(chunk_id)\n",
    "        documents.append(doc[\"chunk_text\"])\n",
    "        metadatas.append({\n",
    "            \"pdf_name\": doc[\"pdf_name\"],\n",
    "            \"page_number\": doc[\"page_number\"],\n",
    "            \"chunk_index\": doc[\"chunk_index\"]\n",
    "        })\n",
    "\n",
    "    # 4. Add to ChromaDB\n",
    "    chroma_collection.add(\n",
    "        ids=ids,\n",
    "        documents=documents,\n",
    "        metadatas=metadatas\n",
    "    )\n",
    "\n",
    "    print(f\"‚úÖ Stored {len(documents)} chunks in ChromaDB.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "913ab123-e376-436d-aba5-2c40f52bb3fc",
   "metadata": {},
   "outputs": [],
   "source": [
    "# store_embedded_chunks_to_chroma(collection)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "id": "4d515a27-693b-4d40-a161-42ac4c866e84",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üì¶ Found Aaron 344 documents in 'pdf_chunks' collection:\n",
      "\n",
      "üß© Chunk 1:\n",
      "PRODUCT  MONOGRAPH \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "PrTEVA-METFORMIN \n",
      "(metformin hydrochloride) \n",
      " \n",
      "500 mg and 850 mg Tablets \n",
      " \n",
      "Teva Standard \n",
      " \n",
      " \n",
      "Oral Antihyperglycemic Agent \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "Teva Canada Limited  \n",
      " \n",
      " \n",
      "                              Date of Preparation: July 25, 2013 \n",
      "30 Novopharm Court  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "Toronto, Ontario \n",
      " \n",
      "Canada M1B 2K9 \n",
      "www.tevacanada.com  \n",
      " \n",
      "Control Number: 165821\n",
      "üî¢ Embedding (first 5 values): [-0.07148081 -0.00065993 -0.11491415 -0.0215324  -0.08020177]\n",
      "----------------------------------------\n",
      "üß© Chunk 2:\n",
      "2\n",
      "PRODUCT  MONOGRAPH \n",
      " \n",
      " \n",
      " \n",
      "TEVA-METFORMIN \n",
      "(metformin hydrochloride) \n",
      " \n",
      " \n",
      "500 mg and 850 mg Tablets \n",
      " \n",
      " \n",
      " \n",
      "THERAPEUTIC  CLASSIFICATION \n",
      " \n",
      "Oral Antihyperglycemic Agent \n",
      " \n",
      " \n",
      "ACTIONS  AND  CLINICAL  PHARMACOLOGY \n",
      " \n",
      "TEVA-METFORMIN (metformin hydrochloride) is a biguanide derivative producing an \n",
      "antihyperglycemic effect which can only be observed in man or in the diabetic animal and only \n",
      "when there is insulin secretion. Metformin, at therapeutic doses, does not cause hypoglycemia\n",
      "üî¢ Embedding (first 5 values): [-0.05293062  0.00680785 -0.09988905 -0.01162534 -0.04215126]\n",
      "----------------------------------------\n",
      "üß© Chunk 3:\n",
      "when there is insulin secretion. Metformin, at therapeutic doses, does not cause hypoglycemia \n",
      "when used alone in man or in the non-diabetic animal, except when using a near lethal dose.  \n",
      "Metformin has no effect on the pancreatic beta cells. The mode of action of metformin is not \n",
      "fully understood. It has been postulated that metformin might potentiate the effect of insulin or \n",
      "that it might enhance the effect of insulin on the peripheral receptor site. This increased\n",
      "üî¢ Embedding (first 5 values): [-0.01336172 -0.00068474 -0.03670098  0.07357362 -0.03063279]\n",
      "----------------------------------------\n",
      "üß© Chunk 4:\n",
      "that it might enhance the effect of insulin on the peripheral receptor site. This increased \n",
      "sensitivity seems to follow an increase in the number of insulin receptors on cell surface \n",
      "membranes.\n",
      "Metformin absorption is relatively slow and may extend over about 6 hours. The drug is excreted\n",
      "üî¢ Embedding (first 5 values): [-0.03788226 -0.05681241 -0.07447562  0.04672715  0.01031269]\n",
      "----------------------------------------\n",
      "üß© Chunk 5:\n",
      "3\n",
      "in urine at high renal clearance rate of about 450 mL/min. The initial elimination of metformin is \n",
      "rapid with a half-life varying between 1.7 and 3 hours. The terminal elimination phase \n",
      "accounting for about 4 to 5 % of the absorbed dose is slow with a half-life between 9 and 17 \n",
      "hours. Metformin is not metabolized. Its main sites of concentration are the intestinal mucosa \n",
      "and the salivary glands. The plasma concentration at steady-state ranges about 1 to 2 mcg/mL.\n",
      "üî¢ Embedding (first 5 values): [ 0.02647839 -0.04214178  0.00774278 -0.02527674 -0.06361166]\n",
      "----------------------------------------\n",
      "üß© Chunk 6:\n",
      "and the salivary glands. The plasma concentration at steady-state ranges about 1 to 2 mcg/mL. \n",
      "Certain drugs may potentiate the effects of metformin (see PRECAUTIONS). \n",
      " \n",
      "A comparative, two-way, single-dose bioavailability study was conducted on two 500 mg \n",
      "metformin hydrochloride tablet products, TEVA-METFORMIN 500 mg and GLUCOPHAGE¬Æ \n",
      "500 mg tablets. The pharmacokinetic data calculated for metformin hydrochloride in the \n",
      "TEVA-METFORMIN and GLUCOPHAGE¬Æ tablet formulations is tabulated below.\n",
      "üî¢ Embedding (first 5 values): [ 0.01473181 -0.0753824  -0.03901548 -0.06917575 -0.08590186]\n",
      "----------------------------------------\n",
      "üß© Chunk 7:\n",
      "TEVA-METFORMIN and GLUCOPHAGE¬Æ tablet formulations is tabulated below. \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "Geometric Mean \n",
      "Arithmetic Mean  (C.V.) \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "Teva-Metformin \n",
      "(1 X 500 mg) \n",
      "Glucophage¬Æ** \n",
      "(1 X 500 mg) \n",
      "Percentage of \n",
      "Glucophage¬Æ \n",
      "AUCT \n",
      "(ngÔÅ¨hr/mL) \n",
      " \n",
      " 3578 \n",
      "3717 \n",
      " \n",
      "(31) \n",
      "3773 \n",
      "3917 \n",
      " \n",
      "(29) \n",
      " \n",
      "95.8 \n",
      "AUCI \n",
      "(ngÔÅ¨hr/mL) \n",
      " \n",
      "4010 \n",
      "4157 \n",
      " \n",
      "(30) \n",
      " 4139 \n",
      "4285 \n",
      " \n",
      "(28) \n",
      " \n",
      "97.9 \n",
      "Cmax \n",
      "(ng/mL) \n",
      "458.6 \n",
      "473.3 \n",
      "(26) \n",
      "493.4 \n",
      "510.7 \n",
      "(28) \n",
      " \n",
      "93.6 \n",
      "Tmax* (hr) \n",
      "4.00 \n",
      " \n",
      "(0.89) \n",
      "4.38 \n",
      " \n",
      "(1.02) \n",
      "--- \n",
      "T¬Ω* (hr) \n",
      "3.60 \n",
      " \n",
      "(0.82) \n",
      " 3.41\n",
      "üî¢ Embedding (first 5 values): [ 0.02078975 -0.0568166  -0.10352941 -0.06004596 -0.09865931]\n",
      "----------------------------------------\n",
      "üß© Chunk 8:\n",
      "(28) \n",
      " \n",
      "93.6 \n",
      "Tmax* (hr) \n",
      "4.00 \n",
      " \n",
      "(0.89) \n",
      "4.38 \n",
      " \n",
      "(1.02) \n",
      "--- \n",
      "T¬Ω* (hr) \n",
      "3.60 \n",
      " \n",
      "(0.82) \n",
      " 3.41 \n",
      " \n",
      "(0.67) \n",
      "--- \n",
      "* For the Tmax and T¬Ω parameters these are the arithmetic means (standard deviation). \n",
      "** Glucophage¬Æ manufactured by Nordic Laboratories., Laval, Quebec, Canada. \n",
      " \n",
      "INDICATIONS\n",
      "üî¢ Embedding (first 5 values): [ 0.0258969  -0.01696305 -0.01247704 -0.03654389 -0.11870481]\n",
      "----------------------------------------\n",
      "üß© Chunk 9:\n",
      "4\n",
      "To control hyperglycemia in TEVA-METFORMIN (metformin HCl) responsive, stable, mild, \n",
      "non-ketosis prone, maturity onset type of diabetes (Type II) which cannot be controlled by \n",
      "proper dietary management, exercise and weight reduction or when insulin therapy is not \n",
      "appropriate. \n",
      " \n",
      "TEVA-METFORMIN (metformin HCl) can be of value for the treatment of obese diabetic \n",
      "patients. \n",
      " \n",
      "CONTRAINDICATIONS \n",
      " \n",
      "‚Ä¢ Unstable and/or insulin-dependent (Type I) diabetes mellitus.\n",
      "üî¢ Embedding (first 5 values): [-0.0388829   0.02910339 -0.06193873  0.04727266 -0.09160373]\n",
      "----------------------------------------\n",
      "üß© Chunk 10:\n",
      "patients. \n",
      " \n",
      "CONTRAINDICATIONS \n",
      " \n",
      "‚Ä¢ Unstable and/or insulin-dependent (Type I) diabetes mellitus. \n",
      "‚Ä¢ Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, \n",
      "history of ketoacidosis with or without coma. Diabetic ketoacidosis should be treated with \n",
      "insulin. \n",
      "‚Ä¢ In patients with a history of lactic acidosis, irrespective of precipitating factors. \n",
      "‚Ä¢ In the presence of renal impairment or when renal function is not known, and also in patients\n",
      "üî¢ Embedding (first 5 values): [ 0.04974268 -0.00181507 -0.01700201  0.02819818 -0.07079072]\n",
      "----------------------------------------\n",
      "üß© Chunk 11:\n",
      "‚Ä¢ In the presence of renal impairment or when renal function is not known, and also in patients \n",
      "with serum creatinine levels above the upper limit of normal range. Renal disease or renal \n",
      "dysfunction (e.g., as suggested by serum creatinine levels ‚â• 136 ¬µmol/L (males), ‚â• 124 \n",
      "¬µmol/L (females) or abnormal creatinine clearance) which may result from conditions such \n",
      "as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see also \n",
      "WARNINGS and PRECAUTIONS).\n",
      "üî¢ Embedding (first 5 values): [ 0.00042693 -0.05484162  0.05251736  0.02143891 -0.00917691]\n",
      "----------------------------------------\n",
      "üß© Chunk 12:\n",
      "WARNINGS and PRECAUTIONS). \n",
      "‚Ä¢ Congestive heart failure requiring pharmacologic treatment. \n",
      "‚Ä¢ In excessive alcohol intake, acute or chronic. \n",
      "‚Ä¢ In patients suffering from severe hepatic dysfunction, since severe hepatic dysfunction has \n",
      "been associated with some cases of lactic acidosis, TEVA-METFORMIN should generally \n",
      "be avoided in patients with clinical or laboratory evidence of hepatic disease. \n",
      "‚Ä¢ TEVA-METFORMIN should be temporarily discontinued in patients undergoing radiologic\n",
      "üî¢ Embedding (first 5 values): [ 0.06318343 -0.05118262 -0.04437222  0.00578955 -0.03655019]\n",
      "----------------------------------------\n",
      "üß© Chunk 13:\n",
      "‚Ä¢ TEVA-METFORMIN should be temporarily discontinued in patients undergoing radiologic \n",
      "studies involving intravascular administration of iodinated contrast materials, because use of\n",
      "üî¢ Embedding (first 5 values): [ 0.04088312 -0.01514064 -0.03816637 -0.02712679 -0.02486245]\n",
      "----------------------------------------\n",
      "üß© Chunk 14:\n",
      "5\n",
      "such products may result in acute alteration of renal function (see WARNINGS and \n",
      "PRECAUTIONS). \n",
      "‚Ä¢ In cases of cardiovascular collapse and in disease states associate with hypoxemia such as \n",
      "cardiorespiratory insufficiency, which are often associated with hyperlactacidemia. \n",
      "‚Ä¢ During stress conditions, such as severe infections, trauma or surgery and the recovery phase \n",
      "thereafter. \n",
      "‚Ä¢ In patients suffering from severe dehydration.\n",
      "üî¢ Embedding (first 5 values): [ 0.01947734  0.01144789  0.05947737  0.04952598 -0.03194745]\n",
      "----------------------------------------\n",
      "üß© Chunk 15:\n",
      "thereafter. \n",
      "‚Ä¢ In patients suffering from severe dehydration. \n",
      "‚Ä¢ Known hypersensitivity or allergy to metformin HCl or any of the excipients. \n",
      "‚Ä¢ During pregnancy. \n",
      " \n",
      "WARNINGS \n",
      " \n",
      "Lactic acidosis: \n",
      "Lactic acidosis is a rare, but serious, metabolic complication that occurs due to metformin \n",
      "accumulation during treatment with TEVA-METFORMIN; when it occurs, it is fatal in \n",
      "approximately 50 % of cases. Lactic acidosis may also occur in association with a number of\n",
      "üî¢ Embedding (first 5 values): [ 0.02699974 -0.09457123 -0.01893068  0.05587403  0.04100899]\n",
      "----------------------------------------\n",
      "üß© Chunk 16:\n",
      "approximately 50 % of cases. Lactic acidosis may also occur in association with a number of \n",
      "pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue \n",
      "hypoperfusion and hypoxemia.  Lactic acidosis is characterized by elevated blood lactate levels \n",
      "(> 5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and an \n",
      "increased lactate/pyruvate ratio. When metformin is implicated as the cause of lactic acidosis,\n",
      "üî¢ Embedding (first 5 values): [ 0.06195631 -0.08120807 -0.00238244  0.05379761 -0.01642806]\n",
      "----------------------------------------\n",
      "üß© Chunk 17:\n",
      "increased lactate/pyruvate ratio. When metformin is implicated as the cause of lactic acidosis, \n",
      "metformin plasma levels > 5 ¬µg/mL are generally found. \n",
      " \n",
      "The reported incidence of lactic acidosis in patients receiving metformin HCl is very low \n",
      "(approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 \n",
      "patient-years). Reported cases have occurred primarily in diabetic patients with significant renal\n",
      "üî¢ Embedding (first 5 values): [ 0.02242049 -0.05021577 -0.01190829  0.03587057 -0.04573692]\n",
      "----------------------------------------\n",
      "üß© Chunk 18:\n",
      "patient-years). Reported cases have occurred primarily in diabetic patients with significant renal \n",
      "insufficiency, including both intrinsic renal disease and renal hypoperfusion, often in the setting \n",
      "of multiple concomitant medical/surgical problems and multiple concomitant medications. \n",
      "Patients with congestive heart failure requiring pharmacologic management, in particular those \n",
      "with unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia,\n",
      "üî¢ Embedding (first 5 values): [ 0.02801556  0.0228048   0.01227926 -0.02156008 -0.08510822]\n",
      "----------------------------------------\n",
      "üß© Chunk 19:\n",
      "6\n",
      "are at increased risk of lactic acidosis. In particular, treatment of the elderly should be \n",
      "accompanied by careful monitoring of renal function. TEVA-METFORMIN treatment should \n",
      "not be initiated in patients ‚â• 80 years of age, unless measurement of creatinine clearance \n",
      "demonstrates that renal function is not reduced, as the patients are more susceptible to \n",
      "developing lactic acidosis. The risk of lactic acidosis increases with the degree of renal\n",
      "üî¢ Embedding (first 5 values): [ 0.03298123 -0.05426721 -0.01832055  0.00041123 -0.05799938]\n",
      "----------------------------------------\n",
      "üß© Chunk 20:\n",
      "developing lactic acidosis. The risk of lactic acidosis increases with the degree of renal \n",
      "dysfunction and the patient's age. The risk of lactic acidosis may, therefore, be significantly \n",
      "decreased by regular monitoring of renal function in patients taking TEVA-METFORMIN and \n",
      "by use of the minimum effective dose of TEVA-METFORMIN. In addition, TEVA-\n",
      "METFORMIN should be promptly withheld in the presence of any condition associated with\n",
      "üî¢ Embedding (first 5 values): [ 0.06207324 -0.05258639 -0.02701888  0.01572692 -0.06693434]\n",
      "----------------------------------------\n",
      "üß© Chunk 21:\n",
      "METFORMIN should be promptly withheld in the presence of any condition associated with \n",
      "hypoxemia, dehydration or sepsis. Because impaired hepatic function may significantly limit the \n",
      "ability to clear lactate, TEVA-METFORMIN should generally be avoided in patients with \n",
      "clinical or laboratory evidence of hepatic disease. Patients should be cautioned against excessive \n",
      "alcohol intake, either acute or chronic, when taking TEVA-METFORMIN (metformin HCl),\n",
      "üî¢ Embedding (first 5 values): [ 0.01572631 -0.03372868 -0.02992261  0.04184739 -0.02213292]\n",
      "----------------------------------------\n",
      "üß© Chunk 22:\n",
      "alcohol intake, either acute or chronic, when taking TEVA-METFORMIN (metformin HCl), \n",
      "since alcohol intake potentiates the effect of metformin HCl on lactate metabolism. In addition, \n",
      "TEVA-METFORMIN should be temporarily discontinued prior to any intravascular \n",
      "radiocontrast study and for any surgical procedure (see PRECAUTIONS). The onset of lactic \n",
      "acidosis often is subtle, and accompanied only by nonspecific symptoms such as malaise,\n",
      "üî¢ Embedding (first 5 values): [ 0.06572758 -0.07498197 -0.03180781  0.05098409 -0.02317609]\n",
      "----------------------------------------\n",
      "üß© Chunk 23:\n",
      "acidosis often is subtle, and accompanied only by nonspecific symptoms such as malaise, \n",
      "myalgias, respiratory distress, increasing somnolence and non-specific abdominal distress. There \n",
      "may be associated hypothermia, hypotension and resistance bradyarrhyhmas with more marked \n",
      "acidosis.  The patient and the patient's physician must be aware of the possible importance of \n",
      "such symptoms and the patient should be instructed to notify the physician immediately if they\n",
      "üî¢ Embedding (first 5 values): [ 0.04008991 -0.00385633 -0.01168941  0.04796936 -0.01166969]\n",
      "----------------------------------------\n",
      "üß© Chunk 24:\n",
      "such symptoms and the patient should be instructed to notify the physician immediately if they \n",
      "occur (see PRECAUTIONS). TEVA-METFORMIN should be withdrawn until the situation is \n",
      "clarified.  Serum electrolytes, ketones, blood glucose and, if indicated, blood pH, lactate levels \n",
      "and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of \n",
      "TEVA-METFORMIN, gastrointestinal symptoms, which are common during initiation of\n",
      "üî¢ Embedding (first 5 values): [ 0.02500399 -0.00447753 -0.02904023  0.0276103  -0.04673325]\n",
      "----------------------------------------\n",
      "üß© Chunk 25:\n",
      "TEVA-METFORMIN, gastrointestinal symptoms, which are common during initiation of \n",
      "therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be \n",
      "due to lactic acidosis or other serious disease. Levels of fasting venous plasma lactate above the \n",
      "upper limit of normal but less than 5 mmol/L in patients taking TEVA-METFORMIN do not \n",
      "necessarily indicate impending lactic acidosis and may be explainable by other mechanisms,\n",
      "üî¢ Embedding (first 5 values): [ 0.05270695 -0.11740914 -0.02472412  0.022543   -0.03130285]\n",
      "----------------------------------------\n",
      "üß© Chunk 26:\n",
      "7\n",
      "such as poorly controlled diabetes or obesity, vigorous physical activity or technical problems in \n",
      "sample handling. Lactic acidosis should be suspected in any diabetic patient with metabolic \n",
      "acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia). \n",
      " \n",
      "Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with \n",
      "lactic acidosis who is taking TEVA-METFORMIN, the drug should be discontinued\n",
      "üî¢ Embedding (first 5 values): [ 0.07391395 -0.0235914  -0.03013532  0.00646725 -0.01615704]\n",
      "----------------------------------------\n",
      "üß© Chunk 27:\n",
      "lactic acidosis who is taking TEVA-METFORMIN, the drug should be discontinued \n",
      "immediately and general supportive measures promptly instituted. Because metformin HCl is \n",
      "dialysable (with clearance of up to 170 mL/min under good hemodynamic conditions), prompt \n",
      "hemodialysis is recommended to correct the acidosis and remove the accumulated metformin. \n",
      "Such management often results in prompt reversal of symptoms and recovery (see \n",
      "CONTRAINDICATIONS and PRECAUTIONS).\n",
      "üî¢ Embedding (first 5 values): [-0.00749533 -0.03897433 -0.03054218 -0.00785188 -0.08169534]\n",
      "----------------------------------------\n",
      "üß© Chunk 28:\n",
      "CONTRAINDICATIONS and PRECAUTIONS). \n",
      " \n",
      "If acidosis of any kind develops, TEVA-METFORMIN should be discontinued immediately. \n",
      " \n",
      "Increased risk of cardiovascular mortality: \n",
      "The administration of oral antidiabetic drugs has been reported to be associated with increased \n",
      "cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This \n",
      "warning is based on the study conducted by the University Group Diabetes Program (UGDP), a\n",
      "üî¢ Embedding (first 5 values): [ 0.0043385   0.01231591 -0.08254055  0.01620849 -0.04643181]\n",
      "----------------------------------------\n",
      "üß© Chunk 29:\n",
      "warning is based on the study conducted by the University Group Diabetes Program (UGDP), a \n",
      "long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering \n",
      "drugs in preventing or delaying vascular complications in patients with non-insulin-dependent \n",
      "diabetes. The study involved 1027 patients who were randomly assigned to one of the five \n",
      "treatment groups. \n",
      " \n",
      "The UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of\n",
      "üî¢ Embedding (first 5 values): [ 0.02693319  0.10088197  0.01258581  0.07927081 -0.02134928]\n",
      "----------------------------------------\n",
      "üß© Chunk 30:\n",
      "The UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of \n",
      "tolbutamide (1.5 g per day) or diet plus a fixed dose of phenformin (100 mg per day), had a rate \n",
      "of cardiovascular mortality approximately 2.5 times that of patients treated with diet alone, \n",
      "resulting in discontinuation of both these treatments in the UGDP study.  Total mortality was \n",
      "increased in both the tolbutamide- and phenformin-treated groups and this increase was\n",
      "üî¢ Embedding (first 5 values): [ 0.02283601  0.01241561  0.0245836  -0.0170177  -0.05456805]\n",
      "----------------------------------------\n",
      "üß© Chunk 31:\n",
      "increased in both the tolbutamide- and phenformin-treated groups and this increase was \n",
      "statistically significant in the phenformin-treated group. Despite controversy regarding the\n",
      "üî¢ Embedding (first 5 values): [ 0.033948   -0.06086996 -0.02899714 -0.00639155 -0.00401304]\n",
      "----------------------------------------\n",
      "üß© Chunk 32:\n",
      "8\n",
      "interpretation of these results, the findings of the UGDP study provide and adequate basis for \n",
      "this warning. The patient should be informed of the potential risks and benefits of TEVA-\n",
      "METFORMIN and alternative modes of therapy. \n",
      " \n",
      "Although only one drug in the sulfonylurea category (tolbutamide) and one in the biguanide \n",
      "category (phenformin) were included in this study, it is prudent from a safety standpoint to\n",
      "üî¢ Embedding (first 5 values): [ 0.0300371  -0.0032753  -0.04699578 -0.00374324 -0.07809898]\n",
      "----------------------------------------\n",
      "üß© Chunk 33:\n",
      "category (phenformin) were included in this study, it is prudent from a safety standpoint to \n",
      "consider that this warning may also apply to other related antidiabetic drugs, in view of the \n",
      "similarities in mode of action and chemical structure among the drugs in each category. \n",
      " \n",
      "The use of TEVA-METFORMIN (metfomin HCl) will not prevent the development of \n",
      "complications peculiar to diabetes mellitus. \n",
      " \n",
      "Use of TEVA-METFORMIN must be considered as treatment in addition to proper dietary\n",
      "üî¢ Embedding (first 5 values): [-0.01458771 -0.03686343 -0.10513712  0.02508101 -0.0363747 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 34:\n",
      "Use of TEVA-METFORMIN must be considered as treatment in addition to proper dietary \n",
      "regimen and not as a substitute for diet. \n",
      " \n",
      "Care should be taken to ensure that TEVA-METFORMIN is not given when a contraindication \n",
      "exists. \n",
      " \n",
      "If during TEVA-METFORMIN therapy the patient develops acute intercurrent disease such as: \n",
      "clinically significant hepatic dysfunction, cardiovascular collapse, congestive heart failure, acute\n",
      "üî¢ Embedding (first 5 values): [-0.03834078 -0.02496734  0.01835976  0.01416827 -0.09198373]\n",
      "----------------------------------------\n",
      "üß© Chunk 35:\n",
      "myocardial infarction, or other conditions complicated by hypoxemia, the drug should be \n",
      "discontinued. \n",
      " \n",
      "Radiologic studies involving the use of iodinated contrast materials (for example, intravenous \n",
      "urogram, intravenous cholangiography, angiography and scans with contrast materials): \n",
      " \n",
      "Intravascular contrast studies with iodinated materials can lead to acute renal failure and have \n",
      "been associated with lactic acidosis in patients receiving TEVA-METFORMIN (see\n",
      "üî¢ Embedding (first 5 values): [ 0.07893921 -0.04063756  0.00887408 -0.01532502  0.01309003]\n",
      "----------------------------------------\n",
      "üß© Chunk 36:\n",
      "been associated with lactic acidosis in patients receiving TEVA-METFORMIN (see \n",
      "CONTRAINDICATIONS). Therefore, in patients in whom any such study is planned, TEVA-\n",
      "üî¢ Embedding (first 5 values): [ 0.04949167 -0.06747205 -0.02592244  0.04742273 -0.06220789]\n",
      "----------------------------------------\n",
      "üß© Chunk 37:\n",
      "9\n",
      "METFORMIN should be discontinued at the time of or prior to the procedure, and withheld for \n",
      "48 hours subsequent to the procedure and reinstituted only after renal function has been \n",
      "re-evaluated and found to be normal. \n",
      " \n",
      "PRECAUTIONS \n",
      " \n",
      "Patient Selection and Follow-up: \n",
      "Careful selection of patients is important. It is imperative that there be rigid attention to diet and \n",
      "careful adjustment of dosage. When TEVA-METFORMIN (metformin HCl) is combined with a\n",
      "üî¢ Embedding (first 5 values): [-0.03065752 -0.01912147 -0.00206644 -0.02713844 -0.09258606]\n",
      "----------------------------------------\n",
      "üß© Chunk 38:\n",
      "careful adjustment of dosage. When TEVA-METFORMIN (metformin HCl) is combined with a \n",
      "sulfonylurea, instruct the patient on hypoglycemic reactions and their control. Regular through \n",
      "follow-up examinations are necessary (see WARNINGS). \n",
      " \n",
      "If vomiting occurs, withdraw drug temporarily, exclude lactic acidosis, then resume dosage \n",
      "cautiously (see ADVERSE REACTIONS). \n",
      " \n",
      "Particular attention should be paid to short range and long range complications which are\n",
      "üî¢ Embedding (first 5 values): [ 0.03619863 -0.03295031 -0.05136681  0.00996588 -0.07729379]\n",
      "----------------------------------------\n",
      "üß© Chunk 39:\n",
      "Particular attention should be paid to short range and long range complications which are \n",
      "peculiar to diabetes. Periodic cardiovascular, ophthalmic, hematological, hepatic and renal \n",
      "assessments are advisable (see WARNINGS). \n",
      " \n",
      "Monitoring of renal function: \n",
      "TEVA-METFORMIN is known to be substantially excreted by the kidney, and the risk of \n",
      "metformin accumulation and lactic acidosis increases with the degree of impairment of renal\n",
      "üî¢ Embedding (first 5 values): [-0.01932415 -0.01754434 -0.04504771  0.01718027 -0.06654477]\n",
      "----------------------------------------\n",
      "üß© Chunk 40:\n",
      "metformin accumulation and lactic acidosis increases with the degree of impairment of renal \n",
      "function. Thus, patients with serum creatinine levels above the upper limit of normal for their \n",
      "age should not receive TEVA-METFORMIN. In patients with advanced age, TEVA-\n",
      "METFORMIN should be carefully titrated to establish the minimum dose for adequate glycemic \n",
      "effect, because aging is associated with reduced renal function. In elderly patients, renal function\n",
      "üî¢ Embedding (first 5 values): [ 0.03640823 -0.03831733 -0.01215763  0.00881764 -0.0887814 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 41:\n",
      "should be monitored regularly and generally, TEVA-METFORMIN should not be titrated to the \n",
      "maximum dose (see DOSAGE AND ADMINISTRATION). \n",
      "Before initiation of TEVA-METFORMIN therapy and every 6 months while on TEVA-\n",
      "üî¢ Embedding (first 5 values): [ 0.03259469 -0.01859774 -0.08836598 -0.02116189 -0.07256091]\n",
      "----------------------------------------\n",
      "üß© Chunk 42:\n",
      "10\n",
      "METFORMIN therapy, renal function should be assessed and verified as being within normal \n",
      "range. \n",
      "In patients in whom development of renal dysfunction is anticipated, renal function should be \n",
      "assessed more frequently and TEVA-METFORMIN discontinued if evidence of renal \n",
      "impairment is present. \n",
      " \n",
      "Use of concomitant medications that may affect renal function or metformin disposition: \n",
      "Concomitant medication(s) that may affect renal function or result in significant hemodynamic\n",
      "üî¢ Embedding (first 5 values): [-0.0419229  -0.03858201  0.0196642  -0.02088063 -0.06920578]\n",
      "----------------------------------------\n",
      "üß© Chunk 43:\n",
      "Concomitant medication(s) that may affect renal function or result in significant hemodynamic \n",
      "change or may interfere with disposition of TEVA-METFORMIN, such as cationic drugs that \n",
      "are eliminated by renal tubular secretion (see DRUG INTERACTIONS), should be used with \n",
      "caution. \n",
      " \n",
      "Hypoxic states: \n",
      "Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute \n",
      "myocardial infarction and other conditions characterized by hypoxemia have been associated\n",
      "üî¢ Embedding (first 5 values): [-0.03049744  0.00215217  0.02309361  0.00129399 -0.00943749]\n",
      "----------------------------------------\n",
      "üß© Chunk 44:\n",
      "myocardial infarction and other conditions characterized by hypoxemia have been associated \n",
      "with lactic acidosis and may also cause prerenal azotemia. When such event occur in patients on \n",
      "TEVA-METFORMIN therapy, the drug should be promptly discontinued. \n",
      " \n",
      "Surgical Procedures: \n",
      "TEVA-METFORMIN therapy should be temporarily suspended for any surgical procedure \n",
      "(except minor procedures not associated with restricted intake of food and fluids). TEVA-\n",
      "üî¢ Embedding (first 5 values): [ 0.01304339  0.0082042  -0.02219206  0.03821504 -0.00308535]\n",
      "----------------------------------------\n",
      "üß© Chunk 45:\n",
      "(except minor procedures not associated with restricted intake of food and fluids). TEVA-\n",
      "METFORMIN should be discontinued 2 days before surgical intervention and should not be \n",
      "restarted until the patient's oral intake has resumed and renal function has been evaluated as \n",
      "normal. \n",
      " \n",
      "Alcohol intake: \n",
      "Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, \n",
      "should be warned against excessive alcohol intake, acute or chronic, while receiving TEVA-\n",
      "üî¢ Embedding (first 5 values): [ 0.02999797 -0.03453256 -0.02332957  0.01177031 -0.06202983]\n",
      "----------------------------------------\n",
      "üß© Chunk 46:\n",
      "should be warned against excessive alcohol intake, acute or chronic, while receiving TEVA-\n",
      "METFORMIN.\n",
      "üî¢ Embedding (first 5 values): [ 0.02215137 -0.01426812 -0.06223406  0.03184272 -0.02865153]\n",
      "----------------------------------------\n",
      "üß© Chunk 47:\n",
      "11\n",
      " \n",
      " \n",
      "Impaired hepatic function: \n",
      "Since impaired hepatic function has been associated with some cases of lactic acidosis, TEVA-\n",
      "METFORMIN should generally be avoided in patients with clinical or laboratory evidence of \n",
      "hepatic disease. \n",
      " \n",
      "Vitamin B12 levels: \n",
      "Impairment of vitamin B12 and folic acid absorption has been reported in some patients.  \n",
      "Therefore, measurements of serum vitamin B12 and folic acid are advisable at least every one to\n",
      "üî¢ Embedding (first 5 values): [ 0.04376631 -0.05806374 -0.0815294   0.00812508 -0.02788653]\n",
      "----------------------------------------\n",
      "üß© Chunk 48:\n",
      "Therefore, measurements of serum vitamin B12 and folic acid are advisable at least every one to \n",
      "two years in patients on long-term treatment with TEVA-METFORMIN. \n",
      " \n",
      "A decrease to subnormal levels of previously normal serum Vitamin B12 levels, without clinical \n",
      "manifestations, is observed in approximately 7 % of patients receiving metformin HCl in \n",
      "controlled clinical trials of 28 weeks duration. Such decrease, possibly due to interference with\n",
      "üî¢ Embedding (first 5 values): [-0.00058774 -0.02223106 -0.07251081  0.01537044 -0.04127695]\n",
      "----------------------------------------\n",
      "üß© Chunk 49:\n",
      "controlled clinical trials of 28 weeks duration. Such decrease, possibly due to interference with \n",
      "B12 absorption from B12-intrinsic factor complex is, however, very rarely associated with anemia \n",
      "and appears to be rapidly reversible with discontinuation of metformin HCl or vitamin B12 \n",
      "supplementation. Measurement of hematologic parameters on an annual basis is advised in \n",
      "patients on TEVA-METFORMIN and any apparent abnormalities should be appropriately\n",
      "üî¢ Embedding (first 5 values): [-0.01693108 -0.02064198 -0.07201951  0.05218393 -0.05104614]\n",
      "----------------------------------------\n",
      "üß© Chunk 50:\n",
      "patients on TEVA-METFORMIN and any apparent abnormalities should be appropriately \n",
      "investigated and managed (see LABORATORY TESTS). Certain individuals (those with \n",
      "inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing \n",
      "subnormal vitamin B12 levels. \n",
      " \n",
      "Change in clinical status of previously controlled diabetic: \n",
      "A diabetic patient previously well controlled on TEVA-METFORMIN who develops laboratory\n",
      "üî¢ Embedding (first 5 values): [ 0.00054285 -0.01427441 -0.08770274  0.02478685 -0.08285542]\n",
      "----------------------------------------\n",
      "üß© Chunk 51:\n",
      "A diabetic patient previously well controlled on TEVA-METFORMIN who develops laboratory \n",
      "abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated \n",
      "promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum \n",
      "electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate and \n",
      "metformin levels. If acidosis of either form occurs, TEVA-METFORMIN must be stopped\n",
      "üî¢ Embedding (first 5 values): [ 0.03325083  0.01100758 -0.05969092  0.0155792  -0.07867556]\n",
      "----------------------------------------\n",
      "üß© Chunk 52:\n",
      "12\n",
      "immediately and appropriate corrective measures initiated (see WARNINGS). \n",
      " \n",
      "Hypoglycemia: \n",
      "Hypoglycemia does not occur in patients receiving TEVA-METFORMIN alone under usual \n",
      "circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise \n",
      "is not compensated by caloric supplementation, or during concomitant use with other glucose \n",
      "lowering agents (such as sulfonylureas) or ethanol.\n",
      "üî¢ Embedding (first 5 values): [ 0.05056122  0.01443628 -0.07091004  0.05284917 -0.03958897]\n",
      "----------------------------------------\n",
      "üß© Chunk 53:\n",
      "lowering agents (such as sulfonylureas) or ethanol. \n",
      " \n",
      "Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency or \n",
      "alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be \n",
      "difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. \n",
      " \n",
      "Loss of control of blood glucose: \n",
      "When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma,\n",
      "üî¢ Embedding (first 5 values): [ 0.0757024   0.02016057 -0.04114473  0.11166775 -0.00316444]\n",
      "----------------------------------------\n",
      "üß© Chunk 54:\n",
      "When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, \n",
      "infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be \n",
      "necessary to withhold TEVA-METFORMIN and temporarily administer insulin. TEVA-\n",
      "METFORMIN may be reinstituted after the acute episode is resolved. \n",
      " \n",
      "The effectiveness of oral antidiabetic drugs in lowering blood glucose to a targeted level\n",
      "üî¢ Embedding (first 5 values): [-0.03457985  0.0408649  -0.06872043  0.03033445 -0.07543606]\n",
      "----------------------------------------\n",
      "üß© Chunk 55:\n",
      "The effectiveness of oral antidiabetic drugs in lowering blood glucose to a targeted level \n",
      "decreases in many patients over a period of time. This phenomenon, which may be due to \n",
      "progression of the underlying disease or to diminished responsiveness to the drug, is known as \n",
      "secondary failure, to distinguish it from primary failure in which the drug is ineffective during \n",
      "initial therapy. Should secondary failure occur with TEVA-METFORMIN or sulfonylurea\n",
      "üî¢ Embedding (first 5 values): [-0.01534323 -0.02365833 -0.06892082 -0.01445346 -0.07023577]\n",
      "----------------------------------------\n",
      "üß© Chunk 56:\n",
      "initial therapy. Should secondary failure occur with TEVA-METFORMIN or sulfonylurea \n",
      "monotherapy, combined therapy with TEVA-METFORMIN (metformin HCl) and sulfonylurea \n",
      "may result in a response. Should secondary failure occur with combined TEVA-\n",
      "METFORMIN/sulfonylurea therapy, it may be necessary to initiate insulin therapy. \n",
      " \n",
      "Laboratory tests: \n",
      "Response to all diabetic therapies should be monitored by periodic measurements of fasting\n",
      "üî¢ Embedding (first 5 values): [-0.04742243 -0.05751257 -0.08229252  0.02191915 -0.08985949]\n",
      "----------------------------------------\n",
      "üß© Chunk 57:\n",
      "13\n",
      "blood glucose and glycosylated hemoglobin levels, with a goal of decreasing these levels toward \n",
      "the normal range. During initial dose titration, fasting glucose can be used to determine the \n",
      "therapeutic response. Thereafter, both glucose and glycosylated hemoglobin should be \n",
      "monitored. Measurements of glycosylated hemoglobin may be especially useful for evaluating \n",
      "long-term control (see DOSAGE AND ADMINISTRATION).\n",
      "üî¢ Embedding (first 5 values): [ 0.01123766  0.01709578 -0.09498217  0.00683736 -0.07963117]\n",
      "----------------------------------------\n",
      "üß© Chunk 58:\n",
      "long-term control (see DOSAGE AND ADMINISTRATION). \n",
      " \n",
      "Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red \n",
      "blood cell indices) and renal function (serum creatinine) should be performed, at least on an \n",
      "annual basis. While megaloblastic anemia has rarely been seen with TEVA-METFORMIN \n",
      "(metformin HCl) therapy, if this is suspected, vitamin B12 deficiency should be excluded. \n",
      " \n",
      "Pregnancy and lactation:\n",
      "üî¢ Embedding (first 5 values): [-0.02883999 -0.02383939 -0.05859409  0.04405217 -0.04991513]\n",
      "----------------------------------------\n",
      "üß© Chunk 59:\n",
      "Pregnancy and lactation: \n",
      "Safety in pregnant women has not been established. Metformin was not teratogenic in rats and \n",
      "rabbits at doses up to 600 mg/kg/day, or about two times the maximum recommended human \n",
      "daily dose on a body surface area basis. Determination of fetal concentrations demonstrated a \n",
      "partial placental barrier to metformin. Because animal reproduction studies are not always \n",
      "predictive of human response, any decision to use this drug should be balanced against the\n",
      "üî¢ Embedding (first 5 values): [-0.0045838  -0.0755391  -0.03358471  0.05453032 -0.00346262]\n",
      "----------------------------------------\n",
      "üß© Chunk 60:\n",
      "predictive of human response, any decision to use this drug should be balanced against the \n",
      "benefits and risks. \n",
      " \n",
      "Because recent information suggests that abnormal blood glucose levels during pregnancy are \n",
      "associated with a higher incidence of congenital abnormalities, there is a consensus among \n",
      "experts that insulin be used during pregnancy to maintain blood glucose levels as close to normal \n",
      "as possible. \n",
      " \n",
      "Nursing mother:\n",
      "üî¢ Embedding (first 5 values): [-0.05220015  0.00013643 -0.10639776  0.02814661  0.03446534]\n",
      "----------------------------------------\n",
      "üß© Chunk 61:\n",
      "as possible. \n",
      " \n",
      "Nursing mother: \n",
      "Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable \n",
      "to those in plasma. Similar studies have not been conducted in nursing mothers, but caution \n",
      "should be exercised in such patients, and a decision should be made whether to discontinue \n",
      "nursing or to discontinue the drug, taking into account the importance of the drug to the mother.\n",
      "üî¢ Embedding (first 5 values): [-0.01992013 -0.11612568 -0.04334601  0.05973959 -0.01760035]\n",
      "----------------------------------------\n",
      "üß© Chunk 62:\n",
      "14\n",
      " \n",
      " \n",
      "Pediatric Use: \n",
      "Safety and effectiveness in pediatric patients have not been established. \n",
      " \n",
      "Geriatric Use: \n",
      "Controlled clinical studies of metformin HCl did not include sufficient numbers of elderly \n",
      "patients to determine whether they respond differently from younger patients, although other \n",
      "reported clinical experience has not identified differences in responses between the elderly and \n",
      "younger patients. TEVA-METFORMIN is known to be substantially excreted by the kidney and\n",
      "üî¢ Embedding (first 5 values): [-0.03388406  0.03352385 -0.0317921  -0.01945221 -0.10605199]\n",
      "----------------------------------------\n",
      "üß© Chunk 63:\n",
      "younger patients. TEVA-METFORMIN is known to be substantially excreted by the kidney and \n",
      "because the risk of serious adverse reactions to the drug is greater in patients with impaired renal \n",
      "function, it should only be used in patients with normal renal function (see \n",
      "CONTRAINDICATIONS and WARNINGS). Because aging is associated with reduced renal \n",
      "function, TEVA-METFORMIN should be used with caution as age increases. Care should be\n",
      "üî¢ Embedding (first 5 values): [ 0.00309969 -0.00182574 -0.02079909 -0.02509897 -0.09119299]\n",
      "----------------------------------------\n",
      "üß© Chunk 64:\n",
      "function, TEVA-METFORMIN should be used with caution as age increases. Care should be \n",
      "taken in dose selection and should be based on careful and regular monitoring or renal function.  \n",
      "Generally, elderly patients should not be titrated to the maximum dose of TEVA-METFORMIN. \n",
      " \n",
      "Drug Interactions: \n",
      "Certain drugs may potentiate the effect of TEVA-METFORMIN, particularly sulfonylurea type \n",
      "of drugs in the treatment of diabetes. The simultaneous administration of these two types of\n",
      "üî¢ Embedding (first 5 values): [ 0.03006215 -0.02504813 -0.08641034 -0.02842374 -0.16120313]\n",
      "----------------------------------------\n",
      "üß© Chunk 65:\n",
      "of drugs in the treatment of diabetes. The simultaneous administration of these two types of \n",
      "drugs could produce a hypoglycemic reaction, especially if they are given in patients already \n",
      "receiving other drugs which, themselves, can potentiate the effect of sulfonylureas. These drugs \n",
      "can be: long-acting sulfonamides, tubercolostatics, phenylbutazone, clofibrate, monoamine \n",
      "oxidase inhibitors, salicylates, probenecid and propanolol.\n",
      "üî¢ Embedding (first 5 values): [ 0.0242259  -0.07225636 -0.07357263  0.0410164  -0.0861491 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 66:\n",
      "oxidase inhibitors, salicylates, probenecid and propanolol. \n",
      " \n",
      "In healthy volunteers, the pharmacokinetics of propranolol and ibuprofen were not affected by \n",
      "metformin when co-administered in single-dose interaction studies. \n",
      " \n",
      "Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with\n",
      "üî¢ Embedding (first 5 values): [ 0.00203626 -0.07168837 -0.05986592  0.09553979  0.03917317]\n",
      "----------------------------------------\n",
      "üß© Chunk 67:\n",
      "15\n",
      "highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, \n",
      "as compared to sulfonylureas, which are extensively bound to serum proteins. \n",
      "Glyburide: \n",
      "In a single-dose interaction study in NIDDM subjects, co-administration of metformin and \n",
      "glyburide did not result in any changes in either metformin pharmacokinetics or \n",
      "pharmacodynamics. Decreases in glyburide AUC and Cmax were observed, but were highly\n",
      "üî¢ Embedding (first 5 values): [ 0.04597112 -0.12471094 -0.04067625  0.01947598 -0.06058849]\n",
      "----------------------------------------\n",
      "üß© Chunk 68:\n",
      "pharmacodynamics. Decreases in glyburide AUC and Cmax were observed, but were highly \n",
      "variable. The single-dose nature of this study and the lack of correlation between glyburide \n",
      "blood levels and pharmacodynamics effects, makes the clinical significance of this interaction \n",
      "uncertain. \n",
      " \n",
      "Furosemide : \n",
      "A single dose study, metformin-furosemide drug interaction study in healthy subjects \n",
      "demonstrated that pharmacokinetic parameters of both compounds were affected by\n",
      "üî¢ Embedding (first 5 values): [ 0.08942352 -0.09029391 -0.07484046  0.04705939 -0.06470111]\n",
      "----------------------------------------\n",
      "üß© Chunk 69:\n",
      "demonstrated that pharmacokinetic parameters of both compounds were affected by \n",
      "co-administration. Furosemide increased the metformin plasma and blood Cmax by 22 % and \n",
      "blood AUC by 15 %, without any significant change in metformin renal clearance. When \n",
      "administered with metformin, the Cmax and AUC of furosemide were 31 % and 12 % smaller, \n",
      "respectively, than when administered alone, and the terminal half-life was decreased by 32 %,\n",
      "üî¢ Embedding (first 5 values): [ 0.07391229 -0.06840345 -0.07678775  0.01086686 -0.06837182]\n",
      "----------------------------------------\n",
      "üß© Chunk 70:\n",
      "respectively, than when administered alone, and the terminal half-life was decreased by 32 %, \n",
      "without any significant change in furosemide renal clearance. No information is available about \n",
      "the interaction of metformin and furosemide when co-administered chronically. \n",
      " \n",
      "Nifedipine: \n",
      "A single-dose, metformin-nifedipine drug interaction study in healthy volunteers demonstrated \n",
      "that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20 % and 9\n",
      "üî¢ Embedding (first 5 values): [ 0.07031778 -0.05616729 -0.01713325  0.00681662 -0.0611185 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 71:\n",
      "that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20 % and 9 \n",
      "%, respectively, and increased the amount excreted in the urine. Tmax and half-life were \n",
      "unaffected. Nifedipine appears to enhance the absorption of metformin.  Metformin had minimal \n",
      "effects on nifedipine. \n",
      " \n",
      "Cationic Drugs: \n",
      "Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine,\n",
      "üî¢ Embedding (first 5 values): [-0.00389298 -0.07504144 -0.03187696  0.02503423  0.00506798]\n",
      "----------------------------------------\n",
      "üß© Chunk 72:\n",
      "16\n",
      "triamterene, trimethoprim, and vancomycin) that are eliminated by renal tubular secretion, \n",
      "theoretically have the potential for interaction with metformin by competing for common renal \n",
      "tubular transport systems. Such an interaction has been observed between metformin and oral \n",
      "cimetidine in normal healthy volunteers in both single and multiple-dose, metformin-cimetidine \n",
      "drug interaction studies, with a 60 % increase in peak metformin plasma and whole blood\n",
      "üî¢ Embedding (first 5 values): [-0.0110835  -0.05913563 -0.01257217 -0.08744712 -0.06825479]\n",
      "----------------------------------------\n",
      "üß© Chunk 73:\n",
      "drug interaction studies, with a 60 % increase in peak metformin plasma and whole blood \n",
      "concentrations and a 40 % increase in plasma and whole blood metformin AUC was observed.  \n",
      "There was no change in elimination half-life in the single-dose study. Metformin had no effect \n",
      "on cimetidine pharmacokinetics. Therefore, careful patient monitoring and dose adjustment of \n",
      "TEVA-METFORMIN or the interfering drug is recommended in patients who are taking cationic\n",
      "üî¢ Embedding (first 5 values): [ 0.02712115 -0.05147216 -0.04297096 -0.00661734 -0.085071  ]\n",
      "----------------------------------------\n",
      "üß© Chunk 74:\n",
      "TEVA-METFORMIN or the interfering drug is recommended in patients who are taking cationic \n",
      "medications that are excreted via renal tubular secretion. \n",
      " \n",
      "Other: \n",
      "Other drugs tend to produce hyperglycemia and may lead to a loss of blood sugar control. These \n",
      "include thiazide and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, \n",
      "estrogen plus progestogen, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,\n",
      "üî¢ Embedding (first 5 values): [-0.03112842 -0.02859188 -0.08146501 -0.0163561  -0.09125351]\n",
      "----------------------------------------\n",
      "üß© Chunk 75:\n",
      "estrogen plus progestogen, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, \n",
      "calcium channel blocking drugs, and isoniazid. When such drugs are administered to patients \n",
      "receiving TEVA-METFORMIN, the patient should be closely observed to maintain adequate \n",
      "glycemic control. \n",
      " \n",
      "Elimination rate of the anticoagulant phenprocoumon has been reported to be increased by 20 % \n",
      "when used concurrently with TEVA-METFORMIN. Therefore, patients receiving\n",
      "üî¢ Embedding (first 5 values): [-0.02718966 -0.03419822 -0.12186629  0.02174998 -0.05590936]\n",
      "----------------------------------------\n",
      "üß© Chunk 76:\n",
      "when used concurrently with TEVA-METFORMIN. Therefore, patients receiving \n",
      "phenprocoumon or other antivitamin K anticoagulants should be monitored carefully when both \n",
      "types of drugs used simultaneously. In such cases, an important increase of prothrombin time \n",
      "may occur upon cessation of TEVA-METFORMIN therapy, with an increased risk of \n",
      "hemorrhage. \n",
      " \n",
      "NOTE: When used as indicated, there has not been a single case of lactic acidosis in\n",
      "üî¢ Embedding (first 5 values): [-0.0091475  -0.07956029 -0.08676107 -0.02057324 -0.01540263]\n",
      "----------------------------------------\n",
      "üß© Chunk 77:\n",
      "NOTE: When used as indicated, there has not been a single case of lactic acidosis in \n",
      "Canada. The reported incidence of lactic acidosis in patients receiving metformin \n",
      "hydrochloride is very low (approximately 0.03 cases/1000 patients/year with\n",
      "üî¢ Embedding (first 5 values): [ 0.04110716 -0.09233419  0.00704365  0.0060188  -0.02818614]\n",
      "----------------------------------------\n",
      "üß© Chunk 78:\n",
      "17\n",
      "approximately 0.015 fatal cases/1000 patients/year). TEVA-METFORMIN should be \n",
      "immediately discontinued in the presence of acidosis. \n",
      "Physicians should instruct their patients to recognize the symptoms which could be signal onset \n",
      "of lactic acidosis (see WARNINGS). \n",
      " \n",
      "ADVERSE REACTIONS \n",
      " \n",
      "Lactic Acidosis: \n",
      "See WARNINGS, PRECAUTIONS, and OVERDOSAGE Sections. \n",
      " \n",
      "Gastrointestinal Reactions: \n",
      "Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence, and\n",
      "üî¢ Embedding (first 5 values): [ 0.08636545 -0.06894974 -0.03494376 -0.00233872 -0.02588125]\n",
      "----------------------------------------\n",
      "üß© Chunk 79:\n",
      "Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence, and \n",
      "anorexia) are the most common reactions to TEVA-METFORMIN and are approximately 30 % \n",
      "more frequent in patients on TEVA-METFORMIN monotherapy than in placebo-treated \n",
      "patients, particularly during initiation of TEVA-METFORMIN therapy. These symptoms are \n",
      "generally transient and resolve spontaneously during continued treatment. Occasionally, \n",
      "temporary dose reduction may be useful.\n",
      "üî¢ Embedding (first 5 values): [ 0.03629743 -0.08171107 -0.01491071  0.01707578 -0.05047327]\n",
      "----------------------------------------\n",
      "üß© Chunk 80:\n",
      "temporary dose reduction may be useful. \n",
      " \n",
      "Because gastrointestinal symptoms during therapy initiation appear to be dose-related, they may \n",
      "be decreased by gradual dose escalation and by having patients take TEVA-METFORMIN \n",
      "(metformin HCl) with meals (see DOSAGE and ADMINISTRATION). \n",
      " \n",
      "Because significant diarrhea and/or vomiting can cause dehydration and prerenal azotemia, \n",
      "TEVA-METFORMIN should be temporarily discontinued, under such circumstances.\n",
      "üî¢ Embedding (first 5 values): [ 0.03038436  0.01871597 -0.00114137  0.0338429  -0.02951211]\n",
      "----------------------------------------\n",
      "üß© Chunk 81:\n",
      "TEVA-METFORMIN should be temporarily discontinued, under such circumstances. \n",
      " \n",
      "For patients who have been stabilized on TEVA-METFORMIN, nonspecific gastrointestinal \n",
      "symptoms should not be attributed to therapy unless intercurrent illness or lactic acidosis have \n",
      "been excluded.\n",
      "üî¢ Embedding (first 5 values): [ 0.01872181 -0.05052793 -0.04316678  0.01010217 -0.0334633 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 82:\n",
      "18\n",
      "Special Senses: \n",
      "During initiation of TEVA-METFORMIN therapy, approximately 3 % patient may complain of \n",
      "an unpleasant or metallic taste, which usually resolves spontaneously. \n",
      "Dermatologic Reactions: \n",
      "The incidence of rash/dermatitis in controlled clinical trials was comparable to placebo for \n",
      "metformin monotherapy and to sulfonylurea for metformin /sulfonylurea therapy. \n",
      " \n",
      "Hematologic: \n",
      "During controlled clinical trials of 29 weeks duration, approximately 9 % of patients on\n",
      "üî¢ Embedding (first 5 values): [-0.00904219 -0.07467829 -0.01599727  0.02403482 -0.08689346]\n",
      "----------------------------------------\n",
      "üß© Chunk 83:\n",
      "During controlled clinical trials of 29 weeks duration, approximately 9 % of patients on \n",
      "metformin HCl monotherapy and 6 % of patients on metformin HCl sulfonylurea therapy \n",
      "developed asymptomatic subnormal serum vitamin B12 levels; serum folic acid levels did not \n",
      "decrease significantly. However, only five cases of megaloblastic anemia have been reported \n",
      "with metformin administration (none during U.S. clinical studies) and no increased incidence of\n",
      "üî¢ Embedding (first 5 values): [-0.00226924 -0.03599615 -0.06716883  0.03606754 -0.09404479]\n",
      "----------------------------------------\n",
      "üß© Chunk 84:\n",
      "with metformin administration (none during U.S. clinical studies) and no increased incidence of \n",
      "neuropathy has been observed. Therefore, serum vitamin B12 levels should be appropriately \n",
      "monitored or periodic parenteral B12 supplementation considered (see also PRECAUTIONS). \n",
      " \n",
      "SYMPTOMS AND TREATMENT OF OVERDOSAGE \n",
      " \n",
      "Available information concerning treatment of a massive overdosage of metformin is very \n",
      "limited. It would be expected that adverse reactions of a more intense character including\n",
      "üî¢ Embedding (first 5 values): [-0.03871406 -0.06866264  0.0014817   0.06329054 -0.02700026]\n",
      "----------------------------------------\n",
      "üß© Chunk 85:\n",
      "limited. It would be expected that adverse reactions of a more intense character including \n",
      "epigastric discomfort, nausea and vomiting followed by diarrhea, drowsiness, weakness, \n",
      "dizziness, malaise and headache might be seen. Should those symptoms persist, lactic acidosis \n",
      "should be excluded. The drug should be discontinued and proper supportive therapy instituted. \n",
      " \n",
      "Hypoglycemia has not been seen even with ingestion of up to 85 grams of metformin, although\n",
      "üî¢ Embedding (first 5 values): [ 0.04001508 -0.04875266 -0.03204615  0.07193414 -0.01569967]\n",
      "----------------------------------------\n",
      "üß© Chunk 86:\n",
      "Hypoglycemia has not been seen even with ingestion of up to 85 grams of metformin, although \n",
      "lactic acidosis has occurred in such circumstances (see WARNINGS). Metformin is dialysable \n",
      "with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, \n",
      "hemodialysis may be useful for removal of accumulated drug from patients in whom metformin \n",
      "overdosage is suspected.\n",
      "üî¢ Embedding (first 5 values): [ 0.00728947 -0.0243776  -0.01269451  0.0158147  -0.06325694]\n",
      "----------------------------------------\n",
      "üß© Chunk 87:\n",
      "19\n",
      " \n",
      " \n",
      " \n",
      "DOSAGE AND ADMINISTRATION \n",
      "In diabetic patients, individual determination of the minimum dose that will lower blood glucose \n",
      "adequately should be made. \n",
      " \n",
      "In patients where on initial trial the maximal recommended dose fails to lower the blood glucose \n",
      "adequately, the drug should be discontinued. Deterioration of the patient's condition can occur \n",
      "during the treatment of diabetes. It is advisable to ascertain the contribution of the drug in the\n",
      "üî¢ Embedding (first 5 values): [ 0.02879944  0.07780112 -0.03799552 -0.02476284 -0.1070099 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 88:\n",
      "during the treatment of diabetes. It is advisable to ascertain the contribution of the drug in the \n",
      "control of blood glucose by discontinuing the medication semi-annually or at least annually with \n",
      "careful monitoring patient. If the need for the drug is not evident, the drug should not be \n",
      "resumed. In some diabetic subjects, short-term administration of the drug may be sufficient \n",
      "during periods of transient loss of blood sugar control.\n",
      "üî¢ Embedding (first 5 values): [-0.01745263  0.0557077  -0.05794745  0.01132236 -0.02765151]\n",
      "----------------------------------------\n",
      "üß© Chunk 89:\n",
      "during periods of transient loss of blood sugar control. \n",
      " \n",
      "The usual dose is 500 mg three or four times a day, or 850 mg two or three times a day. Maximal \n",
      "dose should not exceed 2.55 g a day. To minimize gastric intolerance such as nausea and \n",
      "vomiting TEVA-METFORMIN (metformin HCl) should be taken with food whenever possible.\n",
      "üî¢ Embedding (first 5 values): [ 0.05301383  0.02604834 -0.09294035  0.01792165 -0.11984851]\n",
      "----------------------------------------\n",
      "üß© Chunk 90:\n",
      "20\n",
      "PHARMACEUTICAL INFORMATION \n",
      " \n",
      "Proper Name:  \n",
      " \n",
      "Metformin Hydrochloride \n",
      " \n",
      "Chemical Name: \n",
      " \n",
      "1, 1-Dimethylbiguanide hydrochloride \n",
      " \n",
      "Structural Formula: \n",
      " \n",
      " \n",
      "          NH NH \n",
      "‚ïë      ‚ïë \n",
      "             Me2NCNHCNH2   ¬∑ HCl \n",
      " \n",
      " \n",
      "Molecular Formula:  \n",
      "C4H11N5¬∑HCl  \n",
      " \n",
      " \n",
      "Molecular Weight: \n",
      " \n",
      "165.6 \n",
      " \n",
      "Physical Form: \n",
      " \n",
      "Metformin HCl is a white crystalline powder. \n",
      " \n",
      "Solubility: \n",
      " \n",
      " \n",
      "Metformin HCl is soluble in water and in 95 % ethyl alcohol. It is\n",
      "üî¢ Embedding (first 5 values): [-0.06862162 -0.01400043 -0.03035528 -0.04845534 -0.01723988]\n",
      "----------------------------------------\n",
      "üß© Chunk 91:\n",
      "Solubility: \n",
      " \n",
      " \n",
      "Metformin HCl is soluble in water and in 95 % ethyl alcohol. It is  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "practically insoluble in ether and in chloroform. \n",
      " \n",
      "Melting Point:  \n",
      " \n",
      "225¬∞C. \n",
      " \n",
      "COMPOSITION \n",
      "TEVA-METFORMIN 500 mg Tablet contains 500 mg metformin HCl. Each tablet also contains \n",
      "as non-medicinal ingredients: colloidal silicon dioxide, corn starch, magnesium stearate, \n",
      "microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, Opadry Y-1-7000H\n",
      "üî¢ Embedding (first 5 values): [-0.02557682 -0.04835353 -0.05609865 -0.0270595   0.00426345]\n",
      "----------------------------------------\n",
      "üß© Chunk 92:\n",
      "microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, Opadry Y-1-7000H \n",
      "White (colour composition: hypromellose, macrogol and titanium dioxide).  \n",
      "TEVA-METFORMIN 850 mg Tablet contains 850 mg metformin HCl. Each tablet also contains\n",
      "üî¢ Embedding (first 5 values): [-0.03164244 -0.00979791 -0.04681527 -0.01425474 -0.02672375]\n",
      "----------------------------------------\n",
      "üß© Chunk 93:\n",
      "21\n",
      "as non-medicinal ingredients: corn starch, pregelatinized starch, colloidal silicon dioxide, sodium \n",
      "starch glycolate, microcrystalline cellulose and magnesium stearate. \n",
      " \n",
      "STABILITY AND STORAGE RECOMMENDATIONS \n",
      "Store between 15¬∞C - 30¬∞C.  Unit dose strips should be stored between 15¬∞C - 25¬∞C and \n",
      "protected from high humidity. \n",
      " \n",
      "AVAILABILITY \n",
      " \n",
      "TEVA-METFORMIN (metformin HCl) 500 mg tablets are white to off-white, round, bi-convex\n",
      "üî¢ Embedding (first 5 values): [ 0.00293227 -0.02096093 -0.06247786 -0.00468298 -0.06482853]\n",
      "----------------------------------------\n",
      "üß© Chunk 94:\n",
      "TEVA-METFORMIN (metformin HCl) 500 mg tablets are white to off-white, round, bi-convex \n",
      "bevel-edged coated tablets, engraved modified N deep bisect modified N on one side and 500 on \n",
      "the reverse.  Bottles of 100 and 500 tablets. \n",
      " \n",
      "TEVA-METFORMIN (metformin HCl) 850 mg tablets are white, oval shaped bi-convex \n",
      "compressed tablets engraved modified N on one side and 850 on the reverse. Bottles of 100, 500, \n",
      "1000 tablets and boxes of 100 tablets as unit dose strips. \n",
      " \n",
      "PHARMACOLOGY\n",
      "üî¢ Embedding (first 5 values): [-0.01623805  0.02196581 -0.08288026 -0.06264614 -0.12057076]\n",
      "----------------------------------------\n",
      "üß© Chunk 95:\n",
      "1000 tablets and boxes of 100 tablets as unit dose strips. \n",
      " \n",
      "PHARMACOLOGY \n",
      "Metformin absorption is relatively slow and may extend over about 6 hours. \n",
      " \n",
      "Animal studies with metformin, labeled with 14C have shown that the drug is neither \n",
      "concentrated by liver cells nor is it excreted in the bile; it is concentrated in the intestinal mucosa \n",
      "and salivary glands. \n",
      " \n",
      "It has been shown that, following a 2 g dose of metformin, the blood level remains under 10\n",
      "üî¢ Embedding (first 5 values): [ 0.04636283 -0.0765871  -0.03950446 -0.02552449 -0.08851368]\n",
      "----------------------------------------\n",
      "üß© Chunk 96:\n",
      "It has been shown that, following a 2 g dose of metformin, the blood level remains under 10 \n",
      "mcg/mL even at the peak, occurring 2 hours after absorption. During the experiments, metformin \n",
      "was shown to be devoid of any notable action in the body, apart from its specific metabolic \n",
      "activity.\n",
      "üî¢ Embedding (first 5 values): [-0.01405363 -0.06138116 -0.00113447  0.0791592  -0.05725392]\n",
      "----------------------------------------\n",
      "üß© Chunk 97:\n",
      "22\n",
      "In the healthy animal, metformin lowers blood sugar only at a nearly lethal dose. Different \n",
      "animal species are of unequal sensitivity. On the other hand, the animal with experimental \n",
      "diabetes, is sensitive to a much lower dosage, providing some insulin is still secreted. \n",
      " \n",
      "The antihyperglycemic action of metformin is probably mediated through insulin: \n",
      "Metformin improves the K co-efficient of glucose assimulation. \n",
      "Metformin improves the co-efficient of insulin efficiency.\n",
      "üî¢ Embedding (first 5 values): [-0.04170828  0.02713302 -0.0008871   0.0986341  -0.04697035]\n",
      "----------------------------------------\n",
      "üß© Chunk 98:\n",
      "Metformin improves the co-efficient of insulin efficiency. \n",
      " \n",
      "In the obese diabetic with hyperinsulinemia, metformin is reported to normalize insulin output.  \n",
      "This normalizing effect is concurrent to that of glycemia. \n",
      " \n",
      "Metformin has little effect on liver glycogen of the healthy animal. In low and average doses, no \n",
      "change occurs. In high doses nearing lethal levels, liver glycogen decreases. This lowering\n",
      "üî¢ Embedding (first 5 values): [-0.01372734  0.01473573 -0.08182988  0.06794397 -0.03762088]\n",
      "----------------------------------------\n",
      "üß© Chunk 99:\n",
      "change occurs. In high doses nearing lethal levels, liver glycogen decreases. This lowering \n",
      "precedes the fall in blood sugar. This reaction represents a defense mechanism tending to \n",
      "mobilize body reserves in order to combat hypoglycemia. \n",
      " \n",
      "In the diabetic animal with a low liver glycogen reserve, the opposite occurs and metformin \n",
      "builds up glycogen stores of the liver. In vitro, on muscular tissue isolated in Warburg's\n",
      "üî¢ Embedding (first 5 values): [-0.01646759  0.01854184 -0.04787669  0.04926051 -0.00857764]\n",
      "----------------------------------------\n",
      "üß© Chunk 100:\n",
      "builds up glycogen stores of the liver. In vitro, on muscular tissue isolated in Warburg's \n",
      "apparatus, metformin increases glucose uptake by the muscle. This action follows an aerobic \n",
      "pathway. Even in high concentration, contrary to phenethyl-biguanide, metformin apparently \n",
      "does not block respiration or change carbohydrate metabolism via the anaerobic pathway. \n",
      " \n",
      "Metformin is eliminated in faeces and urine. It is rapidly excreted by the kidneys in an \n",
      "unchanged form.\n",
      "üî¢ Embedding (first 5 values): [-0.06549674  0.01490187 -0.05858875  0.01549817 -0.01923075]\n",
      "----------------------------------------\n",
      "üß© Chunk 101:\n",
      "unchanged form.  \n",
      " \n",
      "Renal clearance is 450 mL/minute; this appears to explain the absence of accumulation. \n",
      " \n",
      "Metabolites of metformin have not been identified, neither by radio-active nor by chemical \n",
      "methods.\n",
      "üî¢ Embedding (first 5 values): [-0.01809174 -0.04066982 -0.03440612 -0.01188882 -0.04388048]\n",
      "----------------------------------------\n",
      "üß© Chunk 102:\n",
      "23\n",
      " \n",
      "A single Rf spot is always present following radiochromatographic study of urine and always \n",
      "corresponds to that of pure metformin. Administration during 10 consecutive days has not shown \n",
      "any sign of accumulation. \n",
      " \n",
      "Inhibition of glyconeogenesis has been observed in animals following its stimulation by fasting, \n",
      "cortisol, alcohol or other substrates such as alanine lactate or pyruvate. However, such an effect\n",
      "üî¢ Embedding (first 5 values): [-0.02411664 -0.06334412 -0.03245373  0.06189796 -0.02941645]\n",
      "----------------------------------------\n",
      "üß© Chunk 103:\n",
      "cortisol, alcohol or other substrates such as alanine lactate or pyruvate. However, such an effect \n",
      "varies according to the type and dosage of the biguanide used, nutritional state of the animal \n",
      "species and design of experimental model. \n",
      " \n",
      "This inhibition of glyconeogenesis is observed only in the presence of insulin and it does not \n",
      "appear to play an important role in man. \n",
      " \n",
      "Inhibition of intestinal absorption of sugars, which is not related to a malasorption phenomenon\n",
      "üî¢ Embedding (first 5 values): [ 0.07558465 -0.02864433 -0.05905077  0.05967482  0.00828367]\n",
      "----------------------------------------\n",
      "üß© Chunk 104:\n",
      "Inhibition of intestinal absorption of sugars, which is not related to a malasorption phenomenon \n",
      "has been observed with biguanides under certain experimental conditions in animal and in man.  \n",
      "In one study, a 20 % retardation of galactose absorption was observed in man receiving \n",
      "metformin. However, such an effect of metformin could not be confirmed in another study in \n",
      "man. \n",
      " \n",
      "Recent findings appear to indicate that most of the metabolic effects of the biguanides are\n",
      "üî¢ Embedding (first 5 values): [ 0.05173216 -0.05981873 -0.01874097  0.06036693 -0.01825618]\n",
      "----------------------------------------\n",
      "üß© Chunk 105:\n",
      "Recent findings appear to indicate that most of the metabolic effects of the biguanides are \n",
      "exerted through a single mechanism, namely inhibition of fatty acid oxidation and of acetyl-CoA \n",
      "generation. \n",
      " \n",
      "However, inhibition of insulin-stimulated lipogenesis which has also been observed appears to \n",
      "be due to the inhibition of acetyl-CoA carboxylase by the biguanides. Such an effect may \n",
      "explain, at least partly, the weight-reducing effect exerted by these drugs in obese diabetic \n",
      "patients.\n",
      "üî¢ Embedding (first 5 values): [ 0.01296648  0.02405073 -0.05596196  0.09609667  0.03053424]\n",
      "----------------------------------------\n",
      "üß© Chunk 106:\n",
      "patients. \n",
      "TOXICOLOGY\n",
      "üî¢ Embedding (first 5 values): [ 0.00876276 -0.02147853 -0.03652216  0.03211251 -0.088727  ]\n",
      "----------------------------------------\n",
      "üß© Chunk 107:\n",
      "24\n",
      "1.  \n",
      "Animal Toxicity \n",
      "Acute Toxicity (LD50) \n",
      "Animal \n",
      " \n",
      " \n",
      "Subcutaneously \n",
      "Orally \n",
      " \n",
      "Mouse  \n",
      " \n",
      " \n",
      "225 mg/kg \n",
      " \n",
      "3500 mg/kg \n",
      "Chicken \n",
      " \n",
      " \n",
      "150 mg/kg \n",
      "Rat \n",
      " \n",
      " \n",
      " \n",
      "300 mg/kg \n",
      " \n",
      "1000 mg/kg \n",
      "Rabbit  \n",
      " \n",
      " \n",
      "150 mg/kg \n",
      " \n",
      "  350 mg/kg \n",
      "Guinea Pig \n",
      " \n",
      " \n",
      "150 mg/kg \n",
      " \n",
      "  500 mg/kg \n",
      " \n",
      "Chronic Toxicity \n",
      " \n",
      "A) \n",
      "The following doses of metformin produced no organ toxicity: \n",
      "Rats \n",
      " \n",
      " \n",
      "125 mg/kg \n",
      "per os for one year \n",
      " \n",
      "Rabbits \n",
      " \n",
      "100 mg/kg \n",
      "per os for one year \n",
      "Dogs  \n",
      " \n",
      "  50 mg/kg \n",
      "subcutaneously for 2 years\n",
      "üî¢ Embedding (first 5 values): [ 0.0520745  -0.0741713   0.01469803  0.00196855 -0.06420065]\n",
      "----------------------------------------\n",
      "üß© Chunk 108:\n",
      "Rabbits \n",
      " \n",
      "100 mg/kg \n",
      "per os for one year \n",
      "Dogs  \n",
      " \n",
      "  50 mg/kg \n",
      "subcutaneously for 2 years \n",
      "Acute or chronic organ toxicity was not produced in the animal species involved. \n",
      " \n",
      "B) \n",
      "A study was carried out during 9 months with 80 rats, male and female, divided in \n",
      "4 groups, with the following dosage regimen: \n",
      "1st Group \n",
      "control \n",
      "2nd Group \n",
      "150 mg/kg per os \n",
      "3rd Group \n",
      "300 mg/kg per os \n",
      "4th Group \n",
      "300 mg/kg per os, dose increased by 100 mg/kg/day every 15 days\n",
      "üî¢ Embedding (first 5 values): [ 0.14508462 -0.02595573  0.04922577  0.06117642 -0.1148427 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 109:\n",
      "300 mg/kg per os \n",
      "4th Group \n",
      "300 mg/kg per os, dose increased by 100 mg/kg/day every 15 days \n",
      "In summary, the authors report the excellence tolerance of metformin by rats, \n",
      "even   \n",
      "when administered in very high doses.  No drug related lesion has been observed. \n",
      " \n",
      "C)  \n",
      "Chronic toxicity studies of 9 months duration were carried through with 16 beagle \n",
      "dogs, although the complete intolerance of this animal species to oral\n",
      "üî¢ Embedding (first 5 values): [ 0.04652899 -0.07533078  0.00462969  0.05943728 -0.12249881]\n",
      "----------------------------------------\n",
      "üß© Chunk 110:\n",
      "25\n",
      "hypoglycemic agents is a well established fact. Trophic and neurologic disorders \n",
      "with cachexia rapidly lead to the dog's death. During the periods of metformin \n",
      "administration, laboratory findings were within normal limits. The levels of \n",
      "enzymes were somewhat elevated, but it is difficult to ascribe a pathological \n",
      "significance to their values, since subjects in the control group were at the same \n",
      "level as treated animals.\n",
      "üî¢ Embedding (first 5 values): [ 0.03781158 -0.0586717   0.00025915  0.0793524  -0.08999997]\n",
      "----------------------------------------\n",
      "üß© Chunk 111:\n",
      "level as treated animals. \n",
      " \n",
      "Pathological studies show an extreme degree of undernutrition in all metformin \n",
      "treated animals. Profound wasting especially marked in fat tissues was evident in \n",
      "all organs. Cachexia appears as the common cause of death of these animals. \n",
      " \n",
      "2.  \n",
      "Human Toxicity \n",
      "In man, no adverse effect has been reported on liver or kidney function, the \n",
      "hematopoietic  system or on the blood vessels.\n",
      "üî¢ Embedding (first 5 values): [ 0.02323609 -0.02022064  0.02798929  0.09355528 -0.04937479]\n",
      "----------------------------------------\n",
      "üß© Chunk 112:\n",
      "hematopoietic  system or on the blood vessels. \n",
      " \n",
      "The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is \n",
      "very low (approximately 0.03 cases /1000 patients/year with approximately 0.015 fatal \n",
      "cases/1000 patients/year). \n",
      " \n",
      "The consecutive administration of both phenformin and metformin to the same patient \n",
      "has allowed for the demonstration of a fundamental difference between these two\n",
      "üî¢ Embedding (first 5 values): [ 0.02730017 -0.06863805 -0.04172176 -0.0152941  -0.03031711]\n",
      "----------------------------------------\n",
      "üß© Chunk 113:\n",
      "has allowed for the demonstration of a fundamental difference between these two \n",
      "biguanides in  relation to lactacidemia. In some instances, patients developed \n",
      "hyperlactacidemia with phenformin when the same patients were presenting normal lactic \n",
      "acid levels while being treated with metformin. In other instances, hyperlactacidemia \n",
      "observed during a treatment  with phenformin did regress when metformin was\n",
      "üî¢ Embedding (first 5 values): [ 0.08168121 -0.05582606  0.01558692  0.03038439 -0.02750766]\n",
      "----------------------------------------\n",
      "üß© Chunk 114:\n",
      "observed during a treatment  with phenformin did regress when metformin was \n",
      "substituted  for phenformin. Metformin may increase lactacidemia but to a degree that is \n",
      "clinically less significant than the elevation seen after phenformin. \n",
      "3.  \n",
      "Teratology \n",
      "Teratological studies were carried out in albino rats divided in three groups:\n",
      "üî¢ Embedding (first 5 values): [ 0.03666462 -0.04621747  0.00825753  0.04690414 -0.04548274]\n",
      "----------------------------------------\n",
      "üß© Chunk 115:\n",
      "26\n",
      "No abnormalities were found, even when high doses were administered. The number of \n",
      " \n",
      "animals was the same in each group. \n",
      " \n",
      "Death rate in the three groups of treated animals and controls was approximately the \n",
      "same. However, the number of living animals in each group treated was slightly lower \n",
      "than in the control group. Also, the frequency of litters exceeding 10 live animals was \n",
      "slightly higher in the control group.  A loss of weight at the time of weaning has been\n",
      "üî¢ Embedding (first 5 values): [ 0.03348713  0.02391595 -0.03309097  0.10232682 -0.03053258]\n",
      "----------------------------------------\n",
      "üß© Chunk 116:\n",
      "slightly higher in the control group.  A loss of weight at the time of weaning has been \n",
      "observed when compared to the control group. \n",
      " \n",
      "Nevertheless, on a statistical basis, differences were shown to be non-significant. There is \n",
      " \n",
      "no difference between the groups of treated animals and the control group regarding the \n",
      " \n",
      "number of stillborn. The number of deaths after birth was slightly higher in metformin\n",
      "üî¢ Embedding (first 5 values): [-0.04013988 -0.01954367 -0.05640097  0.15668313  0.00593936]\n",
      "----------------------------------------\n",
      "üß© Chunk 117:\n",
      "number of stillborn. The number of deaths after birth was slightly higher in metformin \n",
      " \n",
      "treated groups than in the control group, but the comparison of average death rates is not \n",
      " \n",
      "significant (p < 0.05).\n",
      "üî¢ Embedding (first 5 values): [ 0.01251498 -0.06257084 -0.07646021  0.04548686  0.01119859]\n",
      "----------------------------------------\n",
      "üß© Chunk 118:\n",
      "27\n",
      "BIBLIOGRAPHY \n",
      "¬∑ \n",
      "Alberti, K.G.M. et al: Lactic Acidosis, The Lancet, July 2,25-29, 1977. \n",
      " \n",
      "¬∑ \n",
      "Beckmann, R.: R√©sorbtion, distribution dans l'organisme et √©limination de la Metformine. \n",
      "Diab√©tologia, 5:318-324, 1969. \n",
      " \n",
      "¬∑ \n",
      "Benoit, R. et al: Acidose lactique et phenformine. L'Union M√©dicale du Canada, \n",
      "105:1810-1814, 1976. \n",
      " \n",
      "¬∑ \n",
      "Berger, Wet al: Probl√®mes d`actualit√© concernant le m√©canisme d`action des biguanides. \n",
      "Jour. Diab. H√¥tel-Dieu Paris, 239-258, 1975. \n",
      " \n",
      "¬∑\n",
      "üî¢ Embedding (first 5 values): [ 0.05905725 -0.05053736 -0.0044787   0.03527941 -0.00581674]\n",
      "----------------------------------------\n",
      "üß© Chunk 119:\n",
      "Jour. Diab. H√¥tel-Dieu Paris, 239-258, 1975. \n",
      " \n",
      "¬∑ \n",
      "Bermond, P.: The coefficient of insulin efficacy. Effect of Metformin on this parameter. \n",
      "Xi√®me Congr√®s F√©d√©ration Int. Diab√©tologie, Stockholm, 1967. Ed. Excerpa Medica F. \n",
      "Amsterdam, 1968. \n",
      " \n",
      "¬∑ \n",
      "Biron, P.: Metformin monitoring. C.M.A.J., 123:11-12, 1980. \n",
      " \n",
      "¬∑ \n",
      "Bouaziz, Pl.: Apport √† l'√©tude de l'√©preuve d'hyperglyc√©mie provoqu√©e par voie veineuse \n",
      "sous th√©rapie diab√©tique. Th√®se de doctorat en M√©decine, Paris, 1966. \n",
      " \n",
      "¬∑\n",
      "üî¢ Embedding (first 5 values): [-0.03222917 -0.00220736 -0.06134953  0.0381236  -0.06073605]\n",
      "----------------------------------------\n",
      "üß© Chunk 120:\n",
      "sous th√©rapie diab√©tique. Th√®se de doctorat en M√©decine, Paris, 1966. \n",
      " \n",
      "¬∑ \n",
      "Cohen, R.D.: The relative risks of different biguanides in the causation of lactic acidosis. \n",
      "Research and Clinical Forums, 1:(4) 125-134, 1979. \n",
      " \n",
      "¬∑ \n",
      "Cohen, Y. et al: Etude autoradiographique chez la souris d'un antidiab√©tique oral, le N.N. \n",
      "Dim√©thylbiguanide, marqu√© au Cl4 Th√©rapie 109-120, 1961. \n",
      " \n",
      "¬∑ \n",
      "Cohen, Y. et al: Etude autoradiographique chez la souris d'un antidiab√©tique oral marqu√©\n",
      "üî¢ Embedding (first 5 values): [ 0.09485668 -0.01396458 -0.04534381  0.01195544 -0.00627142]\n",
      "----------------------------------------\n",
      "üß© Chunk 121:\n",
      "¬∑ \n",
      "Cohen, Y. et al: Etude autoradiographique chez la souris d'un antidiab√©tique oral marqu√© \n",
      "au Cl4, le N.N. Dim√©thylbiguanide, apr√®s administrations r√©p√©t√©es. Th√©rapie XXIII,\n",
      "üî¢ Embedding (first 5 values): [-0.0098931   0.0529104  -0.10219909 -0.05215011 -0.07945851]\n",
      "----------------------------------------\n",
      "üß© Chunk 122:\n",
      "28\n",
      "1185-1191, 1968. \n",
      "¬∑ \n",
      "Daubresse, J.C. et al: Acidose lactique et th√©rapeutique par biguanides. M√©d. et Hyg. \n",
      "1168, 1975. \n",
      " \n",
      "¬∑ \n",
      "Debry, G. et al: Etude du mode d`excr√©tion du N.N.Dim√©thylbiguanide chex le \n",
      "diab√©tique adulte. Th√©rapie, XX: 351-358, 1963. \n",
      " \n",
      "¬∑ \n",
      "Derot, M. et al: Retrospective study of the cardiovascular fate of 190 patients treated for \n",
      "5 year or more with biguanides alone. Abstracts, 1lth Annual Meeting, Munich Sept., \n",
      "1975. \n",
      " \n",
      "¬∑\n",
      "üî¢ Embedding (first 5 values): [ 0.06649538  0.01648707 -0.03170929  0.01860525 -0.00397692]\n",
      "----------------------------------------\n",
      "üß© Chunk 123:\n",
      "5 year or more with biguanides alone. Abstracts, 1lth Annual Meeting, Munich Sept., \n",
      "1975. \n",
      " \n",
      "¬∑ \n",
      "Duval, D.: Contribution √† l'√©tude de l'action hypoglyc√©miante des biguanides. Th√®se de \n",
      "Doctorat en M√©decine, Paris, 1960. \n",
      " \n",
      "¬∑ \n",
      "Duwoos, H. et al: Hyperlactacid√©mie r√©versible induite par la phenformine avec asth√©nie \n",
      "musculaire et signes cardio-respiratoires. Presse M√©d. 78: 23-26, 1970. \n",
      " \n",
      "¬∑ \n",
      "Hermann, L.S.: Metformin: A review of its pharmacological properties and therapeutic\n",
      "üî¢ Embedding (first 5 values): [ 0.02326843 -0.02439308  0.00817108  0.05282811 -0.0896748 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 124:\n",
      "¬∑ \n",
      "Hermann, L.S.: Metformin: A review of its pharmacological properties and therapeutic \n",
      "use. Diab√®te et M√©tabolisme, 3:233-245, 1979. \n",
      " \n",
      "¬∑ \n",
      "Hermann, L.S.: Metabolic effects of Metformin in relation to clinical effects and side \n",
      "effects in Biguanide Therapy Today. International Congress and Symposium, series \n",
      "published by the Royal Society of Medicine, 48:17-43, 1981. \n",
      " \n",
      "¬∑ \n",
      "Holle, A. et al: Biguanide treatment increases the number of insulin receptor sites on\n",
      "üî¢ Embedding (first 5 values): [-0.01284065 -0.00332069 -0.08139023  0.04249734 -0.02591436]\n",
      "----------------------------------------\n",
      "üß© Chunk 125:\n",
      "¬∑ \n",
      "Holle, A. et al: Biguanide treatment increases the number of insulin receptor sites on \n",
      "human erythrocytes. The New Engl. J. Med. 305:10, 563-566, 1981. \n",
      " \n",
      "¬∑ \n",
      "Hunt, J. A. et al: The use of phenformin and metformin. Letter to the Editor, C.M.A.J., \n",
      "117:(5)429-430, 1977.\n",
      "üî¢ Embedding (first 5 values): [ 0.0205458   0.00057733 -0.10356597  0.02495661 -0.03399074]\n",
      "----------------------------------------\n",
      "üß© Chunk 126:\n",
      "29\n",
      " \n",
      " \n",
      "¬∑ \n",
      "Irsigler, K.: Glucoseutilisation and Plasmaliporide bei adiposen Patienten unter dem \n",
      "Einfluss von Dimethylbiguanide (GLUCOPHAGE¬Æ). wiener med. Wsch. 119:191-194, \n",
      "1969. \n",
      " \n",
      "¬∑ \n",
      "Isnard, F. et al: Acidose lactique et biguanides. Etat actuel de la question en France. \n",
      "Journ√©es \n",
      "Annuelles de diab√©tologie de l'H√¥tel-Dieu 362-375, 1977. \n",
      " \n",
      "¬∑ \n",
      "Joncas, F: Evaluation clinique de GLUCOPHAGE¬Æ pour le traitement du diab√®te de \n",
      "l'adulte.\n",
      "üî¢ Embedding (first 5 values): [ 0.01242365 -0.00090979 -0.07619491  0.03709117 -0.0727157 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 127:\n",
      "¬∑ \n",
      "Joncas, F: Evaluation clinique de GLUCOPHAGE¬Æ pour le traitement du diab√®te de \n",
      "l'adulte. \n",
      "H√¥pital Maisonneuve, Montr√©al. L'Union M√©dicale du Canada, Jan. Issue, 1972. \n",
      " \n",
      "¬∑ \n",
      "Laurendeau, Ed. et al: Traitement du diab√®te sucr√© chez des patients √¢g√©s, hospitalis√©s \n",
      "avec le N.N. Dim√©thylbuguanide (GLUCOPHAGE¬Æ). H√¥pital Notre-Dame de la Merci. \n",
      "Montr√©al, 1970. Ref Lab. Franca (non publi√©). \n",
      " \n",
      "¬∑ \n",
      "Lefebvre, P. et al: Le m√©canisme d'action des biaguanides. Biguanides et s√©cr√©tion\n",
      "üî¢ Embedding (first 5 values): [ 0.02123802 -0.00344188 -0.03749808 -0.00890207 -0.08242494]\n",
      "----------------------------------------\n",
      "üß© Chunk 128:\n",
      "¬∑ \n",
      "Lefebvre, P. et al: Le m√©canisme d'action des biaguanides. Biguanides et s√©cr√©tion \n",
      "insulinique. Congr√®s International de Diab√©tologie de R√©mini, 1968. \n",
      " \n",
      "¬∑ \n",
      "Mainguet, P. et al: Le diab√®te, 20:(1)39, 1972. \n",
      " \n",
      "¬∑ \n",
      "McKlish, A. Toxicit√© du N.N. Dim√©thylbiguanide chez le chien Beagle. Centre de \n",
      "recherches Laval, Qu√©bec (1970). Ref. Laboratoires Franca Inc. (non publi√©). \n",
      " \n",
      "¬∑ \n",
      "Meyer, F. et al: Donn√©es nouvelles sur le m√©canisme d'action des biguanide\n",
      "üî¢ Embedding (first 5 values): [ 0.01353066  0.06164149 -0.03011457  0.03059614 -0.02598509]\n",
      "----------------------------------------\n",
      "üß© Chunk 129:\n",
      "¬∑ \n",
      "Meyer, F. et al: Donn√©es nouvelles sur le m√©canisme d'action des biguanide \n",
      "hypoglyc√©miants. Journ√©e annuelles de diab√©tologie de l'h√¥tel-Dieu, 341-347, 1967.\n",
      "üî¢ Embedding (first 5 values): [ 0.05361642  0.08535462 -0.01076107  0.06041007 -0.03238576]\n",
      "----------------------------------------\n",
      "üß© Chunk 130:\n",
      "30\n",
      "¬∑ \n",
      "Pelletier, G. et al: Etude de toxicit√© chronique de N.N. Dim√©thylbiguanide chez le rat. \n",
      "Centre de recherche Laval, Qu√©bec. Ref. Laboratoires Franca Inc. (non publi√©e). \n",
      " \n",
      "¬∑ \n",
      "Pelletier, G. et al: Etude t√©ratologique avec le N.N. Dim√©thylbiguanide chez le rat. Centre \n",
      "de Recherche Laval, Qu√©bec. Ref. laboratoires Franca Inc. (non publi√©e) 1970. \n",
      " \n",
      "¬∑ \n",
      "Pignard, P.: Dosage spectrotom√©trique du N.N. Dim√©thylbiguanide dans le sang et l'urine. \n",
      "Annales de Biologie Clinique. 20:225-233, 1962.\n",
      "üî¢ Embedding (first 5 values): [ 0.02218267 -0.00412298 -0.0381831  -0.02239113 -0.04005513]\n",
      "----------------------------------------\n",
      "üß© Chunk 131:\n",
      "Annales de Biologie Clinique. 20:225-233, 1962. \n",
      " \n",
      "¬∑ \n",
      "Sterne, J.: Oral Hypoglycemic agents. Medicinal Chemistry, 9(5):193-294, 1969. \n",
      " \n",
      "¬∑ \n",
      "Sterne, J.M. et al: Oral hypoglycemic agents: Clinical pharmacology and therapeutic use. \n",
      "Drugs, 14:41-56, 1977. \n",
      " \n",
      "¬∑ \n",
      "Sterne, J.: Pharmacology and mechanism of action of the antidiabetic biguanides. Paper \n",
      "read in Moscow, April 1977, Unpublished. \n",
      " \n",
      "¬∑ \n",
      "Stowers, J.M.: Long-term therapy with biguanides in:Biguanide Therapy Today,\n",
      "üî¢ Embedding (first 5 values): [ 0.05651401  0.02205293 -0.04894567  0.02720332 -0.04373332]\n",
      "----------------------------------------\n",
      "üß© Chunk 132:\n",
      "¬∑ \n",
      "Stowers, J.M.: Long-term therapy with biguanides in:Biguanide Therapy Today, \n",
      "International Congress and Symposium, Series published by the Royal Society of \n",
      "Medecin, 48:49-57, 1981. \n",
      " \n",
      "¬∑ \n",
      "Stowers, J.M.et al: Oral hypoglycemic agents: Clinical pharmacology and therapeutic \n",
      "use. Drugs, 14:41-56, 1977. \n",
      " \n",
      " \n",
      "¬∑ \n",
      "Vague, P. Effet d'une dose unique de metformine sur la tol√©rance au glucose des sujets \n",
      "normaux ou ob√®ses. Le Diab√®te, 18:35-39, 1970. \n",
      " \n",
      "¬∑\n",
      "üî¢ Embedding (first 5 values): [ 0.05996801  0.02362989 -0.05747539  0.0232593  -0.05672627]\n",
      "----------------------------------------\n",
      "üß© Chunk 133:\n",
      "normaux ou ob√®ses. Le Diab√®te, 18:35-39, 1970. \n",
      " \n",
      "¬∑ \n",
      "Vermulen, A. et al: Influence of dimethylbiguanide (metformin) on carbohydrate\n",
      "üî¢ Embedding (first 5 values): [-0.02273279  0.014287   -0.07976602  0.05965294 -0.04274847]\n",
      "----------------------------------------\n",
      "üß© Chunk 134:\n",
      "31\n",
      "metabolism in obese, non diabetic women. Diabetologia, 8:8-11, 1972. \n",
      " \n",
      "¬∑ \n",
      "A two-way, single-dose, comparative bioavailability study of metformin hydrochloride \n",
      "500 mg tablets administered a 1 X 500 mg tablet in normal male volunteers. Completed \n",
      "September, 1995.  Data on file at Teva Canada Limited. \n",
      " \n",
      "¬∑ \n",
      "Glucophage (Metformin Hydrochloride) Product Monograph, Aventis Pharma Inc., \n",
      "Laval, Quebec, June 22, 2000.\n",
      "üî¢ Embedding (first 5 values): [-0.01057188 -0.00216332 -0.09919473 -0.00826254 -0.03546347]\n",
      "----------------------------------------\n",
      "üß© Chunk 135:\n",
      "GLUCOPHAGE¬Æ  \n",
      "(metformin hydrochloride) Tablets  \n",
      "GLUCOPHAGE¬Æ XR  \n",
      "(metformin hydrochloride) Extended-Release Tablets  \n",
      "DESCRIPTION \n",
      "GLUCOPHAGE¬Æ (metformin hydrochloride) Tablets and GLUCOPHAGE¬Æ XR (metformin \n",
      "hydrochloride) Extended-Release Tablets are oral antihyperglycemic drugs used in the \n",
      "management of type 2 diabetes. Metformin hydrochloride (N,N-dimethylimidodicarbonimidic \n",
      "diamide hydrochloride) is not chemically or pharmacologically related to any other classes of\n",
      "üî¢ Embedding (first 5 values): [-0.05816728 -0.05971582 -0.06703177 -0.09594478 -0.04140754]\n",
      "----------------------------------------\n",
      "üß© Chunk 136:\n",
      "diamide hydrochloride) is not chemically or pharmacologically related to any other classes of \n",
      "oral antihyperglycemic agents. The structural formula is as shown: structural formula\n",
      "Metformin hydrochloride is a white to off-white crystalline compound with a molecular formula \n",
      "of C4H11N5 ‚Ä¢ HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble \n",
      "in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is\n",
      "üî¢ Embedding (first 5 values): [-0.02758463 -0.01065291 -0.09112455 -0.06608897 -0.01360972]\n",
      "----------------------------------------\n",
      "üß© Chunk 137:\n",
      "in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is \n",
      "12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. \n",
      "GLUCOPHAGE tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Each \n",
      "tablet contains the inactive ingredients povidone and magnesium stearate. In addition, the coating \n",
      "for the 500 mg and 850 mg tablets contains hypromellose and the coating for the 1000 mg tablet\n",
      "üî¢ Embedding (first 5 values): [-0.03932725 -0.0552402  -0.07855188 -0.06244257 -0.07324157]\n",
      "----------------------------------------\n",
      "üß© Chunk 138:\n",
      "for the 500 mg and 850 mg tablets contains hypromellose and the coating for the 1000 mg tablet \n",
      "contains hypromellose and polyethylene glycol. \n",
      "GLUCOPHAGE XR contains 500 mg or 750 mg of metformin hydrochloride as the active \n",
      "ingredient. \n",
      "GLUCOPHAGE XR 500 mg tablets contain the inactive ingredients sodium carboxymethyl \n",
      "cellulose, hypromellose, microcrystalline cellulose, and magnesium stearate. \n",
      "1\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "üî¢ Embedding (first 5 values): [-0.02170471 -0.04061815 -0.04793963 -0.09298038 -0.02415239]\n",
      "----------------------------------------\n",
      "üß© Chunk 139:\n",
      "1\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.00411919 -0.09151844 -0.09989631 -0.03827856  0.00643031]\n",
      "----------------------------------------\n",
      "üß© Chunk 140:\n",
      "GLUCOPHAGE XR 750 mg tablets contain the inactive ingredients sodium carboxymethyl \n",
      "cellulose, hypromellose, and magnesium stearate. \n",
      "System Components and Performance‚ÄìGLUCOPHAGE XR comprises a dual hydrophilic \n",
      "polymer matrix system. Metformin hydrochloride is combined with a drug release controlling \n",
      "polymer to form an \"inner\" phase, which is then incorporated as discrete particles into an \n",
      "\"external\" phase of a second polymer. After administration, fluid from the gastrointestinal (GI)\n",
      "üî¢ Embedding (first 5 values): [-0.03607172 -0.09251802 -0.04161913 -0.07690406 -0.06118255]\n",
      "----------------------------------------\n",
      "üß© Chunk 141:\n",
      "\"external\" phase of a second polymer. After administration, fluid from the gastrointestinal (GI) \n",
      "tract enters the tablet, causing the polymers to hydrate and swell. Drug is released slowly from \n",
      "the dosage form by a process of diffusion through the gel matrix that is essentially independent \n",
      "of pH. The hydrated polymer system is not rigid and is expected to be broken up by normal \n",
      "peristalsis in the GI tract. The biologically inert components of the tablet may occasionally\n",
      "üî¢ Embedding (first 5 values): [ 0.01884331 -0.12033687 -0.04317544  0.00164239 -0.02870378]\n",
      "----------------------------------------\n",
      "üß© Chunk 142:\n",
      "peristalsis in the GI tract. The biologically inert components of the tablet may occasionally \n",
      "remain intact during GI transit and will be eliminated in the feces as a soft, hydrated mass. \n",
      "CLINICAL PHARMACOLOGY \n",
      "Mechanism of Action \n",
      "Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type \n",
      "2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms\n",
      "üî¢ Embedding (first 5 values): [-0.03832011 -0.05056264 -0.06597575  0.04619959 -0.09827705]\n",
      "----------------------------------------\n",
      "üß© Chunk 143:\n",
      "2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms \n",
      "of action are different from other classes of oral antihyperglycemic agents. Metformin decreases \n",
      "hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin \n",
      "sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, \n",
      "metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal\n",
      "üî¢ Embedding (first 5 values): [-0.03231087 -0.01665279 -0.05923437  0.02952145 -0.0595366 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 144:\n",
      "metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal \n",
      "subjects (except in special circumstances, see PRECAUTIONS) and does not cause \n",
      "hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting \n",
      "insulin levels and day-long plasma insulin response may actually decrease. \n",
      "Pharmacokinetics \n",
      "Absorption and Bioavailability \n",
      "The absolute bioavailability of a GLUCOPHAGE 500 mg tablet given under fasting conditions\n",
      "üî¢ Embedding (first 5 values): [-0.01496783 -0.01054801 -0.05856541  0.03538746 -0.02922055]\n",
      "----------------------------------------\n",
      "üß© Chunk 145:\n",
      "The absolute bioavailability of a GLUCOPHAGE 500 mg tablet given under fasting conditions \n",
      "is approximately 50% to 60%. Studies using single oral doses of GLUCOPHAGE 500 to \n",
      "1500 mg, and 850 to 2550 mg, indicate that there is a lack of dose proportionality with \n",
      "increasing doses, which is due to decreased absorption rather than an alteration in elimination. \n",
      "Food decreases the extent of and slightly delays the absorption of metformin, as shown by\n",
      "üî¢ Embedding (first 5 values): [ 0.02953971 -0.07692982 -0.02932822 -0.03580825 -0.10588326]\n",
      "----------------------------------------\n",
      "üß© Chunk 146:\n",
      "Food decreases the extent of and slightly delays the absorption of metformin, as shown by \n",
      "approximately a 40% lower mean peak plasma concentration (Cmax), a 25% lower area under the \n",
      "plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak \n",
      "plasma concentration (Tmax) following administration of a single 850 mg tablet of metformin \n",
      "2\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "üî¢ Embedding (first 5 values): [-0.03896922 -0.06128403 -0.01038259  0.05451092 -0.02044353]\n",
      "----------------------------------------\n",
      "üß© Chunk 147:\n",
      "2\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.00082482 -0.09089499 -0.10033897 -0.04180982  0.00502423]\n",
      "----------------------------------------\n",
      "üß© Chunk 148:\n",
      "with food, compared to the same tablet strength administered fasting. The clinical relevance of \n",
      "these decreases is unknown. \n",
      "Following a single oral dose of GLUCOPHAGE XR, Cmax is achieved with a median value of \n",
      "7 hours and a range of 4 to 8 hours. Peak plasma levels are approximately 20% lower compared \n",
      "to the same dose of GLUCOPHAGE, however, the extent of absorption (as measured by AUC) \n",
      "is similar to GLUCOPHAGE.\n",
      "üî¢ Embedding (first 5 values): [ 0.03356964 -0.0789622  -0.02835033 -0.01844408 -0.11518027]\n",
      "----------------------------------------\n",
      "üß© Chunk 149:\n",
      "is similar to GLUCOPHAGE. \n",
      "At steady state, the AUC and Cmax are less than dose proportional for GLUCOPHAGE XR \n",
      "within the range of 500 to 2000 mg administered once daily. Peak plasma levels are \n",
      "approximately 0.6, 1.1, 1.4, and 1.8 ¬µg/mL for 500, 1000, 1500, and 2000 mg once-daily doses, \n",
      "respectively. The extent of metformin absorption (as measured by AUC) from \n",
      "GLUCOPHAGE XR at a 2000 mg once-daily dose is similar to the same total daily dose\n",
      "üî¢ Embedding (first 5 values): [-0.00105376 -0.10227288 -0.04787399  0.00599604 -0.06272957]\n",
      "----------------------------------------\n",
      "üß© Chunk 150:\n",
      "GLUCOPHAGE XR at a 2000 mg once-daily dose is similar to the same total daily dose \n",
      "administered as GLUCOPHAGE tablets 1000 mg twice daily. After repeated administration of \n",
      "GLUCOPHAGE XR, metformin did not accumulate in plasma. \n",
      "Within-subject variability in Cmax and AUC of metformin from GLUCOPHAGE XR is \n",
      "comparable to that with GLUCOPHAGE. \n",
      "Although the extent of metformin absorption (as measured by AUC) from the\n",
      "üî¢ Embedding (first 5 values): [-0.00761129 -0.08692883 -0.01982663 -0.00410708 -0.08060724]\n",
      "----------------------------------------\n",
      "üß© Chunk 151:\n",
      "Although the extent of metformin absorption (as measured by AUC) from the \n",
      "GLUCOPHAGE XR tablet increased by approximately 50% when given with food, there was no \n",
      "effect of food on Cmax and Tmax of metformin. Both high and low fat meals had the same effect \n",
      "on the pharmacokinetics of GLUCOPHAGE XR. \n",
      "Distribution \n",
      "The apparent volume of distribution (V/F) of metformin following single oral doses of \n",
      "GLUCOPHAGE 850 mg averaged 654 ¬± 358 L. Metformin is negligibly bound to plasma\n",
      "üî¢ Embedding (first 5 values): [ 0.00603422 -0.0694072  -0.01958803 -0.01392992 -0.09492569]\n",
      "----------------------------------------\n",
      "üß© Chunk 152:\n",
      "GLUCOPHAGE 850 mg averaged 654 ¬± 358 L. Metformin is negligibly bound to plasma \n",
      "proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin \n",
      "partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing \n",
      "schedules of GLUCOPHAGE, steady state plasma concentrations of metformin are reached \n",
      "within 24 to 48 hours and are generally <1 ¬µg/mL. During controlled clinical trials of\n",
      "üî¢ Embedding (first 5 values): [-0.00702235 -0.06737188 -0.02987425  0.00913428 -0.10295068]\n",
      "----------------------------------------\n",
      "üß© Chunk 153:\n",
      "within 24 to 48 hours and are generally <1 ¬µg/mL. During controlled clinical trials of \n",
      "GLUCOPHAGE, maximum metformin plasma levels did not exceed 5 ¬µg/mL, even at maximum \n",
      "doses. \n",
      "Metabolism and Elimination \n",
      "Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted \n",
      "unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been \n",
      "3\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "üî¢ Embedding (first 5 values): [-0.01368329 -0.06505828 -0.00683414 -0.00183582 -0.08840398]\n",
      "----------------------------------------\n",
      "üß© Chunk 154:\n",
      "3\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.00037    -0.0974304  -0.10851596 -0.04636299  0.00626679]\n",
      "----------------------------------------\n",
      "üß© Chunk 155:\n",
      "identified in humans) nor biliary excretion. Renal clearance (see Table 1) is approximately \n",
      "3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major \n",
      "route of metformin elimination. Following oral administration, approximately 90% of the \n",
      "absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma \n",
      "elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is\n",
      "üî¢ Embedding (first 5 values): [ 0.01466828 -0.00441955  0.00203528 -0.0116459  -0.07033997]\n",
      "----------------------------------------\n",
      "üß© Chunk 156:\n",
      "elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is \n",
      "approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of \n",
      "distribution. \n",
      "Specific Populations \n",
      "Patients with Type 2 Diabetes \n",
      "In the presence of normal renal function, there are no differences between single- or multiple-\n",
      "dose pharmacokinetics of metformin between patients with type 2 diabetes and normal subjects\n",
      "üî¢ Embedding (first 5 values): [ 0.01356664  0.00861555  0.00136434  0.02742731 -0.05102682]\n",
      "----------------------------------------\n",
      "üß© Chunk 157:\n",
      "dose pharmacokinetics of metformin between patients with type 2 diabetes and normal subjects \n",
      "(see Table 1), nor is there any accumulation of metformin in either group at usual clinical doses. \n",
      "The pharmacokinetics of GLUCOPHAGE XR in patients with type 2 diabetes are comparable to \n",
      "those in healthy normal adults. \n",
      "Renal Impairment \n",
      "In patients with decreased renal function, the plasma and blood half-life of metformin is \n",
      "prolonged \n",
      "and \n",
      "the\n",
      "CONTRAINDICATIONS, \n",
      "ADMINISTRATION). \n",
      " \n",
      "renal\n",
      "üî¢ Embedding (first 5 values): [ 0.00967804 -0.0623491  -0.01758693 -0.0381046  -0.12082586]\n",
      "----------------------------------------\n",
      "üß© Chunk 158:\n",
      "prolonged \n",
      "and \n",
      "the\n",
      "CONTRAINDICATIONS, \n",
      "ADMINISTRATION). \n",
      " \n",
      "renal \n",
      "clearance \n",
      "is \n",
      "decreased\n",
      "WARNINGS, \n",
      "PRECAUTIONS,\n",
      " \n",
      "(see \n",
      "Table \n",
      " \n",
      "and \n",
      "D\n",
      "1;\n",
      "OSAGE\n",
      " \n",
      "also \n",
      "see \n",
      "AND \n",
      "Hepatic Impairment \n",
      "No pharmacokinetic studies of metformin have been conducted in patients with hepatic \n",
      "insufficiency (see PRECAUTIONS). \n",
      "Geriatrics \n",
      "Limited data from controlled pharmacokinetic studies of GLUCOPHAGE in healthy elderly\n",
      "üî¢ Embedding (first 5 values): [ 0.01026359 -0.04200837 -0.00319399 -0.00790613 -0.09440883]\n",
      "----------------------------------------\n",
      "üß© Chunk 159:\n",
      "Geriatrics \n",
      "Limited data from controlled pharmacokinetic studies of GLUCOPHAGE in healthy elderly \n",
      "subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, \n",
      "and Cmax is increased, compared to healthy young subjects. From these data, it appears that the \n",
      "change in metformin pharmacokinetics with aging is primarily accounted for by a change in \n",
      "renal function (see Table 1; also see WARNINGS, PRECAUTIONS, and DOSAGE AND \n",
      "ADMINISTRATION). \n",
      "4\n",
      "üî¢ Embedding (first 5 values): [ 0.02152063 -0.02339342 -0.00636276  0.00100962 -0.10221057]\n",
      "----------------------------------------\n",
      "üß© Chunk 160:\n",
      "renal function (see Table 1; also see WARNINGS, PRECAUTIONS, and DOSAGE AND \n",
      "ADMINISTRATION). \n",
      "4\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.01556338 -0.0396753  -0.02944938 -0.10023946 -0.06966948]\n",
      "----------------------------------------\n",
      "üß© Chunk 161:\n",
      "Table 1: Select Mean (¬±S.D.) Metformin Pharmacokinetic Parameters Following Single or \n",
      "Multiple Oral Doses of GLUCOPHAGE \n",
      "Subject Groups: GLUCOPHAGE dosea \n",
      "(number of subjects) \n",
      "Cmax \n",
      "b \n",
      "(¬µg/mL) \n",
      "Tmax \n",
      "c \n",
      "(hrs) \n",
      "Renal Clearance \n",
      "(mL/min) \n",
      "Healthy, nondiabetic adults: \n",
      "500 mg single dose (24) \n",
      "850 mg single dose (74)d \n",
      "850 mg three times daily for 19 dosese (9) \n",
      "1.03 (¬±0.33) \n",
      "1.60 (¬±0.38) \n",
      "2.01 (¬±0.42) \n",
      "2.75 (¬±0.81) \n",
      "2.64 (¬±0.82) \n",
      "1.79 (¬±0.94) \n",
      "600 (¬±132) \n",
      "552 (¬±139) \n",
      "642 (¬±173)\n",
      "üî¢ Embedding (first 5 values): [ 0.0746778  -0.05273787 -0.05201197 -0.03313498 -0.14538421]\n",
      "----------------------------------------\n",
      "üß© Chunk 162:\n",
      "2.01 (¬±0.42) \n",
      "2.75 (¬±0.81) \n",
      "2.64 (¬±0.82) \n",
      "1.79 (¬±0.94) \n",
      "600 (¬±132) \n",
      "552 (¬±139) \n",
      "642 (¬±173) \n",
      "Adults with type 2 diabetes: \n",
      "850 mg single dose (23) \n",
      "850 mg three times daily for 19 dosese (9) \n",
      "1.48 (¬±0.5) \n",
      "1.90 (¬±0.62) \n",
      "3.32 (¬±1.08) \n",
      "2.01 (¬±1.22) \n",
      "491 (¬±138) \n",
      "550 (¬±160) \n",
      "Elderlyf, healthy nondiabetic adults: \n",
      "850 mg single dose (12) \n",
      "2.45 (¬±0.70) \n",
      "2.71 (¬±1.05) \n",
      "412 (¬±98) \n",
      "Renal-impaired adults: \n",
      "850 mg single dose \n",
      "Mild (CLcr \n",
      "g 61-90 mL/min) (5) \n",
      "Moderate (CLcr 31-60 mL/min) (4)\n",
      "üî¢ Embedding (first 5 values): [ 0.07610506 -0.02648535 -0.00778748 -0.03815089 -0.07163305]\n",
      "----------------------------------------\n",
      "üß© Chunk 163:\n",
      "850 mg single dose \n",
      "Mild (CLcr \n",
      "g 61-90 mL/min) (5) \n",
      "Moderate (CLcr 31-60 mL/min) (4) \n",
      "Severe (CLcr 10-30 mL/min) (6) \n",
      "1.86 (¬±0.52) \n",
      "4.12 (¬±1.83) \n",
      "3.93 (¬±0.92) \n",
      "3.20 (¬±0.45) \n",
      "3.75 (¬±0.50) \n",
      "4.01 (¬±1.10) \n",
      "384 (¬±122) \n",
      "108 (¬±57) \n",
      "130 (¬±90) \n",
      "a All doses given fasting except the first 18 doses of the multiple dose studies \n",
      "b Peak plasma concentration \n",
      "c Time to peak plasma concentration \n",
      "d Combined results (average means) of five studies: mean age 32 years (range 23-59 years)\n",
      "üî¢ Embedding (first 5 values): [ 0.06650173 -0.03625599 -0.00663446 -0.06828962 -0.10361864]\n",
      "----------------------------------------\n",
      "üß© Chunk 164:\n",
      "d Combined results (average means) of five studies: mean age 32 years (range 23-59 years) \n",
      "e Kinetic study done following dose 19, given fasting \n",
      "f Elderly subjects, mean age 71 years (range 65-81 years) \n",
      "g \n",
      "2\n",
      "CLcr = creatinine clearance normalized to body surface area of 1.73 m\n",
      "Pediatrics \n",
      "After administration of a single oral GLUCOPHAGE 500 mg tablet with food, geometric mean \n",
      "metformin Cmax and AUC differed less than 5% between pediatric type 2 diabetic patients\n",
      "üî¢ Embedding (first 5 values): [ 0.01087327 -0.0593524  -0.00427037 -0.0341877  -0.07441864]\n",
      "----------------------------------------\n",
      "üß© Chunk 165:\n",
      "metformin Cmax and AUC differed less than 5% between pediatric type 2 diabetic patients \n",
      "(12-16 years of age) and gender- and weight-matched healthy adults (20-45 years of age), all \n",
      "with normal renal function. \n",
      "Gender \n",
      "Metformin pharmacokinetic parameters did not differ significantly between normal subjects and \n",
      "patients with type 2 diabetes when analyzed according to gender (males = 19, females = 16). \n",
      "5\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "üî¢ Embedding (first 5 values): [-0.01717849 -0.04171947 -0.03928874  0.05098187 -0.07418792]\n",
      "----------------------------------------\n",
      "üß© Chunk 166:\n",
      "5\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.00341912 -0.09363873 -0.09272373 -0.03440183  0.02011238]\n",
      "----------------------------------------\n",
      "üß© Chunk 167:\n",
      "Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic \n",
      "effect of GLUCOPHAGE was comparable in males and females. \n",
      "Race \n",
      "No studies of metformin pharmacokinetic parameters according to race have been performed. In \n",
      "controlled clinical studies of GLUCOPHAGE in patients with type 2 diabetes, the \n",
      "antihyperglycemic effect was comparable in whites (n=249), blacks (n=51), and Hispanics \n",
      "(n=24). \n",
      "Clinical Studies \n",
      "GLUCOPHAGE\n",
      "üî¢ Embedding (first 5 values): [-0.00052823 -0.02135046 -0.03501208  0.01469829 -0.11004446]\n",
      "----------------------------------------\n",
      "üß© Chunk 168:\n",
      "(n=24). \n",
      "Clinical Studies \n",
      "GLUCOPHAGE \n",
      "In a double-blind, placebo-controlled, multicenter US clinical trial involving obese patients with \n",
      "type 2 diabetes whose hyperglycemia was not adequately controlled with dietary management \n",
      "alone (baseline fasting plasma glucose [FPG] of approximately 240 mg/dL), treatment with \n",
      "GLUCOPHAGE (up to 2550 mg/day) for 29 weeks resulted in significant mean net reductions in \n",
      "fasting and postprandial plasma glucose (PPG) and hemoglobin A1c (HbA1c) of 59 mg/dL,\n",
      "üî¢ Embedding (first 5 values): [-0.00278149  0.00186913 -0.01282756  0.01398093 -0.11891569]\n",
      "----------------------------------------\n",
      "üß© Chunk 169:\n",
      "fasting and postprandial plasma glucose (PPG) and hemoglobin A1c (HbA1c) of 59 mg/dL, \n",
      "83 mg/dL, and 1.8%, respectively, compared to the placebo group (see Table 2). \n",
      "Table 2: GLUCOPHAGE vs Placebo Summary of Mean Changes from Baseline* in \n",
      "Fasting Plasma Glucose, HbA1c, and Body Weight, at Final Visit (29-week study) \n",
      "GLUCOPHAGE \n",
      "(n=141) \n",
      "Placebo \n",
      "(n=145) \n",
      "p-Value \n",
      "FPG (mg/dL) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "241.5 \n",
      "‚Äì53.0 \n",
      "237.7 \n",
      "6.3 \n",
      "NS** \n",
      "0.001 \n",
      "Hemoglobin A1c (%) \n",
      "Baseline\n",
      "üî¢ Embedding (first 5 values): [ 0.01670123 -0.0153301  -0.06747765 -0.01269857 -0.08254722]\n",
      "----------------------------------------\n",
      "üß© Chunk 170:\n",
      "Change at FINAL VISIT \n",
      "241.5 \n",
      "‚Äì53.0 \n",
      "237.7 \n",
      "6.3 \n",
      "NS** \n",
      "0.001 \n",
      "Hemoglobin A1c (%) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "8.4 \n",
      "‚Äì1.4 \n",
      "8.2 \n",
      "0.4 \n",
      "NS** \n",
      "0.001 \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "201.0 \n",
      "‚Äì1.4 \n",
      "206.0 \n",
      "‚Äì2.4 \n",
      "NS** \n",
      "NS** \n",
      "* All patients on diet therapy at Baseline \n",
      "** Not statistically significant \n",
      "A 29-week, double-blind, placebo-controlled study of GLUCOPHAGE and glyburide, alone and\n",
      "üî¢ Embedding (first 5 values): [ 0.05035253 -0.02888064 -0.02174209  0.02696878 -0.09398954]\n",
      "----------------------------------------\n",
      "üß© Chunk 171:\n",
      "A 29-week, double-blind, placebo-controlled study of GLUCOPHAGE and glyburide, alone and \n",
      "in combination, was conducted in obese patients with type 2 diabetes who had failed to achieve \n",
      "adequate glycemic control while on maximum doses of glyburide (baseline FPG of \n",
      "approximately 250 mg/dL) (see Table 3). Patients randomized to the combination arm started \n",
      "therapy with GLUCOPHAGE 500 mg and glyburide 20 mg. At the end of each week of the first\n",
      "üî¢ Embedding (first 5 values): [ 0.06698947 -0.00150075 -0.04636235  0.02977374 -0.11168712]\n",
      "----------------------------------------\n",
      "üß© Chunk 172:\n",
      "therapy with GLUCOPHAGE 500 mg and glyburide 20 mg. At the end of each week of the first \n",
      "4 weeks of the trial, these patients had their dosages of GLUCOPHAGE increased by 500 mg if \n",
      "they had failed to reach target fasting plasma glucose. After week 4, such dosage adjustments \n",
      "6\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.02387492 -0.00200739 -0.07214343 -0.0172851  -0.1253373 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 173:\n",
      "were made monthly, although no patient was allowed to exceed GLUCOPHAGE 2500 mg. \n",
      "Patients in the GLUCOPHAGE only arm (metformin plus placebo) followed the same titration \n",
      "schedule. At the end of the trial, approximately 70% of the patients in the combination group \n",
      "were taking GLUCOPHAGE 2000 mg/glyburide 20 mg or GLUCOPHAGE 2500 mg/glyburide \n",
      "20 mg. Patients randomized to continue on glyburide experienced worsening of glycemic\n",
      "üî¢ Embedding (first 5 values): [ 0.053172   -0.01553415 -0.03483782  0.01596358 -0.11695798]\n",
      "----------------------------------------\n",
      "üß© Chunk 174:\n",
      "20 mg. Patients randomized to continue on glyburide experienced worsening of glycemic \n",
      "control, with mean increases in FPG, PPG, and HbA1c of 14 mg/dL, 3 mg/dL, and 0.2%, \n",
      "respectively. In contrast, those randomized to GLUCOPHAGE (up to 2500 mg/day) experienced \n",
      "a slight improvement, with mean reductions in FPG, PPG, and HbA1c of 1 mg/dL, 6 mg/dL, and \n",
      "0.4%, respectively. The combination of GLUCOPHAGE and glyburide was effective in reducing\n",
      "üî¢ Embedding (first 5 values): [ 0.04916945 -0.00178577 -0.00773116  0.02929534 -0.10192264]\n",
      "----------------------------------------\n",
      "üß© Chunk 175:\n",
      "0.4%, respectively. The combination of GLUCOPHAGE and glyburide was effective in reducing \n",
      "FPG, PPG, and HbA1c levels by 63 mg/dL, 65 mg/dL, and 1.7%, respectively. Compared to \n",
      "results of glyburide treatment alone, the net differences with combination treatment were \n",
      "‚Äì77 mg/dL, ‚Äì68 mg/dL, and ‚Äì1.9%, respectively (see Table 3). \n",
      "Table 3: Combined GLUCOPHAGE/Glyburide (Comb) vs Glyburide (Glyb) or \n",
      "GLUCOPHAGE (GLU) Monotherapy: Summary of Mean Changes from Baseline* in\n",
      "üî¢ Embedding (first 5 values): [ 0.03051274 -0.02824433 -0.00347673 -0.01378789 -0.13439444]\n",
      "----------------------------------------\n",
      "üß© Chunk 176:\n",
      "GLUCOPHAGE (GLU) Monotherapy: Summary of Mean Changes from Baseline* in \n",
      "Fasting Plasma Glucose, HbA1c, and Body Weight, at Final Visit (29-week study) \n",
      "Comb \n",
      "(n=213) \n",
      "Glyb \n",
      "(n=209) \n",
      "GLU \n",
      "(n=210) \n",
      "p-values \n",
      "Glyb vs \n",
      "Comb \n",
      "GLU vs \n",
      "Comb \n",
      "GLU vs \n",
      "Glyb \n",
      "Fasting Plasma Glucose (mg/dL) \n",
      "Baseline \n",
      "250.5 \n",
      "247.5 \n",
      "253.9 \n",
      "NS** \n",
      "NS** \n",
      "NS** \n",
      "Change at FINAL VISIT \n",
      "‚Äì63.5 \n",
      "13.7 \n",
      "‚Äì0.9 \n",
      "0.001 \n",
      "0.001 \n",
      "0.025 \n",
      "Hemoglobin A1c (%) \n",
      "Baseline \n",
      "8.8 \n",
      "8.5 \n",
      "8.9 \n",
      "NS** \n",
      "NS** \n",
      "0.007 \n",
      "Change at FINAL VISIT \n",
      "‚Äì1.7 \n",
      "0.2 \n",
      "‚Äì0.4\n",
      "üî¢ Embedding (first 5 values): [-0.01266506 -0.0346708  -0.02660992 -0.00150701 -0.11320128]\n",
      "----------------------------------------\n",
      "üß© Chunk 177:\n",
      "Baseline \n",
      "8.8 \n",
      "8.5 \n",
      "8.9 \n",
      "NS** \n",
      "NS** \n",
      "0.007 \n",
      "Change at FINAL VISIT \n",
      "‚Äì1.7 \n",
      "0.2 \n",
      "‚Äì0.4 \n",
      "0.001 \n",
      "0.001 \n",
      "0.001 \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "202.2 \n",
      "203.0 \n",
      "204.0 \n",
      "NS** \n",
      "NS** \n",
      "NS** \n",
      "Change at FINAL VISIT \n",
      "0.9 \n",
      "‚Äì0.7 \n",
      "‚Äì8.4 \n",
      "0.011 \n",
      "0.001 \n",
      "0.001 \n",
      "* All patients on glyburide, 20 mg/day, at Baseline \n",
      "** Not statistically significant \n",
      "The magnitude of the decline in fasting blood glucose concentration following the institution of\n",
      "üî¢ Embedding (first 5 values): [ 0.04388014  0.01428525 -0.04939761  0.03797249 -0.0610274 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 178:\n",
      "The magnitude of the decline in fasting blood glucose concentration following the institution of \n",
      "GLUCOPHAGE Tablets therapy was proportional to the level of fasting hyperglycemia. Patients \n",
      "with type 2 diabetes with higher fasting glucose concentrations experienced greater declines in \n",
      "plasma glucose and glycosylated hemoglobin. \n",
      "In clinical studies, GLUCOPHAGE, alone or in combination with a sulfonylurea, lowered mean\n",
      "üî¢ Embedding (first 5 values): [ 0.02322218 -0.02604811 -0.05610903  0.00972536 -0.11692769]\n",
      "----------------------------------------\n",
      "üß© Chunk 179:\n",
      "In clinical studies, GLUCOPHAGE, alone or in combination with a sulfonylurea, lowered mean \n",
      "fasting serum triglycerides, total cholesterol, and LDL cholesterol levels, and had no adverse \n",
      "effects on other lipid levels (see Table 4). \n",
      "7\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.02300038 -0.10073487 -0.06676547 -0.01162172 -0.11347534]\n",
      "----------------------------------------\n",
      "üß© Chunk 180:\n",
      "Table 4: Summary of Mean Percent Change From Baseline of Major Serum Lipid \n",
      "Variables at Final Visit (29-week studies) \n",
      "GLUCOPHAGE vs \n",
      "Placebo \n",
      "Combined GLUCOPHAGE/Glyburide \n",
      "vs Monotherapy \n",
      "GLUCOPHAGE \n",
      "(n=141) \n",
      "Placebo \n",
      "(n=145) \n",
      "GLUCOPHAGE \n",
      "(n=210) \n",
      "GLUCOPHAGE/ \n",
      "Glyburide \n",
      "(n=213) \n",
      "Glyburide \n",
      "(n=209) \n",
      "Total Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "211.0 \n",
      "‚Äì5% \n",
      "212.3 \n",
      "1% \n",
      "213.1 \n",
      "‚Äì2% \n",
      "215.6 \n",
      "‚Äì4% \n",
      "219.6 \n",
      "1% \n",
      "Total Triglycerides (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT\n",
      "üî¢ Embedding (first 5 values): [ 0.06520429 -0.10718195 -0.04385585 -0.00807953 -0.08734001]\n",
      "----------------------------------------\n",
      "üß© Chunk 181:\n",
      "‚Äì2% \n",
      "215.6 \n",
      "‚Äì4% \n",
      "219.6 \n",
      "1% \n",
      "Total Triglycerides (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "236.1 \n",
      "‚Äì16% \n",
      "203.5 \n",
      "1% \n",
      "242.5 \n",
      "‚Äì3% \n",
      "215.0 \n",
      "‚Äì8% \n",
      "266.1 \n",
      "4% \n",
      "LDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "135.4 \n",
      "‚Äì8% \n",
      "138.5 \n",
      "1% \n",
      "134.3 \n",
      "‚Äì4% \n",
      "136.0 \n",
      "‚Äì6% \n",
      "137.5 \n",
      "3% \n",
      "HDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "39.0 \n",
      "2% \n",
      "40.5 \n",
      "‚Äì1% \n",
      "37.2 \n",
      "5% \n",
      "39.0 \n",
      "3% \n",
      "37.0 \n",
      "1% \n",
      "In contrast to sulfonylureas, body weight of individuals on GLUCOPHAGE tended to remain\n",
      "üî¢ Embedding (first 5 values): [ 0.02502072 -0.12762253 -0.05052093  0.01873876 -0.08838958]\n",
      "----------------------------------------\n",
      "üß© Chunk 182:\n",
      "37.0 \n",
      "1% \n",
      "In contrast to sulfonylureas, body weight of individuals on GLUCOPHAGE tended to remain \n",
      "stable or even decrease somewhat (see Tables 2 and 3). \n",
      "A 24-week, double-blind, placebo-controlled study of GLUCOPHAGE plus insulin versus \n",
      "insulin plus placebo was conducted in patients with type 2 diabetes who failed to achieve \n",
      "adequate glycemic control on insulin alone (see Table 5). Patients randomized to receive\n",
      "üî¢ Embedding (first 5 values): [ 0.01363015 -0.04120502 -0.06530925  0.0667968  -0.12902309]\n",
      "----------------------------------------\n",
      "üß© Chunk 183:\n",
      "adequate glycemic control on insulin alone (see Table 5). Patients randomized to receive \n",
      "GLUCOPHAGE plus insulin achieved a reduction in HbA1c of 2.10%, compared to a 1.56% \n",
      "reduction in HbA1c achieved by insulin plus placebo. The improvement in glycemic control was \n",
      "achieved at the final study visit with 16% less insulin, 93.0 U/day vs 110.6 U/day, \n",
      "GLUCOPHAGE plus insulin versus insulin plus placebo, respectively, p=0.04. \n",
      "8\n",
      "Reference ID: 4079189\n",
      "üî¢ Embedding (first 5 values): [-0.00257058  0.02579121 -0.05751552  0.03727894 -0.08073347]\n",
      "----------------------------------------\n",
      "üß© Chunk 184:\n",
      "8\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.00499648 -0.08104096 -0.09175495 -0.03082243  0.00740218]\n",
      "----------------------------------------\n",
      "üß© Chunk 185:\n",
      "Table 5: Combined GLUCOPHAGE/Insulin vs Placebo/Insulin Summary of Mean \n",
      "Changes from Baseline in HbA1c and Daily Insulin Dose \n",
      "GLUCOPHAGE/ \n",
      "Insulin \n",
      "(n=26) \n",
      "Placebo/ \n",
      "Insulin \n",
      "(n=28) \n",
      "Treatment \n",
      "Difference \n",
      "Mean ¬± SE \n",
      "Hemoglobin A1c (%) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "8.95 \n",
      "‚Äì2.10 \n",
      "9.32 \n",
      "‚Äì1.56 \n",
      "‚Äì0.54 ¬± 0.43a \n",
      "Insulin Dose (U/day) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "93.12 \n",
      "‚Äì0.15 \n",
      "94.64 \n",
      "15.93 \n",
      "‚Äì16.08 ¬± 7.77b\n",
      "üî¢ Embedding (first 5 values): [ 0.02663681 -0.027401   -0.05999853 -0.01691778 -0.06731951]\n",
      "----------------------------------------\n",
      "üß© Chunk 186:\n",
      "Insulin Dose (U/day) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "93.12 \n",
      "‚Äì0.15 \n",
      "94.64 \n",
      "15.93 \n",
      "‚Äì16.08 ¬± 7.77b \n",
      "a Statistically significant using analysis of covariance with baseline as covariate (p=0.04)  \n",
      "Not significant using analysis of variance (values shown in table)  \n",
      "b Statistically significant for insulin (p=0.04) \n",
      "A second double-blind, placebo-controlled study (n=51), with 16 weeks of randomized \n",
      "treatment, demonstrated that in patients with type 2 diabetes controlled on insulin for 8 weeks\n",
      "üî¢ Embedding (first 5 values): [ 0.09125267  0.04366067 -0.01866142  0.05684235 -0.0181011 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 187:\n",
      "treatment, demonstrated that in patients with type 2 diabetes controlled on insulin for 8 weeks \n",
      "with an average HbA1c of 7.46 ¬± 0.97%, the addition of GLUCOPHAGE maintained similar \n",
      "glycemic control (HbA1c 7.15 ¬± 0.61 vs 6.97 ¬± 0.62 for GLUCOPHAGE plus insulin and \n",
      "placebo plus insulin, respectively) with 19% less insulin versus baseline (reduction of 23.68 ¬± \n",
      "30.22 vs an increase of 0.43 ¬± 25.20 units for GLUCOPHAGE plus insulin and placebo plus\n",
      "üî¢ Embedding (first 5 values): [ 0.0021613  -0.00762861 -0.05545791  0.02392734 -0.11829328]\n",
      "----------------------------------------\n",
      "üß© Chunk 188:\n",
      "30.22 vs an increase of 0.43 ¬± 25.20 units for GLUCOPHAGE plus insulin and placebo plus \n",
      "insulin, p<0.01). In addition, this study demonstrated that the combination of GLUCOPHAGE \n",
      "plus insulin resulted in reduction in body weight of 3.11 ¬± 4.30 lbs, compared to an increase of \n",
      "1.30 ¬± 6.08 lbs for placebo plus insulin, p=0.01. \n",
      "GLUCOPHAGE XR \n",
      "A 24-week, double-blind, placebo-controlled study of GLUCOPHAGE XR, taken once daily\n",
      "üî¢ Embedding (first 5 values): [ 0.01088487  0.0019009  -0.04561469  0.02640087 -0.0785197 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 189:\n",
      "A 24-week, double-blind, placebo-controlled study of GLUCOPHAGE XR, taken once daily \n",
      "with the evening meal, was conducted in patients with type 2 diabetes who had failed to achieve \n",
      "glycemic control with diet and exercise (HbA1c 7.0%-10.0%, FPG 126-270 mg/dL). Patients \n",
      "entering the study had a mean baseline HbA1c of 8.0% and a mean baseline FPG of 176 mg/dL. \n",
      "After 12 weeks treatment, mean HbA1c had increased from baseline by 0.1% and mean FPG\n",
      "üî¢ Embedding (first 5 values): [ 0.00936125 -0.01267381 -0.05083661 -0.00521632 -0.11513679]\n",
      "----------------------------------------\n",
      "üß© Chunk 190:\n",
      "After 12 weeks treatment, mean HbA1c had increased from baseline by 0.1% and mean FPG \n",
      "decreased from baseline by 2 mg/dL in the placebo group, compared with a decrease in mean \n",
      "HbA1c of 0.6% and a decrease in mean FPG of 23 mg/dL in patients treated with \n",
      "GLUCOPHAGE XR 1000 mg once daily. Subsequently, the treatment dose was increased to \n",
      "1500 mg once daily if HbA1c was ‚â•7.0% but <8.0% (patients with HbA1c ‚â•8.0% were\n",
      "üî¢ Embedding (first 5 values): [ 0.02770037 -0.02648983 -0.03817831 -0.05367311 -0.13569857]\n",
      "----------------------------------------\n",
      "üß© Chunk 191:\n",
      "1500 mg once daily if HbA1c was ‚â•7.0% but <8.0% (patients with HbA1c ‚â•8.0% were \n",
      "discontinued from the study). At the final visit (24-week), mean HbA1c had increased 0.2% from \n",
      "baseline in placebo patients and decreased 0.6% with GLUCOPHAGE XR. \n",
      "9\n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.01766578 -0.03372232 -0.08871072 -0.01766659 -0.10168089]\n",
      "----------------------------------------\n",
      "üß© Chunk 192:\n",
      "A 16-week, double-blind, placebo-controlled, dose-response study of GLUCOPHAGE XR, \n",
      "taken once daily with the evening meal or twice daily with meals, was conducted in patients with \n",
      "type 2 diabetes who had failed to achieve glycemic control with diet and exercise (HbA1c 7.0%¬≠\n",
      "11.0%, FPG 126-280 mg/dL). Changes in glycemic control and body weight are shown in Table \n",
      "6. \n",
      "Table 6: Summary of Mean Changes from Baseline* in HbA1c, Fasting Plasma Glucose,\n",
      "üî¢ Embedding (first 5 values): [ 0.01084781  0.00012389 -0.02937721  0.01597806 -0.10309375]\n",
      "----------------------------------------\n",
      "üß© Chunk 193:\n",
      "6. \n",
      "Table 6: Summary of Mean Changes from Baseline* in HbA1c, Fasting Plasma Glucose, \n",
      "and Body Weight at Final Visit (16-week study) \n",
      "GLUCOPHAGE XR \n",
      "Placebo \n",
      "500 mg \n",
      "Once \n",
      "Daily \n",
      "1000 mg \n",
      "Once \n",
      "Daily \n",
      "1500 mg \n",
      "Once \n",
      "Daily \n",
      "2000 mg \n",
      "Once \n",
      "Daily \n",
      "1000 mg \n",
      "Twice \n",
      "Daily \n",
      "Hemoglobin A1c (%) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "p-valuea \n",
      "(n=115) \n",
      "8.2 \n",
      "‚Äì0.4 \n",
      "<0.001 \n",
      "(n=115) \n",
      "8.4 \n",
      "‚Äì0.6 \n",
      "<0.001 \n",
      "(n=111) \n",
      "8.3 \n",
      "‚Äì0.9 \n",
      "<0.001 \n",
      "(n=125) \n",
      "8.4 \n",
      "‚Äì0.8 \n",
      "<0.001 \n",
      "(n=112) \n",
      "8.4 \n",
      "‚Äì1.1 \n",
      "<0.001 \n",
      "(n=111) \n",
      "8.4 \n",
      "0.1 \n",
      "‚Äì\n",
      "üî¢ Embedding (first 5 values): [ 0.00916205 -0.01180431 -0.06229629 -0.00747173 -0.10701036]\n",
      "----------------------------------------\n",
      "üß© Chunk 194:\n",
      "8.3 \n",
      "‚Äì0.9 \n",
      "<0.001 \n",
      "(n=125) \n",
      "8.4 \n",
      "‚Äì0.8 \n",
      "<0.001 \n",
      "(n=112) \n",
      "8.4 \n",
      "‚Äì1.1 \n",
      "<0.001 \n",
      "(n=111) \n",
      "8.4 \n",
      "0.1 \n",
      "‚Äì \n",
      "FPG (mg/dL) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "p-valuea \n",
      "(n=126) \n",
      "182.7 \n",
      "‚Äì15.2 \n",
      "<0.001 \n",
      "(n=118) \n",
      "183.7 \n",
      "‚Äì19.3 \n",
      "<0.001 \n",
      "(n=120) \n",
      "178.9 \n",
      "‚Äì28.5 \n",
      "<0.001 \n",
      "(n=132) \n",
      "181.0 \n",
      "‚Äì29.9 \n",
      "<0.001 \n",
      "(n=122) \n",
      "181.6 \n",
      "‚Äì33.6 \n",
      "<0.001 \n",
      "(n=113) \n",
      "179.6 \n",
      "7.6 \n",
      "‚Äì \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "p-valuea \n",
      "(n=125) \n",
      "192.9 \n",
      "‚Äì1.3 \n",
      "NS** \n",
      "(n=119) \n",
      "191.8 \n",
      "‚Äì1.3 \n",
      "NS** \n",
      "(n=117) \n",
      "188.3 \n",
      "‚Äì0.7 \n",
      "NS** \n",
      "(n=131) \n",
      "195.4 \n",
      "‚Äì1.5\n",
      "üî¢ Embedding (first 5 values): [ 0.0076154   0.02772073 -0.03014058  0.01724525 -0.07178367]\n",
      "----------------------------------------\n",
      "üß© Chunk 195:\n",
      "192.9 \n",
      "‚Äì1.3 \n",
      "NS** \n",
      "(n=119) \n",
      "191.8 \n",
      "‚Äì1.3 \n",
      "NS** \n",
      "(n=117) \n",
      "188.3 \n",
      "‚Äì0.7 \n",
      "NS** \n",
      "(n=131) \n",
      "195.4 \n",
      "‚Äì1.5 \n",
      "NS** \n",
      "(n=119) \n",
      "192.5 \n",
      "‚Äì2.2 \n",
      "NS** \n",
      "(n=113) \n",
      "194.3 \n",
      "‚Äì1.8 \n",
      "‚Äì \n",
      "* All patients on diet therapy at Baseline \n",
      "a All comparisons versus Placebo \n",
      "** Not statistically significant \n",
      "Compared with placebo, improvement in glycemic control was seen at all dose levels of \n",
      "GLUCOPHAGE XR Extended-Release Tablets and treatment was not associated with any\n",
      "üî¢ Embedding (first 5 values): [ 0.01136163 -0.06123713 -0.05143589 -0.05655758 -0.08525445]\n",
      "----------------------------------------\n",
      "üß© Chunk 196:\n",
      "GLUCOPHAGE XR Extended-Release Tablets and treatment was not associated with any \n",
      "significant change in weight (see DOSAGE AND ADMINISTRATION for dosing \n",
      "recommendations for GLUCOPHAGE and GLUCOPHAGE XR). \n",
      "A 24-week, double-blind, randomized study of GLUCOPHAGE XR, taken once daily with the \n",
      "evening meal, and GLUCOPHAGE Tablets, taken twice daily (with breakfast and evening \n",
      "meal), was conducted in patients with type 2 diabetes who had been treated with\n",
      "üî¢ Embedding (first 5 values): [ 0.01953874 -0.0141736  -0.0114865  -0.00290507 -0.08414192]\n",
      "----------------------------------------\n",
      "üß© Chunk 197:\n",
      "meal), was conducted in patients with type 2 diabetes who had been treated with \n",
      "GLUCOPHAGE 500 mg twice daily for at least 8 weeks prior to study entry. The \n",
      "GLUCOPHAGE dose had not necessarily been titrated to achieve a specific level of glycemic \n",
      "control prior to study entry. Patients qualified for the study if HbA1c was ‚â§8.5% and FPG was \n",
      "‚â§200 mg/dL. Changes in glycemic control and body weight are shown in Table 7. \n",
      "10 \n",
      "Reference ID: 4079189\n",
      "üî¢ Embedding (first 5 values): [ 0.04480503  0.02395354 -0.04700144  0.04107535 -0.11657414]\n",
      "----------------------------------------\n",
      "üß© Chunk 198:\n",
      "10 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.00335568 -0.08908005 -0.10223844 -0.04214799  0.01283978]\n",
      "----------------------------------------\n",
      "üß© Chunk 199:\n",
      "Table 7: Summary of Mean Changes from Baseline* in HbA1c, Fasting Plasma Glucose, \n",
      "and Body Weight at Week 12 and at Final Visit (24-week study) \n",
      "GLUCOPHAGE \n",
      "500 mg \n",
      "Twice Daily \n",
      "GLUCOPHAGE XR \n",
      "1000 mg \n",
      "Once Daily \n",
      "1500 mg \n",
      "Once Daily \n",
      "Hemoglobin A1c (%) \n",
      "(n=67) \n",
      "(n=72) \n",
      "(n=66) \n",
      "Baseline \n",
      "7.06 \n",
      "6.99 \n",
      "7.02 \n",
      "Change at 12 Weeks \n",
      "0.14 \n",
      "0.23 \n",
      "0.04 \n",
      "(95% CI) \n",
      "(‚Äì0.03, 0.31) \n",
      "(0.10, 0.36) \n",
      "(‚Äì0.08, 0.15) \n",
      "Change at FINAL VISIT \n",
      "0.14a \n",
      "0.27 \n",
      "0.13 \n",
      "(95% CI) \n",
      "(‚Äì0.04, 0.31) \n",
      "(0.11, 0.43) \n",
      "(‚Äì0.02, 0.28)\n",
      "üî¢ Embedding (first 5 values): [ 0.02521822 -0.01605239 -0.03952138  0.00842376 -0.09807886]\n",
      "----------------------------------------\n",
      "üß© Chunk 200:\n",
      "Change at FINAL VISIT \n",
      "0.14a \n",
      "0.27 \n",
      "0.13 \n",
      "(95% CI) \n",
      "(‚Äì0.04, 0.31) \n",
      "(0.11, 0.43) \n",
      "(‚Äì0.02, 0.28) \n",
      "FPG (mg/dL) \n",
      "(n=69) \n",
      "(n=72) \n",
      "(n=70) \n",
      "Baseline \n",
      "127.2 \n",
      "131.0 \n",
      "131.4 \n",
      "Change at 12 Weeks \n",
      "12.9 \n",
      "9.5 \n",
      "3.7 \n",
      "(95% CI) \n",
      "(6.5, 19.4) \n",
      "(4.4, 14.6) \n",
      "(‚Äì0.4, 7.8) \n",
      "Change at FINAL VISIT \n",
      "14.0 \n",
      "11.5 \n",
      "7.6 \n",
      "(95% CI) \n",
      "(7.0, 21.0) \n",
      "(4.4, 18.6) \n",
      "(1.0, 14.2) \n",
      "Body Weight (lbs) \n",
      "(n=71) \n",
      "(n=74) \n",
      "(n=71) \n",
      "Baseline \n",
      "210.3 \n",
      "202.8 \n",
      "192.7 \n",
      "Change at 12 Weeks \n",
      "0.4 \n",
      "0.9 \n",
      "0.7 \n",
      "(95% CI) \n",
      "(‚Äì0.4, 1.5) \n",
      "(0.0, 2.0) \n",
      "(‚Äì0.4, 1.8)\n",
      "üî¢ Embedding (first 5 values): [ 0.0005874   0.05020889  0.04143443  0.03554309 -0.04453992]\n",
      "----------------------------------------\n",
      "üß© Chunk 201:\n",
      "202.8 \n",
      "192.7 \n",
      "Change at 12 Weeks \n",
      "0.4 \n",
      "0.9 \n",
      "0.7 \n",
      "(95% CI) \n",
      "(‚Äì0.4, 1.5) \n",
      "(0.0, 2.0) \n",
      "(‚Äì0.4, 1.8) \n",
      "Change at FINAL VISIT \n",
      "0.9 \n",
      "1.1 \n",
      "0.9 \n",
      "(95% CI) \n",
      "(‚Äì0.4, 2.2) \n",
      "(‚Äì0.2, 2.4) \n",
      "(‚Äì0.4, 2.0) \n",
      "* All patients on GLUCOPHAGE 500 mg twice daily at Baseline \n",
      "a n=68 \n",
      "After 12 weeks of treatment, there was an increase in mean HbA1c in all groups; in the \n",
      "GLUCOPHAGE XR 1000 mg group, the increase from baseline of 0.23% was statistically \n",
      "significant (see DOSAGE AND ADMINISTRATION).\n",
      "üî¢ Embedding (first 5 values): [ 0.03519171 -0.05458881 -0.01726463 -0.02411122 -0.14387979]\n",
      "----------------------------------------\n",
      "üß© Chunk 202:\n",
      "significant (see DOSAGE AND ADMINISTRATION). \n",
      "Changes in lipid parameters in the previously described placebo-controlled dose-response study \n",
      "of GLUCOPHAGE XR are shown in Table 8. \n",
      "11 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.00128273 -0.07228452 -0.07129665 -0.04417802 -0.05607388]\n",
      "----------------------------------------\n",
      "üß© Chunk 203:\n",
      "Table 8: Summary of Mean Percent Changes from Baseline* in Major Lipid Variables at \n",
      "Final Visit (16-week study) \n",
      "GLUCOPHAGE XR \n",
      "Placebo \n",
      "500 mg \n",
      "Once \n",
      "Daily \n",
      "1000 mg \n",
      "Once \n",
      "Daily \n",
      "1500 mg \n",
      "Once \n",
      "Daily \n",
      "2000 mg \n",
      "Once \n",
      "Daily \n",
      "1000 mg \n",
      "Twice \n",
      "Daily \n",
      "Total Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=120) \n",
      "210.3 \n",
      "1.0% \n",
      "(n=113) \n",
      "218.1 \n",
      "1.7% \n",
      "(n=110) \n",
      "214.6 \n",
      "0.7% \n",
      "(n=126) \n",
      "204.4 \n",
      "‚Äì1.6% \n",
      "(n=117) \n",
      "208.2 \n",
      "‚Äì2.6% \n",
      "(n=110) \n",
      "208.6 \n",
      "2.6% \n",
      "Total Triglycerides (mg/dL) \n",
      "Baseline\n",
      "üî¢ Embedding (first 5 values): [ 0.03707645 -0.10128544 -0.04925539  0.00368643 -0.11112894]\n",
      "----------------------------------------\n",
      "üß© Chunk 204:\n",
      "204.4 \n",
      "‚Äì1.6% \n",
      "(n=117) \n",
      "208.2 \n",
      "‚Äì2.6% \n",
      "(n=110) \n",
      "208.6 \n",
      "2.6% \n",
      "Total Triglycerides (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=120) \n",
      "220.2 \n",
      "14.5% \n",
      "(n=113) \n",
      "211.9 \n",
      "9.4% \n",
      "(n=110) \n",
      "198.0 \n",
      "15.1% \n",
      "(n=126) \n",
      "194.2 \n",
      "14.9% \n",
      "(n=117) \n",
      "179.0 \n",
      "9.4% \n",
      "(n=110) \n",
      "211.7 \n",
      "10.9% \n",
      "LDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=119) \n",
      "131.0 \n",
      "‚Äì1.4% \n",
      "(n=113) \n",
      "134.9 \n",
      "‚Äì1.6% \n",
      "(n=109) \n",
      "135.8 \n",
      "‚Äì3.5% \n",
      "(n=126) \n",
      "125.8 \n",
      "‚Äì3.3% \n",
      "(n=117) \n",
      "131.4 \n",
      "‚Äì5.5% \n",
      "(n=107) \n",
      "131.9 \n",
      "3.2% \n",
      "HDL-Cholesterol (mg/dL)\n",
      "üî¢ Embedding (first 5 values): [ 0.05330456 -0.113262   -0.0291364  -0.00403055 -0.09096322]\n",
      "----------------------------------------\n",
      "üß© Chunk 205:\n",
      "‚Äì3.5% \n",
      "(n=126) \n",
      "125.8 \n",
      "‚Äì3.3% \n",
      "(n=117) \n",
      "131.4 \n",
      "‚Äì5.5% \n",
      "(n=107) \n",
      "131.9 \n",
      "3.2% \n",
      "HDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=120) \n",
      "40.8 \n",
      "6.2% \n",
      "(n=108) \n",
      "41.6 \n",
      "8.6% \n",
      "(n=108) \n",
      "40.6 \n",
      "5.5% \n",
      "(n=125) \n",
      "40.2 \n",
      "6.1% \n",
      "(n=117) \n",
      "42.4 \n",
      "7.1% \n",
      "(n=108) \n",
      "39.4 \n",
      "5.8% \n",
      "* All patients on diet therapy at Baseline \n",
      "Changes in lipid parameters in the previously described study of GLUCOPHAGE and \n",
      "GLUCOPHAGE XR are shown in Table 9. \n",
      "12 \n",
      "Reference ID: 4079189\n",
      "üî¢ Embedding (first 5 values): [-0.02318617 -0.10899135 -0.05072702 -0.00378206 -0.13666598]\n",
      "----------------------------------------\n",
      "üß© Chunk 206:\n",
      "GLUCOPHAGE XR are shown in Table 9. \n",
      "12 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.01130664 -0.11028975 -0.07500921 -0.0892731   0.00135476]\n",
      "----------------------------------------\n",
      "üß© Chunk 207:\n",
      "Table 9: Summary of Mean Percent Changes from Baseline* in Major Lipid Variables at \n",
      "Final Visit (24-week study) \n",
      "GLUCOPHAGE \n",
      "GLUCOPHAGE XR \n",
      "500 mg \n",
      "Twice Daily \n",
      "1000 mg \n",
      "Once Daily \n",
      "1500 mg \n",
      "Once Daily \n",
      "Total Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=68) \n",
      "199.0 \n",
      "0.1% \n",
      "(n=70) \n",
      "201.9 \n",
      "1.3% \n",
      "(n=66) \n",
      "201.6 \n",
      "0.1% \n",
      "Total Triglycerides (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=68) \n",
      "178.0 \n",
      "6.3% \n",
      "(n=70) \n",
      "169.2 \n",
      "25.3% \n",
      "(n=66) \n",
      "206.8 \n",
      "33.4% \n",
      "LDL-Cholesterol (mg/dL)\n",
      "üî¢ Embedding (first 5 values): [ 0.04967785 -0.09355049 -0.03179693  0.01182467 -0.11181613]\n",
      "----------------------------------------\n",
      "üß© Chunk 208:\n",
      "(n=68) \n",
      "178.0 \n",
      "6.3% \n",
      "(n=70) \n",
      "169.2 \n",
      "25.3% \n",
      "(n=66) \n",
      "206.8 \n",
      "33.4% \n",
      "LDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=68) \n",
      "122.1 \n",
      "‚àí1.3% \n",
      "(n=70) \n",
      "126.2 \n",
      "‚àí3.3% \n",
      "(n=66) \n",
      "115.7 \n",
      "‚àí3.7% \n",
      "HDL-Cholesterol (mg/dL) \n",
      "Baseline \n",
      "Mean % Change at FINAL VISIT \n",
      "(n=68) \n",
      "41.9 \n",
      "4.8% \n",
      "(n=70) \n",
      "41.7 \n",
      "1.0% \n",
      "(n=65) \n",
      "44.6 \n",
      "‚Äì2.1% \n",
      "* All patients on GLUCOPHAGE 500 mg twice daily at Baseline \n",
      "Pediatric Clinical Studies\n",
      "üî¢ Embedding (first 5 values): [ 0.01099299 -0.08936824 -0.05171875 -0.01250632 -0.14268214]\n",
      "----------------------------------------\n",
      "üß© Chunk 209:\n",
      "‚Äì2.1% \n",
      "* All patients on GLUCOPHAGE 500 mg twice daily at Baseline \n",
      "Pediatric Clinical Studies \n",
      "In a double-blind, placebo-controlled study in pediatric patients aged 10 to 16 years with type \n",
      "2 diabetes (mean FPG 182.2 mg/dL), treatment with GLUCOPHAGE (up to 2000 mg/day) for \n",
      "up to 16 weeks (mean duration of treatment 11 weeks) resulted in a significant mean net \n",
      "reduction in FPG of 64.3 mg/dL, compared with placebo (see Table 10).\n",
      "üî¢ Embedding (first 5 values): [ 0.01754104 -0.00135098 -0.02098106 -0.00414335 -0.1244001 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 210:\n",
      "reduction in FPG of 64.3 mg/dL, compared with placebo (see Table 10). \n",
      "Table 10: GLUCOPHAGE vs Placebo (Pediatricsa) Summary of Mean Changes from \n",
      "Baseline* in Plasma Glucose and Body Weight at Final Visit \n",
      "GLUCOPHAGE \n",
      "Placebo \n",
      "p-Value \n",
      "FPG (mg/dL) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "(n=37) \n",
      "162.4 \n",
      "‚Äì42.9 \n",
      "(n=36) \n",
      "192.3 \n",
      "21.4 \n",
      "<0.001 \n",
      "Body Weight (lbs) \n",
      "Baseline \n",
      "Change at FINAL VISIT \n",
      "(n=39) \n",
      "205.3 \n",
      "‚Äì3.3 \n",
      "(n=38) \n",
      "189.0 \n",
      "‚Äì2.0 \n",
      "NS** \n",
      "a Pediatric patients mean age 13.8 years (range 10-16 years)\n",
      "üî¢ Embedding (first 5 values): [ 0.01640762  0.02513199 -0.04104125 -0.03373253 -0.08044627]\n",
      "----------------------------------------\n",
      "üß© Chunk 211:\n",
      "‚Äì3.3 \n",
      "(n=38) \n",
      "189.0 \n",
      "‚Äì2.0 \n",
      "NS** \n",
      "a Pediatric patients mean age 13.8 years (range 10-16 years) \n",
      "* All patients on diet therapy at Baseline \n",
      "** Not statistically significant \n",
      "INDICATIONS AND USAGE \n",
      "GLUCOPHAGE (metformin hydrochloride) Tablets is indicated as an adjunct to diet and \n",
      "exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. \n",
      "13 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "üî¢ Embedding (first 5 values): [-0.03659649 -0.02377756 -0.05807177 -0.01710254 -0.09205838]\n",
      "----------------------------------------\n",
      "üß© Chunk 212:\n",
      "13 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.01095217 -0.07442771 -0.10870617 -0.05344499  0.00710505]\n",
      "----------------------------------------\n",
      "üß© Chunk 213:\n",
      "GLUCOPHAGE XR (metformin hydrochloride) Extended-Release Tablets is indicated as an \n",
      "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. \n",
      "CONTRAINDICATIONS \n",
      "GLUCOPHAGE and GLUCOPHAGE XR are contraindicated in patients with: \n",
      "1.  Severe renal impairment (eGFR below 30 mL/min/1.73 m2) (see WARNINGS and \n",
      "PRECAUTIONS). \n",
      "2.  Known hypersensitivity to metformin hydrochloride.\n",
      "üî¢ Embedding (first 5 values): [-0.05543121 -0.03191112 -0.01870523 -0.04135575 -0.0219758 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 214:\n",
      "PRECAUTIONS). \n",
      "2.  Known hypersensitivity to metformin hydrochloride. \n",
      "3.  Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without \n",
      "coma. Diabetic ketoacidosis should be treated with insulin. \n",
      "WARNINGS \n",
      "WARNING: LACTIC ACIDOSIS \n",
      "Postmarketing cases of metformin-associated lactic acidosis have resulted in death, \n",
      "hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin¬≠\n",
      "üî¢ Embedding (first 5 values): [-0.00178438 -0.03211089 -0.04186475  0.01109864  0.02195988]\n",
      "----------------------------------------\n",
      "üß© Chunk 215:\n",
      "hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin¬≠\n",
      "associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such \n",
      "as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin¬≠\n",
      "associated \n",
      "lactic \n",
      "acidosis \n",
      "was \n",
      "characterized \n",
      "by \n",
      "elevated \n",
      "blood \n",
      "lactate \n",
      "levels \n",
      "(>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an\n",
      "üî¢ Embedding (first 5 values): [ 0.0161604  -0.0746462   0.00375672  0.08742507  0.0093819 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 216:\n",
      "levels \n",
      "(>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an \n",
      "increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL (see \n",
      "PRECAUTIONS). \n",
      "Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use \n",
      "of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or \n",
      "greater, having a radiological study with contrast, surgery and other procedures, hypoxic states\n",
      "üî¢ Embedding (first 5 values): [ 0.04571842 -0.08456136 -0.00022151  0.03892141 -0.01775726]\n",
      "----------------------------------------\n",
      "üß© Chunk 217:\n",
      "greater, having a radiological study with contrast, surgery and other procedures, hypoxic states \n",
      "(e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. \n",
      "Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk \n",
      "groups are provided (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, \n",
      "and PRECAUTIONS). \n",
      "If metformin-associated lactic acidosis is suspected, immediately discontinue GLUCOPHAGE or\n",
      "üî¢ Embedding (first 5 values): [ 0.06142177 -0.05119574 -0.00492153  0.03893808 -0.02334514]\n",
      "----------------------------------------\n",
      "üß© Chunk 218:\n",
      "If metformin-associated lactic acidosis is suspected, immediately discontinue GLUCOPHAGE or \n",
      "GLUCOPHAGE XR and institute general supportive measures in a hospital setting. Prompt \n",
      "hemodialysis is recommended (see PRECAUTIONS). \n",
      "14 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.0137251  -0.09482396 -0.01484642 -0.02104051 -0.05564919]\n",
      "----------------------------------------\n",
      "üß© Chunk 219:\n",
      "PRECAUTIONS \n",
      "General \n",
      "‚Ä¢  Lactic acidosis‚ÄîThere have been postmarketing cases of metformin-associated lactic \n",
      "acidosis, including fatal cases. These cases had a subtle onset and were accompanied by \n",
      "nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or \n",
      "increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred \n",
      "with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated\n",
      "üî¢ Embedding (first 5 values): [ 0.05621629 -0.07209852  0.00440236  0.06288648 -0.0107731 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 220:\n",
      "with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated \n",
      "blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria \n",
      "or ketonemia), and an increased lactate:pyruvate ratio; metformin plasma levels were \n",
      "generally >5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood \n",
      "levels which may increase the risk of lactic acidosis, especially in patients at risk.\n",
      "üî¢ Embedding (first 5 values): [ 0.02086987 -0.09129205  0.00854184  0.04278517 -0.01812665]\n",
      "----------------------------------------\n",
      "üß© Chunk 221:\n",
      "levels which may increase the risk of lactic acidosis, especially in patients at risk. \n",
      "If metformin-associated lactic acidosis is suspected, general supportive measures should be \n",
      "instituted promptly in a hospital setting, along with immediate discontinuation of \n",
      "GLUCOPHAGE or GLUCOPHAGE XR. In GLUCOPHAGE or GLUCOPHAGE XR \n",
      "treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is\n",
      "üî¢ Embedding (first 5 values): [ 0.00993319 -0.09331308  0.00057995  0.0126516  -0.05433441]\n",
      "----------------------------------------\n",
      "üß© Chunk 222:\n",
      "treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is \n",
      "recommended to correct the acidosis and remove accumulated metformin (metformin \n",
      "hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic \n",
      "conditions). Hemodialysis has often resulted in reversal of symptoms and recovery. \n",
      "Educate patients and their families about the symptoms of lactic acidosis and, if these\n",
      "üî¢ Embedding (first 5 values): [-0.02978383 -0.0493026   0.03047028  0.01721495 -0.08205494]\n",
      "----------------------------------------\n",
      "üß© Chunk 223:\n",
      "Educate patients and their families about the symptoms of lactic acidosis and, if these \n",
      "symptoms occur, instruct them to discontinue GLUCOPHAGE or GLUCOPHAGE XR and \n",
      "report these symptoms to their healthcare provider. \n",
      "For each of the known and possible risk factors for metformin-associated lactic acidosis, \n",
      "recommendations to reduce the risk of and manage metformin-associated lactic acidosis are \n",
      "provided below:\n",
      "üî¢ Embedding (first 5 values): [ 0.03127436 -0.07324424  0.02016344  0.01665493 -0.02988318]\n",
      "----------------------------------------\n",
      "üß© Chunk 224:\n",
      "provided below: \n",
      "‚Ä¢  Renal impairment‚ÄîThe postmarketing metformin-associated lactic acidosis cases primarily \n",
      "occurred in patients with significant renal impairment. \n",
      "The risk of metformin accumulation and metformin-associated lactic acidosis increases with \n",
      "the severity of renal impairment because metformin is substantially excreted by the kidney.  \n",
      "Clinical recommendations based upon the patient‚Äôs renal function include (see DOSAGE \n",
      "AND ADMINISTRATION, CLINICAL PHARMACOLOGY): \n",
      "15\n",
      "üî¢ Embedding (first 5 values): [ 0.02170993 -0.08078408  0.02580985  0.01935835 -0.05927246]\n",
      "----------------------------------------\n",
      "üß© Chunk 225:\n",
      "AND ADMINISTRATION, CLINICAL PHARMACOLOGY): \n",
      "15 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.013585   -0.08232164 -0.09982585 -0.05099346 -0.0388388 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 226:\n",
      "o  Before initiating GLUCOPHAGE or GLUCOPHAGE XR, obtain an estimated \n",
      "glomerular filtration rate (eGFR) \n",
      "o  GLUCOPHAGE or GLUCOPHAGE XR is contraindicated in patients with an eGFR less \n",
      "than 30 mL/min/1.73 m2 (see CONTRAINDICATIONS). \n",
      "o  Initiation of GLUCOPHAGE or GLUCOPHAGE XR is not recommended in patients \n",
      "with eGFR between 30-45 mL/min/1.73 m2 . \n",
      "o  Obtain an eGFR at least annually in all patients taking GLUCOPHAGE or\n",
      "üî¢ Embedding (first 5 values): [ 0.01587463 -0.00956354  0.00284134 -0.04827603 -0.04385687]\n",
      "----------------------------------------\n",
      "üß© Chunk 227:\n",
      "o  Obtain an eGFR at least annually in all patients taking GLUCOPHAGE or \n",
      "GLUCOPHAGE XR. In patients at risk for the development of renal impairment (e.g., \n",
      "the elderly), renal function should be assessed more frequently. \n",
      "o  In patients taking GLUCOPHAGE or GLUCOPHAGE XR whose eGFR falls below \n",
      "45 mL/min/1.73 m2, assess the benefit and risk of continuing therapy. \n",
      "‚Ä¢  Drug interactions‚ÄîThe concomitant use of GLUCOPHAGE or GLUCOPHAGE XR with\n",
      "üî¢ Embedding (first 5 values): [ 0.03156174 -0.0077827   0.00443071 -0.05848423 -0.05098261]\n",
      "----------------------------------------\n",
      "üß© Chunk 228:\n",
      "‚Ä¢  Drug interactions‚ÄîThe concomitant use of GLUCOPHAGE or GLUCOPHAGE XR with \n",
      "specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair \n",
      "renal function, result in significant hemodynamic change, interfere with acid-base balance, or \n",
      "increase metformin accumulation. Consider more frequent monitoring of patients. \n",
      "‚Ä¢  Age 65 or greater‚ÄîThe risk of metformin-associated lactic acidosis increases with the\n",
      "üî¢ Embedding (first 5 values): [ 0.03937874 -0.08991683 -0.01260643 -0.02267617 -0.05235527]\n",
      "----------------------------------------\n",
      "üß© Chunk 229:\n",
      "‚Ä¢  Age 65 or greater‚ÄîThe risk of metformin-associated lactic acidosis increases with the \n",
      "patient‚Äôs age because elderly patients have a greater likelihood of having hepatic, renal, or \n",
      "cardiac impairment than younger patients. Assess renal function more frequently in elderly \n",
      "patients. \n",
      "‚Ä¢  Radiologic studies with contrast‚ÄîAdministration of intravascular iodinated contrast agents \n",
      "in metformin-treated patients has led to an acute decrease in renal function and the\n",
      "üî¢ Embedding (first 5 values): [ 1.06299199e-01 -6.81331307e-02 -7.11219109e-05  1.18859485e-02\n",
      " -4.02832814e-02]\n",
      "----------------------------------------\n",
      "üß© Chunk 230:\n",
      "in metformin-treated patients has led to an acute decrease in renal function and the \n",
      "occurrence of lactic acidosis. Stop GLUCOPHAGE or GLUCOPHAGE XR at the time of, or \n",
      "prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and \n",
      "60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart \n",
      "failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate\n",
      "üî¢ Embedding (first 5 values): [ 0.06223493 -0.09878691  0.01726156 -0.01995216 -0.02791005]\n",
      "----------------------------------------\n",
      "üß© Chunk 231:\n",
      "failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate \n",
      "eGFR 48 hours after the imaging procedure, and restart GLUCOPHAGE or GLUCOPHAGE \n",
      "XR if renal function is stable. \n",
      "‚Ä¢  Surgery and other procedures‚ÄîWithholding of food and fluids during surgical or other \n",
      "procedures may increase the risk for volume depletion, hypotension, and renal impairment. \n",
      "GLUCOPHAGE or GLUCOPHAGE XR should be temporarily discontinued while patients\n",
      "üî¢ Embedding (first 5 values): [ 0.0392587  -0.01703713  0.04829682 -0.06369745 -0.01034738]\n",
      "----------------------------------------\n",
      "üß© Chunk 232:\n",
      "GLUCOPHAGE or GLUCOPHAGE XR should be temporarily discontinued while patients \n",
      "have restricted food and fluid intake. \n",
      "16 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.00201026 -0.05825622 -0.04481307 -0.07466126 -0.00382512]\n",
      "----------------------------------------\n",
      "üß© Chunk 233:\n",
      "‚Ä¢  Hypoxic states‚ÄîSeveral of the postmarketing cases of metformin-associated lactic acidosis \n",
      "occurred in the setting of acute congestive heart failure (particularly when accompanied by \n",
      "hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial \n",
      "infarction, sepsis, and other conditions associated with hypoxemia have been associated with \n",
      "lactic acidosis and may cause prerenal azotemia. When such an event occurs, discontinue \n",
      "GLUCOPHAGE or GLUCOPHAGE XR.\n",
      "üî¢ Embedding (first 5 values): [ 0.01971866 -0.05903159  0.01516538  0.04328501  0.02176537]\n",
      "----------------------------------------\n",
      "üß© Chunk 234:\n",
      "GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "‚Ä¢  Excessive alcohol intake‚ÄîAlcohol is known to potentiate the effect of metformin on lactate \n",
      "metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or \n",
      "chronic, while receiving GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "‚Ä¢  Hepatic impairment‚ÄîPatients with hepatic impairment have developed cases of metformin¬≠\n",
      "associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher\n",
      "üî¢ Embedding (first 5 values): [ 0.0584977  -0.09950668  0.00144277  0.01000019 -0.03907076]\n",
      "----------------------------------------\n",
      "üß© Chunk 235:\n",
      "associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher \n",
      "lactate blood levels. Therefore, avoid use of GLUCOPHAGE and GLUCOPHAGE XR in \n",
      "patients with clinical or laboratory evidence of hepatic disease. \n",
      "Vitamin B12 levels‚ÄîIn controlled clinical trials of GLUCOPHAGE of 29 weeks duration, a \n",
      "decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical\n",
      "üî¢ Embedding (first 5 values): [ 0.06117854 -0.08201431 -0.04415002 -0.03146086 -0.04317692]\n",
      "----------------------------------------\n",
      "üß© Chunk 236:\n",
      "decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical \n",
      "manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to \n",
      "interference with B12 absorption from the B12-intrinsic factor complex, is, however, very rarely \n",
      "associated with anemia and appears to be rapidly reversible with discontinuation of \n",
      "GLUCOPHAGE or vitamin B12 supplementation. Measurement of hematologic parameters on an\n",
      "üî¢ Embedding (first 5 values): [ 0.003245   -0.03785804 -0.08034608  0.03810333 -0.0591986 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 237:\n",
      "GLUCOPHAGE or vitamin B12 supplementation. Measurement of hematologic parameters on an \n",
      "annual basis is advised in patients on GLUCOPHAGE or GLUCOPHAGE XR and any apparent \n",
      "abnormalities should be appropriately investigated and managed (see PRECAUTIONS: \n",
      "Laboratory Tests). \n",
      "Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to \n",
      "be predisposed to developing subnormal vitamin B12 levels. In these patients, routine serum\n",
      "üî¢ Embedding (first 5 values): [ 0.01247935 -0.01876832 -0.08889784 -0.03736696 -0.07920371]\n",
      "----------------------------------------\n",
      "üß© Chunk 238:\n",
      "be predisposed to developing subnormal vitamin B12 levels. In these patients, routine serum \n",
      "vitamin B12 measurements at 2- to 3-year intervals may be useful. \n",
      "Hypoglycemia‚ÄîHypoglycemia does not occur in patients receiving GLUCOPHAGE or \n",
      "GLUCOPHAGE XR alone under usual circumstances of use, but could occur when caloric \n",
      "intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or\n",
      "üî¢ Embedding (first 5 values): [ 0.03415399 -0.00300727 -0.06452526  0.02187562 -0.05153903]\n",
      "----------------------------------------\n",
      "üß© Chunk 239:\n",
      "intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or \n",
      "during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or \n",
      "ethanol. \n",
      "17 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.04193825 -0.03250521 -0.08609705  0.05053701 -0.03954291]\n",
      "----------------------------------------\n",
      "üß© Chunk 240:\n",
      "Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or \n",
      "alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be \n",
      "difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. \n",
      "Macrovascular outcomes‚ÄîThere have been no clinical studies establishing conclusive evidence \n",
      "of macrovascular risk reduction with GLUCOPHAGE or GLUCOPHAGE XR or any other \n",
      "antidiabetic drug.\n",
      "üî¢ Embedding (first 5 values): [ 0.06565998  0.05103664 -0.04762049  0.04666664 -0.01288006]\n",
      "----------------------------------------\n",
      "üß© Chunk 241:\n",
      "of macrovascular risk reduction with GLUCOPHAGE or GLUCOPHAGE XR or any other \n",
      "antidiabetic drug. \n",
      "Information for Patients \n",
      "Patients should be informed of the potential risks and benefits of GLUCOPHAGE or \n",
      "GLUCOPHAGE XR and of alternative modes of therapy. They should also be informed about \n",
      "the importance of adherence to dietary instructions, of a regular exercise program, and of regular \n",
      "testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters.\n",
      "üî¢ Embedding (first 5 values): [-0.0050456   0.04967615 -0.02531977 -0.02988834 -0.08507819]\n",
      "----------------------------------------\n",
      "üß© Chunk 242:\n",
      "testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters. \n",
      "The risks of lactic acidosis, its symptoms, and conditions that predispose to its development, as \n",
      "noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. \n",
      "Patients should be advised to discontinue GLUCOPHAGE or GLUCOPHAGE XR immediately \n",
      "and to promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise,\n",
      "üî¢ Embedding (first 5 values): [ 0.06900617 -0.04778085 -0.0224327   0.00258708 -0.04393226]\n",
      "----------------------------------------\n",
      "üß© Chunk 243:\n",
      "unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any \n",
      "dose level of GLUCOPHAGE or GLUCOPHAGE XR, gastrointestinal symptoms, which are \n",
      "common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence \n",
      "of gastrointestinal symptoms could be due to lactic acidosis or other serious disease. \n",
      "Patients should be counseled against excessive alcohol intake, either acute or chronic, while \n",
      "receiving GLUCOPHAGE or GLUCOPHAGE XR.\n",
      "üî¢ Embedding (first 5 values): [ 0.04647047 -0.13442665 -0.01996058  0.05168942 -0.02592509]\n",
      "----------------------------------------\n",
      "üß© Chunk 244:\n",
      "receiving GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "GLUCOPHAGE or GLUCOPHAGE XR alone does not usually cause hypoglycemia, although it \n",
      "may occur when GLUCOPHAGE or GLUCOPHAGE XR is used in conjunction with oral \n",
      "sulfonylureas and insulin. When initiating combination therapy, the risks of hypoglycemia, its \n",
      "symptoms and treatment, and conditions that predispose to its development should be explained \n",
      "to patients and responsible family members. (See Patient Information printed below.)\n",
      "üî¢ Embedding (first 5 values): [ 0.00760756 -0.01041123 -0.04940509 -0.02350317 -0.06766579]\n",
      "----------------------------------------\n",
      "üß© Chunk 245:\n",
      "to patients and responsible family members. (See Patient Information printed below.) \n",
      "Patients should be informed that GLUCOPHAGE XR must be swallowed whole and not crushed \n",
      "or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft \n",
      "mass that may resemble the original tablet. \n",
      "18 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.01029902 -0.07689975 -0.09484289 -0.08986731 -0.02624302]\n",
      "----------------------------------------\n",
      "üß© Chunk 246:\n",
      "Laboratory Tests \n",
      "Response to all diabetic therapies should be monitored by periodic measurements of fasting \n",
      "blood glucose and glycosylated hemoglobin levels, with a goal of decreasing these levels toward \n",
      "the normal range. During initial dose titration, fasting glucose can be used to determine the \n",
      "therapeutic response. Thereafter, both glucose and glycosylated hemoglobin should be \n",
      "monitored. Measurements of glycosylated hemoglobin may be especially useful for evaluating\n",
      "üî¢ Embedding (first 5 values): [ 0.00360426  0.01868297 -0.10246115  0.02845727 -0.07200526]\n",
      "----------------------------------------\n",
      "üß© Chunk 247:\n",
      "monitored. Measurements of glycosylated hemoglobin may be especially useful for evaluating \n",
      "long-term control (see also DOSAGE AND ADMINISTRATION). \n",
      "Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red \n",
      "blood cell indices) and renal function (serum creatinine) should be performed, at least on an \n",
      "annual basis. While megaloblastic anemia has rarely been seen with GLUCOPHAGE therapy, if \n",
      "this is suspected, vitamin B12 deficiency should be excluded.\n",
      "üî¢ Embedding (first 5 values): [ 0.00221263 -0.01285523 -0.07595611  0.02402508 -0.07525337]\n",
      "----------------------------------------\n",
      "üß© Chunk 248:\n",
      "this is suspected, vitamin B12 deficiency should be excluded. \n",
      "Instruct patients to inform their doctor that they are taking GLUCOPHAGE or GLUCOPHAGE \n",
      "XR prior to any surgical or radiological procedure, as temporary discontinuation of \n",
      "GLUCOPHAGE or GLUCOPHAGE XR may be required until renal function has been \n",
      "confirmed to be normal (see PRECAUTIONS). \n",
      "Drug Interactions (Clinical Evaluation of Drug Interactions Conducted \n",
      "with GLUCOPHAGE)\n",
      "üî¢ Embedding (first 5 values): [ 0.00596795 -0.00621994 -0.0663636  -0.05587496 -0.05492012]\n",
      "----------------------------------------\n",
      "üß© Chunk 249:\n",
      "Drug Interactions (Clinical Evaluation of Drug Interactions Conducted \n",
      "with GLUCOPHAGE) \n",
      "Glyburide‚ÄîIn a single-dose interaction study in type 2 diabetes patients, coadministration of \n",
      "metformin and glyburide did not result in any changes in either metformin pharmacokinetics or \n",
      "pharmacodynamics. Decreases in glyburide AUC and Cmax were observed, but were highly \n",
      "variable. The single-dose nature of this study and the lack of correlation between glyburide blood\n",
      "üî¢ Embedding (first 5 values): [ 0.01268199 -0.06202472 -0.04755011  0.02763744 -0.11617273]\n",
      "----------------------------------------\n",
      "üß© Chunk 250:\n",
      "variable. The single-dose nature of this study and the lack of correlation between glyburide blood \n",
      "levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain \n",
      "(see \n",
      "DOSAGE \n",
      "AND \n",
      "ADMINISTRATION: \n",
      "Concomitant \n",
      "GLUCOPHAGE \n",
      "or \n",
      "GLUCOPHAGE XR and Oral Sulfonylurea Therapy in Adult Patients). \n",
      "Furosemide‚ÄîA single-dose, metformin-furosemide drug interaction study in healthy subjects\n",
      "üî¢ Embedding (first 5 values): [ 0.09796853 -0.08366884 -0.06041927 -0.00847063 -0.14537343]\n",
      "----------------------------------------\n",
      "üß© Chunk 251:\n",
      "Furosemide‚ÄîA single-dose, metformin-furosemide drug interaction study in healthy subjects \n",
      "demonstrated that pharmacokinetic parameters of both compounds were affected by \n",
      "coadministration. Furosemide increased the metformin plasma and blood Cmax by 22% and blood \n",
      "AUC by 15%, without any significant change in metformin renal clearance. When administered \n",
      "with metformin, the Cmax and AUC of furosemide were 31% and 12% smaller, respectively, than\n",
      "üî¢ Embedding (first 5 values): [ 0.06577182 -0.05724441 -0.04834912  0.00551587 -0.06647886]\n",
      "----------------------------------------\n",
      "üß© Chunk 252:\n",
      "with metformin, the Cmax and AUC of furosemide were 31% and 12% smaller, respectively, than \n",
      "when administered alone, and the terminal half-life was decreased by 32%, without any \n",
      "significant change in furosemide renal clearance. No information is available about the \n",
      "interaction of metformin and furosemide when coadministered chronically. \n",
      "19 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.02992656 -0.05892223 -0.07681195  0.01847334 -0.04113461]\n",
      "----------------------------------------\n",
      "üß© Chunk 253:\n",
      "Nifedipine‚ÄîA single-dose, metformin-nifedipine drug interaction study in normal healthy \n",
      "volunteers demonstrated that coadministration of nifedipine increased plasma metformin Cmax \n",
      "and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. Tmax and \n",
      "half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin \n",
      "had minimal effects on nifedipine. \n",
      "Drugs that reduce metformin clearance‚ÄîConcomitant use of drugs that interfere with common\n",
      "üî¢ Embedding (first 5 values): [-0.01530949 -0.06355838  0.0065381   0.03440627 -0.01479418]\n",
      "----------------------------------------\n",
      "üß© Chunk 254:\n",
      "Drugs that reduce metformin clearance‚ÄîConcomitant use of drugs that interfere with common \n",
      "renal tubular transport systems involved in the renal elimination of metformin (e.g., organic \n",
      "cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as \n",
      "ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to \n",
      "metformin and may increase the risk for lactic acidosis. Consider the benefits and risks of\n",
      "üî¢ Embedding (first 5 values): [ 0.02113644 -0.08059186  0.00744819 -0.01124291 -0.03500395]\n",
      "----------------------------------------\n",
      "üß© Chunk 255:\n",
      "metformin and may increase the risk for lactic acidosis. Consider the benefits and risks of \n",
      "concomitant use. Such interaction between metformin and oral cimetidine has been observed in \n",
      "normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug \n",
      "interaction studies, with a 60% increase in peak metformin plasma and whole blood \n",
      "concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no\n",
      "üî¢ Embedding (first 5 values): [ 0.03393726 -0.09450995 -0.04593794  0.01278418 -0.05645933]\n",
      "----------------------------------------\n",
      "üß© Chunk 256:\n",
      "concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no \n",
      "change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine \n",
      "pharmacokinetics. \n",
      "In healthy volunteers, the pharmacokinetics of metformin and propranolol, and metformin and \n",
      "ibuprofen were not affected when coadministered in single-dose interaction studies. \n",
      "Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with\n",
      "üî¢ Embedding (first 5 values): [-0.01734429 -0.07812249 -0.03450858  0.04494688 -0.01925462]\n",
      "----------------------------------------\n",
      "üß© Chunk 257:\n",
      "Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with \n",
      "highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, \n",
      "as compared to the sulfonylureas, which are extensively bound to serum proteins. \n",
      "Other‚ÄîCertain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. \n",
      "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid\n",
      "üî¢ Embedding (first 5 values): [-0.03960561 -0.08179374 -0.055911    0.02245255 -0.04139696]\n",
      "----------------------------------------\n",
      "üß© Chunk 258:\n",
      "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid \n",
      "products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium \n",
      "channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving \n",
      "GLUCOPHAGE or GLUCOPHAGE XR, the patient should be closely observed for loss of \n",
      "blood glucose control. When such drugs are withdrawn from a patient receiving GLUCOPHAGE\n",
      "üî¢ Embedding (first 5 values): [-0.04075733 -0.01176064 -0.08886877 -0.03835304 -0.07309356]\n",
      "----------------------------------------\n",
      "üß© Chunk 259:\n",
      "blood glucose control. When such drugs are withdrawn from a patient receiving GLUCOPHAGE \n",
      "or GLUCOPHAGE XR, the patient should be observed closely for hypoglycemia. \n",
      "Carbonic \n",
      "anhydrase \n",
      "inhibitors‚ÄîTopiramate \n",
      "or \n",
      "other \n",
      "carbonic \n",
      "anhydrase \n",
      "inhibitors \n",
      "(e.g., zonisamide, acetazolamide or dichlorphenamide) frequently cause a decrease in serum \n",
      "bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of\n",
      "üî¢ Embedding (first 5 values): [-0.01480447  0.0187352  -0.11068913  0.03035665  0.02221987]\n",
      "----------------------------------------\n",
      "üß© Chunk 260:\n",
      "bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of \n",
      "these drugs with GLUCOPHAGE or GLUCOPHAGE XR may increase the risk for lactic \n",
      "acidosis. Consider more frequent monitoring of these patients. \n",
      "20 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.03717727 -0.03964905 -0.07145223 -0.05429678 -0.02123044]\n",
      "----------------------------------------\n",
      "üß© Chunk 261:\n",
      "Alcohol‚ÄîAlcohol is known to potentiate the effect of metformin on lactate metabolism. Warn \n",
      "patients against excessive alcohol intake while receiving GLUCOPHAGE OR GLUCOPHAGE \n",
      "XR. \n",
      "Carcinogenesis, Mutagenesis, Impairment of Fertility \n",
      "Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) \n",
      "and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and\n",
      "üî¢ Embedding (first 5 values): [ 0.03014558 -0.0753383  -0.03970259  0.00561228 -0.02028615]\n",
      "----------------------------------------\n",
      "üß© Chunk 262:\n",
      "and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and \n",
      "1500 mg/kg/day, respectively. These doses are both approximately 4 times the maximum \n",
      "recommended human daily dose of 2000 mg based on body surface area comparisons. No \n",
      "evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, \n",
      "there was no tumorigenic potential observed with metformin in male rats. There was, however,\n",
      "üî¢ Embedding (first 5 values): [ 0.02273267 -0.03443275 -0.00770531  0.01489037 -0.06353125]\n",
      "----------------------------------------\n",
      "üß© Chunk 263:\n",
      "there was no tumorigenic potential observed with metformin in male rats. There was, however, \n",
      "an increased incidence of benign stromal uterine polyps in female rats treated with \n",
      "900 mg/kg/day. \n",
      "There was no evidence of a mutagenic potential of metformin in the following in vitro tests: \n",
      "Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal \n",
      "aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also \n",
      "negative.\n",
      "üî¢ Embedding (first 5 values): [-0.03208163 -0.06464344 -0.00815199  0.01476153 -0.06748995]\n",
      "----------------------------------------\n",
      "üß© Chunk 264:\n",
      "negative. \n",
      "Fertility of male or female rats was unaffected by metformin when administered at doses as high \n",
      "as 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily \n",
      "dose based on body surface area comparisons. \n",
      "Pregnancy \n",
      "Teratogenic Effects: Pregnancy Category B \n",
      "Recent information strongly suggests that abnormal blood glucose levels during pregnancy are \n",
      "associated with a higher incidence of congenital abnormalities. Most experts recommend that\n",
      "üî¢ Embedding (first 5 values): [-0.04220637 -0.03257497 -0.03581737  0.05271569 -0.03815847]\n",
      "----------------------------------------\n",
      "üß© Chunk 265:\n",
      "associated with a higher incidence of congenital abnormalities. Most experts recommend that \n",
      "insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible. \n",
      "Because animal reproduction studies are not always predictive of human response, \n",
      "GLUCOPHAGE and GLUCOPHAGE XR should not be used during pregnancy unless clearly \n",
      "needed. \n",
      "There are no adequate and well-controlled studies in pregnant women with GLUCOPHAGE or\n",
      "üî¢ Embedding (first 5 values): [-0.063798    0.00120943 -0.09317613  0.01982508 -0.00904818]\n",
      "----------------------------------------\n",
      "üß© Chunk 266:\n",
      "needed. \n",
      "There are no adequate and well-controlled studies in pregnant women with GLUCOPHAGE or \n",
      "GLUCOPHAGE XR. Metformin was not teratogenic in rats and rabbits at doses up to \n",
      "600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended \n",
      "human daily dose of 2000 mg based on body surface area comparisons for rats and rabbits, \n",
      "21 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "üî¢ Embedding (first 5 values): [ 0.00859034 -0.09105197 -0.01259524  0.02322924 -0.06700385]\n",
      "----------------------------------------\n",
      "üß© Chunk 267:\n",
      "21 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.01497943 -0.07067986 -0.09087092 -0.0176569   0.00021012]\n",
      "----------------------------------------\n",
      "üß© Chunk 268:\n",
      "respectively. Determination of fetal concentrations demonstrated a partial placental barrier to \n",
      "metformin. \n",
      "Nursing Mothers \n",
      "Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable \n",
      "to those in plasma. Similar studies have not been conducted in nursing mothers. Because the \n",
      "potential for hypoglycemia in nursing infants may exist, a decision should be made whether to\n",
      "üî¢ Embedding (first 5 values): [-0.02617572 -0.09216017 -0.0626975   0.0982856   0.01181203]\n",
      "----------------------------------------\n",
      "üß© Chunk 269:\n",
      "potential for hypoglycemia in nursing infants may exist, a decision should be made whether to \n",
      "discontinue nursing or to discontinue the drug, taking into account the importance of the drug to \n",
      "the mother. If GLUCOPHAGE or GLUCOPHAGE XR is discontinued, and if diet alone is \n",
      "inadequate for controlling blood glucose, insulin therapy should be considered. \n",
      "Pediatric Use \n",
      "The safety and effectiveness of GLUCOPHAGE for the treatment of type 2 diabetes have been\n",
      "üî¢ Embedding (first 5 values): [-0.0125617  -0.01595222 -0.06668065 -0.0036528  -0.06786287]\n",
      "----------------------------------------\n",
      "üß© Chunk 270:\n",
      "The safety and effectiveness of GLUCOPHAGE for the treatment of type 2 diabetes have been \n",
      "established in pediatric patients ages 10 to 16 years (studies have not been conducted in pediatric \n",
      "patients below the age of 10 years). Use of GLUCOPHAGE in this age group is supported by \n",
      "evidence from adequate and well-controlled studies of GLUCOPHAGE in adults with additional \n",
      "data from a controlled clinical study in pediatric patients ages 10 to 16 years with type\n",
      "üî¢ Embedding (first 5 values): [ 0.00750262  0.0082766  -0.01604784 -0.01563998 -0.13472849]\n",
      "----------------------------------------\n",
      "üß© Chunk 271:\n",
      "data from a controlled clinical study in pediatric patients ages 10 to 16 years with type \n",
      "2 diabetes, which demonstrated a similar response in glycemic control to that seen in adults. (See \n",
      "CLINICAL PHARMACOLOGY: Pediatric Clinical Studies.) In this study, adverse effects \n",
      "were similar to those described in adults. (See ADVERSE REACTIONS: Pediatric Patients.) \n",
      "A maximum \n",
      "daily dose \n",
      "of \n",
      "2000 \n",
      "mg \n",
      "is \n",
      "recommended. \n",
      "(See DOSAGE \n",
      "AND \n",
      "ADMINISTRATION: Recommended Dosing Schedule: Pediatrics.)\n",
      "üî¢ Embedding (first 5 values): [ 0.03231198  0.04154703 -0.01532132  0.05994193 -0.09236637]\n",
      "----------------------------------------\n",
      "üß© Chunk 272:\n",
      "mg \n",
      "is \n",
      "recommended. \n",
      "(See DOSAGE \n",
      "AND \n",
      "ADMINISTRATION: Recommended Dosing Schedule: Pediatrics.) \n",
      "Safety and effectiveness of GLUCOPHAGE XR in pediatric patients have not been established. \n",
      "Geriatric Use \n",
      "Controlled clinical studies of GLUCOPHAGE and GLUCOPHAGE XR did not include \n",
      "sufficient numbers of elderly patients to determine whether they respond differently from \n",
      "younger patients, although other reported clinical experience has not identified differences in\n",
      "üî¢ Embedding (first 5 values): [ 0.01738214 -0.01623491 -0.01388758 -0.0504751  -0.07566525]\n",
      "----------------------------------------\n",
      "üß© Chunk 273:\n",
      "younger patients, although other reported clinical experience has not identified differences in \n",
      "responses between the elderly and younger patients. \n",
      "In general, dose selection for an elderly patient should be cautious, usually starting at the low end \n",
      "of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac \n",
      "function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis.\n",
      "üî¢ Embedding (first 5 values): [ 0.13801089 -0.00467654 -0.00118052  0.00522085 -0.07415921]\n",
      "----------------------------------------\n",
      "üß© Chunk 274:\n",
      "function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. \n",
      "Assess renal function more frequently in elderly patients (see WARNINGS, PRECAUTIONS, \n",
      "and DOSAGE AND ADMINISTRATION). \n",
      "22 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.03455677 -0.031672   -0.04541085 -0.04228323 -0.06193216]\n",
      "----------------------------------------\n",
      "üß© Chunk 275:\n",
      "ADVERSE REACTIONS \n",
      "In a US double-blind clinical study of GLUCOPHAGE in patients with type 2 diabetes, a total of \n",
      "141 patients received GLUCOPHAGE therapy (up to 2550 mg per day) and 145 patients \n",
      "received placebo. Adverse reactions reported in greater than 5% of the GLUCOPHAGE patients, \n",
      "and that were more common in GLUCOPHAGE- than placebo-treated patients, are listed in \n",
      "Table 11. \n",
      "Table 11: Most Common Adverse Reactions (>5.0 Percent) in a Placebo-Controlled\n",
      "üî¢ Embedding (first 5 values): [ 0.016218   -0.02923213 -0.01633966  0.02406174 -0.09194347]\n",
      "----------------------------------------\n",
      "üß© Chunk 276:\n",
      "Table 11. \n",
      "Table 11: Most Common Adverse Reactions (>5.0 Percent) in a Placebo-Controlled \n",
      "Clinical Study of GLUCOPHAGE Monotherapy* \n",
      "Adverse Reaction \n",
      "GLUCOPHAGE \n",
      "Monotherapy \n",
      "(n=141) \n",
      "Placebo \n",
      "(n=145) \n",
      "% of Patients \n",
      "Diarrhea \n",
      "53.2 \n",
      "11.7 \n",
      "Nausea/Vomiting \n",
      "25.5 \n",
      "8.3 \n",
      "Flatulence \n",
      "12.1 \n",
      "5.5 \n",
      "Asthenia \n",
      "9.2 \n",
      "5.5 \n",
      "Indigestion \n",
      "7.1 \n",
      "4.1 \n",
      "Abdominal Discomfort \n",
      "6.4 \n",
      "4.8 \n",
      "Headache \n",
      "5.7 \n",
      "4.8 \n",
      "* Reactions that were more common in GLUCOPHAGE- than placebo-treated patients.\n",
      "üî¢ Embedding (first 5 values): [ 0.02590551 -0.08459728  0.00018332  0.0056765  -0.07971846]\n",
      "----------------------------------------\n",
      "üß© Chunk 277:\n",
      "5.7 \n",
      "4.8 \n",
      "* Reactions that were more common in GLUCOPHAGE- than placebo-treated patients. \n",
      "Diarrhea led to discontinuation of study medication in 6% of patients treated with \n",
      "GLUCOPHAGE. Additionally, the following adverse reactions were reported in ‚â•1.0% to ‚â§5.0% \n",
      "of GLUCOPHAGE patients and were more commonly reported with GLUCOPHAGE than \n",
      "placebo: abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash,\n",
      "üî¢ Embedding (first 5 values): [-0.02011747 -0.04945806  0.01215048 -0.04007479 -0.10564706]\n",
      "----------------------------------------\n",
      "üß© Chunk 278:\n",
      "placebo: abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, \n",
      "sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, palpitation. \n",
      "In worldwide clinical trials over 900 patients with type 2 diabetes have been treated with \n",
      "GLUCOPHAGE XR in placebo- and active-controlled studies. In placebo-controlled trials, 781 \n",
      "patients were administered GLUCOPHAGE XR and 195 patients received placebo. Adverse\n",
      "üî¢ Embedding (first 5 values): [-0.00899003 -0.0620973  -0.03546554 -0.01062864 -0.0906732 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 279:\n",
      "patients were administered GLUCOPHAGE XR and 195 patients received placebo. Adverse \n",
      "reactions reported in greater than 5% of the GLUCOPHAGE XR patients, and that were more \n",
      "common in GLUCOPHAGE XR- than placebo-treated patients, are listed in Table 12. \n",
      "23 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.01735192 -0.05527042 -0.07143244 -0.0834479  -0.081619  ]\n",
      "----------------------------------------\n",
      "üß© Chunk 280:\n",
      "Table 12: Most Common Adverse Reactions (>5.0 Percent) in Placebo-Controlled Studies \n",
      "of GLUCOPHAGE XR* \n",
      "Adverse Reaction \n",
      "GLUCOPHAGE XR \n",
      "(n=781) \n",
      "Placebo \n",
      "(n=195) \n",
      "% of Patients \n",
      "Diarrhea \n",
      "9.6 \n",
      "2.6 \n",
      "Nausea/Vomiting \n",
      "6.5 \n",
      "1.5 \n",
      "* Reactions that were more common in GLUCOPHAGE XR- than placebo-treated patients. \n",
      "Diarrhea led to discontinuation of study medication in 0.6% of patients treated with \n",
      "GLUCOPHAGE XR. Additionally, the following adverse reactions were reported in ‚â•1.0% to\n",
      "üî¢ Embedding (first 5 values): [ 0.03286623 -0.08943725 -0.00379578 -0.05277134 -0.04834747]\n",
      "----------------------------------------\n",
      "üß© Chunk 281:\n",
      "GLUCOPHAGE XR. Additionally, the following adverse reactions were reported in ‚â•1.0% to \n",
      "‚â§5.0% of GLUCOPHAGE XR patients and were more commonly reported with \n",
      "GLUCOPHAGE XR than placebo: abdominal pain, constipation, distention abdomen, \n",
      "dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste \n",
      "disturbance. \n",
      "Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with \n",
      "postmarketing use of metformin. \n",
      "Pediatric Patients\n",
      "üî¢ Embedding (first 5 values): [-0.01456602 -0.10020794  0.0002919  -0.02588765 -0.07657301]\n",
      "----------------------------------------\n",
      "üß© Chunk 282:\n",
      "postmarketing use of metformin. \n",
      "Pediatric Patients \n",
      "In clinical trials with GLUCOPHAGE in pediatric patients with type 2 diabetes, the profile of \n",
      "adverse reactions was similar to that observed in adults. \n",
      "OVERDOSAGE \n",
      "Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than \n",
      "50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association \n",
      "with metformin hydrochloride has been established. Lactic acidosis has been reported in\n",
      "üî¢ Embedding (first 5 values): [-0.00165756 -0.03164342 -0.02100839  0.0031951  -0.02384978]\n",
      "----------------------------------------\n",
      "üß© Chunk 283:\n",
      "with metformin hydrochloride has been established. Lactic acidosis has been reported in \n",
      "approximately 32% of metformin overdose cases (see WARNINGS). Metformin is dialyzable \n",
      "with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, \n",
      "hemodialysis may be useful for removal of accumulated drug from patients in whom metformin \n",
      "overdosage is suspected. \n",
      "DOSAGE AND ADMINISTRATION \n",
      "There is no fixed dosage regimen for the management of hyperglycemia in patients with type\n",
      "üî¢ Embedding (first 5 values): [-0.01052741 -0.05798291 -0.02477873 -0.00608494 -0.07922738]\n",
      "----------------------------------------\n",
      "üß© Chunk 284:\n",
      "There is no fixed dosage regimen for the management of hyperglycemia in patients with type \n",
      "2 diabetes with GLUCOPHAGE or GLUCOPHAGE XR or any other pharmacologic agent. \n",
      "Dosage of GLUCOPHAGE or GLUCOPHAGE XR must be individualized on the basis of both \n",
      "effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The \n",
      "maximum recommended daily dose of GLUCOPHAGE is 2550 mg in adults and 2000 mg in \n",
      "24 \n",
      "Reference ID: 4079189\n",
      "üî¢ Embedding (first 5 values): [ 0.03476327 -0.020322   -0.0104382  -0.04073327 -0.14791732]\n",
      "----------------------------------------\n",
      "üß© Chunk 285:\n",
      "24 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.00506893 -0.07437108 -0.10537947 -0.03499762 -0.00682428]\n",
      "----------------------------------------\n",
      "üß© Chunk 286:\n",
      "pediatric patients (10-16 years of age); the maximum recommended daily dose of \n",
      "GLUCOPHAGE XR in adults is 2000 mg. \n",
      "GLUCOPHAGE should be given in divided doses with meals while GLUCOPHAGE XR should \n",
      "generally be given once daily with the evening meal. GLUCOPHAGE or GLUCOPHAGE XR \n",
      "should be started at a low dose, with gradual dose escalation, both to reduce gastrointestinal side \n",
      "effects and to permit identification of the minimum dose required for adequate glycemic control \n",
      "of the patient.\n",
      "üî¢ Embedding (first 5 values): [ 0.05638025 -0.0114675  -0.01306746 -0.08722106 -0.1306223 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 287:\n",
      "of the patient. \n",
      "During treatment initiation and dose titration (see Recommended Dosing Schedule), fasting \n",
      "plasma glucose should be used to determine the therapeutic response to GLUCOPHAGE or \n",
      "GLUCOPHAGE XR and identify the minimum effective dose for the patient. Thereafter, \n",
      "glycosylated hemoglobin should be measured at intervals of approximately 3 months. The \n",
      "therapeutic goal should be to decrease both fasting plasma glucose and glycosylated\n",
      "üî¢ Embedding (first 5 values): [ 0.00260315  0.03339866 -0.08450372 -0.02725313 -0.10786669]\n",
      "----------------------------------------\n",
      "üß© Chunk 288:\n",
      "therapeutic goal should be to decrease both fasting plasma glucose and glycosylated \n",
      "hemoglobin levels to normal or near normal by using the lowest effective dose of \n",
      "GLUCOPHAGE or GLUCOPHAGE XR, either when used as monotherapy or in \n",
      "combination with sulfonylurea or insulin. \n",
      "Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary \n",
      "failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of\n",
      "üî¢ Embedding (first 5 values): [ 0.01967679  0.03589394 -0.05723035 -0.01869456 -0.0928438 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 289:\n",
      "failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of \n",
      "medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after \n",
      "an initial period of effectiveness. \n",
      "Short-term administration of GLUCOPHAGE or GLUCOPHAGE XR may be sufficient during \n",
      "periods of transient loss of control in patients usually well-controlled on diet alone. \n",
      "GLUCOPHAGE XR tablets must be swallowed whole and never crushed or chewed.\n",
      "üî¢ Embedding (first 5 values): [-0.0118388  -0.00358886 -0.00423523 -0.04582816 -0.07012428]\n",
      "----------------------------------------\n",
      "üß© Chunk 290:\n",
      "GLUCOPHAGE XR tablets must be swallowed whole and never crushed or chewed. \n",
      "Occasionally, the inactive ingredients of GLUCOPHAGE XR will be eliminated in the feces as a \n",
      "soft, hydrated mass. (See Patient Information printed below.) \n",
      "Recommended Dosing Schedule \n",
      "Adults \n",
      "The usual starting dose of GLUCOPHAGE Tablets is 500 mg twice a day or 850 mg once a day, \n",
      "given with meals.  In general, clinically significant responses are not seen at doses below 1500\n",
      "üî¢ Embedding (first 5 values): [ 0.06713039 -0.04931581 -0.03498854 -0.06923837 -0.09148623]\n",
      "----------------------------------------\n",
      "üß© Chunk 291:\n",
      "given with meals.  In general, clinically significant responses are not seen at doses below 1500 \n",
      "mg per day.  Dosage increases should be made in increments of 500 mg weekly or 850 mg every \n",
      "2 weeks, up to a total of 2000 mg per day, given in divided doses. The dosage of \n",
      "GLUCOPHAGE must be individualized on the basis of both effectiveness and tolerability. \n",
      "Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For \n",
      "25 \n",
      "Reference ID: 4079189\n",
      "üî¢ Embedding (first 5 values): [ 0.04480878 -0.0494645  -0.04336467 -0.01473891 -0.17782067]\n",
      "----------------------------------------\n",
      "üß© Chunk 292:\n",
      "25 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.00783498 -0.08412687 -0.09928446 -0.04770692  0.01548765]\n",
      "----------------------------------------\n",
      "üß© Chunk 293:\n",
      "those patients requiring additional glycemic control, GLUCOPHAGE may be given to a \n",
      "maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given \n",
      "3 times a day with meals. \n",
      "The usual starting dose of GLUCOPHAGE XR (metformin hydrochloride) Extended-Release \n",
      "Tablets is 500 mg once daily with the evening meal.  In general, clinically significant responses \n",
      "are not seen at doses below 1500 mg per day.  Dosage increases should be made in increments of\n",
      "üî¢ Embedding (first 5 values): [ 0.01785794 -0.03750254 -0.02197064 -0.06214042 -0.10979561]\n",
      "----------------------------------------\n",
      "üß© Chunk 294:\n",
      "are not seen at doses below 1500 mg per day.  Dosage increases should be made in increments of \n",
      "500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal. The dosage of \n",
      "GLUCOPHAGE XR must be individualized on the basis of both effectiveness and tolerability. If \n",
      "glycemic control is not achieved on GLUCOPHAGE XR 2000 mg once daily, a trial of \n",
      "GLUCOPHAGE XR 1000 mg twice daily should be considered. If higher doses of metformin\n",
      "üî¢ Embedding (first 5 values): [ 0.01709799 -0.0493727  -0.03162747 -0.04883316 -0.13693015]\n",
      "----------------------------------------\n",
      "üß© Chunk 295:\n",
      "GLUCOPHAGE XR 1000 mg twice daily should be considered. If higher doses of metformin \n",
      "are required, GLUCOPHAGE should be used at total daily doses up to 2550 mg administered in \n",
      "divided daily doses, as described above. (See CLINICAL PHARMACOLOGY: Clinical \n",
      "Studies.) \n",
      "Patients receiving GLUCOPHAGE treatment may be safely switched to GLUCOPHAGE XR \n",
      "once daily at the same total daily dose, up to 2000 mg once daily. Following a switch from\n",
      "üî¢ Embedding (first 5 values): [ 0.0081626  -0.05970044 -0.01118475 -0.04120648 -0.13653703]\n",
      "----------------------------------------\n",
      "üß© Chunk 296:\n",
      "once daily at the same total daily dose, up to 2000 mg once daily. Following a switch from \n",
      "GLUCOPHAGE to GLUCOPHAGE XR, glycemic control should be closely monitored and \n",
      "dosage adjustments made accordingly (see CLINICAL PHARMACOLOGY: Clinical \n",
      "Studies). \n",
      "Pediatrics \n",
      "The usual starting dose of GLUCOPHAGE is 500 mg twice a day, given with meals. Dosage \n",
      "increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day,\n",
      "üî¢ Embedding (first 5 values): [ 0.04720642 -0.03149727 -0.02495085 -0.02921713 -0.16828343]\n",
      "----------------------------------------\n",
      "üß© Chunk 297:\n",
      "increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, \n",
      "given in divided doses. The dosage of GLUCOPHAGE must be individualized on the basis of \n",
      "both effectiveness and tolerability. Safety and effectiveness of GLUCOPHAGE XR in pediatric \n",
      "patients have not been established. \n",
      "Recommendations for Use in Renal Impairment \n",
      "Assess renal function prior to initiation of GLUCOPHAGE or GLUCOPHAGE XR and \n",
      "periodically thereafter.\n",
      "üî¢ Embedding (first 5 values): [ 0.00639566 -0.01620858  0.01170911 -0.08675183 -0.13102779]\n",
      "----------------------------------------\n",
      "üß© Chunk 298:\n",
      "periodically thereafter. \n",
      "GLUCOPHAGE or GLUCOPHAGE XR is contraindicated in patients with an estimated \n",
      "glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m2 . \n",
      "Initiation of GLUCOPHAGE or GLUCOPHAGE XR in patients with an eGFR between 30 ‚Äì 45 \n",
      "mL/minute/1.73 m2 is not recommended.  \n",
      "In patients taking GLUCOPHAGE or GLUCOPHAGE XR whose eGFR later falls below 45 \n",
      "mL/min/1.73 m2, assess the benefit risk of continuing therapy.  \n",
      "26 \n",
      "Reference ID: 4079189\n",
      "üî¢ Embedding (first 5 values): [ 0.01342737 -0.01350988  0.00451946 -0.06998823 -0.03146609]\n",
      "----------------------------------------\n",
      "üß© Chunk 299:\n",
      "mL/min/1.73 m2, assess the benefit risk of continuing therapy.  \n",
      "26 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.03091972 -0.02671197 -0.09667012  0.01162135  0.02565667]\n",
      "----------------------------------------\n",
      "üß© Chunk 300:\n",
      "Discontinue GLUCOPHAGE or GLUCOPHAGE XR if the patient‚Äôs eGFR later falls below 30 \n",
      "mL/minute/1.73 m2 (See WARNINGS and PRECAUTIONS). \n",
      "Discontinuation for Iodinated Contrast Imaging Procedures \n",
      "Discontinue GLUCOPHAGE or GLUCOPHAGE XR at the time of, or prior to, an iodinated \n",
      "contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in \n",
      "patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be\n",
      "üî¢ Embedding (first 5 values): [ 0.05564521 -0.03886585  0.00516443 -0.0584544   0.00834961]\n",
      "----------------------------------------\n",
      "üß© Chunk 301:\n",
      "patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be \n",
      "administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging \n",
      "procedure; restart GLUCOPHAGE or GLUCOPHAGE XR if renal function is stable. \n",
      "Concomitant GLUCOPHAGE or GLUCOPHAGE XR and Oral \n",
      "Sulfonylurea Therapy in Adult Patients \n",
      "If patients have not responded to 4 weeks of the maximum dose of GLUCOPHAGE or\n",
      "üî¢ Embedding (first 5 values): [ 0.06215118 -0.06359267  0.00388746 -0.05847669 -0.03791727]\n",
      "----------------------------------------\n",
      "üß© Chunk 302:\n",
      "If patients have not responded to 4 weeks of the maximum dose of GLUCOPHAGE or \n",
      "GLUCOPHAGE XR monotherapy, consideration should be given to gradual addition of an oral \n",
      "sulfonylurea while continuing GLUCOPHAGE or GLUCOPHAGE XR at the maximum dose, \n",
      "even if prior primary or secondary failure to a sulfonylurea has occurred. Clinical and \n",
      "pharmacokinetic drug-drug interaction data are currently available only for metformin plus \n",
      "glyburide (glibenclamide).\n",
      "üî¢ Embedding (first 5 values): [ 0.02005153 -0.12141112 -0.01228439 -0.07619236 -0.15244587]\n",
      "----------------------------------------\n",
      "üß© Chunk 303:\n",
      "glyburide (glibenclamide). \n",
      "With concomitant GLUCOPHAGE or GLUCOPHAGE XR and sulfonylurea therapy, the \n",
      "desired control of blood glucose may be obtained by adjusting the dose of each drug. In a clinical \n",
      "trial of patients with type 2 diabetes and prior failure on glyburide, patients started on \n",
      "GLUCOPHAGE 500 mg and glyburide 20 mg were titrated to 1000/20 mg, 1500/20 mg, \n",
      "2000/20 mg, or 2500/20 mg of GLUCOPHAGE and glyburide, respectively, to reach the goal of\n",
      "üî¢ Embedding (first 5 values): [ 0.00936293 -0.02093688 -0.08509343 -0.00468379 -0.11161879]\n",
      "----------------------------------------\n",
      "üß© Chunk 304:\n",
      "2000/20 mg, or 2500/20 mg of GLUCOPHAGE and glyburide, respectively, to reach the goal of \n",
      "glycemic control as measured by FPG, HbA1c, and plasma glucose response (see CLINICAL \n",
      "PHARMACOLOGY: Clinical Studies). However, attempts should be made to identify the \n",
      "minimum effective dose of each drug to achieve this goal. With concomitant GLUCOPHAGE or \n",
      "GLUCOPHAGE XR and sulfonylurea therapy, the risk of hypoglycemia associated with\n",
      "üî¢ Embedding (first 5 values): [ 0.04956394 -0.01538985 -0.08204097 -0.00749155 -0.11965816]\n",
      "----------------------------------------\n",
      "üß© Chunk 305:\n",
      "GLUCOPHAGE XR and sulfonylurea therapy, the risk of hypoglycemia associated with \n",
      "sulfonylurea therapy continues and may be increased. Appropriate precautions should be taken. \n",
      "(See Package Insert of the respective sulfonylurea.) \n",
      "If patients have not satisfactorily responded to 1 to 3 months of concomitant therapy with the \n",
      "maximum dose of GLUCOPHAGE or GLUCOPHAGE XR and the maximum dose of an oral \n",
      "sulfonylurea, consider therapeutic alternatives including switching to insulin with or without\n",
      "üî¢ Embedding (first 5 values): [ 0.02144878 -0.06011584 -0.07597736 -0.00350303 -0.10154748]\n",
      "----------------------------------------\n",
      "üß© Chunk 306:\n",
      "sulfonylurea, consider therapeutic alternatives including switching to insulin with or without \n",
      "GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "27 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.03509831 -0.09773334 -0.13245402 -0.00497317 -0.0692912 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 307:\n",
      "Concomitant GLUCOPHAGE or GLUCOPHAGE XR and Insulin \n",
      "Therapy in Adult Patients \n",
      "The current insulin dose should be continued upon initiation of GLUCOPHAGE or \n",
      "GLUCOPHAGE XR therapy. GLUCOPHAGE or GLUCOPHAGE XR therapy should be \n",
      "initiated at 500 mg once daily in patients on insulin therapy. For patients not responding \n",
      "adequately, the dose of GLUCOPHAGE or GLUCOPHAGE XR should be increased by 500 mg \n",
      "after approximately 1 week and by 500 mg every week thereafter until adequate glycemic control\n",
      "üî¢ Embedding (first 5 values): [ 0.00926067  0.00622651 -0.05796422 -0.03812665 -0.09720123]\n",
      "----------------------------------------\n",
      "üß© Chunk 308:\n",
      "after approximately 1 week and by 500 mg every week thereafter until adequate glycemic control \n",
      "is achieved. The maximum recommended daily dose is 2500 mg for GLUCOPHAGE and \n",
      "2000 mg for GLUCOPHAGE XR. It is recommended that the insulin dose be decreased by \n",
      "10% to 25% when fasting plasma glucose concentrations decrease to less than 120 mg/dL in \n",
      "patients receiving concomitant insulin and GLUCOPHAGE or GLUCOPHAGE XR. Further\n",
      "üî¢ Embedding (first 5 values): [ 0.04336888  0.02074696 -0.06301667 -0.02766332 -0.11220074]\n",
      "----------------------------------------\n",
      "üß© Chunk 309:\n",
      "patients receiving concomitant insulin and GLUCOPHAGE or GLUCOPHAGE XR. Further \n",
      "adjustment should be individualized based on glucose-lowering response. \n",
      "Specific Patient Populations \n",
      "GLUCOPHAGE or GLUCOPHAGE XR are not recommended for use in pregnancy. \n",
      "GLUCOPHAGE is not recommended in patients below the age of 10 years. GLUCOPHAGE XR \n",
      "is not recommended in pediatric patients (below the age of 17 years). \n",
      "The initial and maintenance dosing of GLUCOPHAGE or GLUCOPHAGE XR should be\n",
      "üî¢ Embedding (first 5 values): [-0.00306983  0.00409685 -0.0331263  -0.02071393 -0.06856965]\n",
      "----------------------------------------\n",
      "üß© Chunk 310:\n",
      "The initial and maintenance dosing of GLUCOPHAGE or GLUCOPHAGE XR should be \n",
      "conservative in patients with advanced age, due to the potential for decreased renal function in \n",
      "this population. Any dosage adjustment should be based on a careful assessment of renal \n",
      "function. \n",
      "28 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.03857375 -0.05657825 -0.04117519 -0.08844469 -0.12412275]\n",
      "----------------------------------------\n",
      "üß© Chunk 311:\n",
      "HOW SUPPLIED \n",
      "GLUCOPHAGE¬Æ (metformin hydrochloride) Tablets \n",
      "500 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6060-05 \n",
      "500 mg \n",
      "Bottles of 500 \n",
      "NDC 0087-6060-10 \n",
      "850 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6070-05 \n",
      "1000 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6071-11 \n",
      "GLUCOPHAGE 500 mg tablets are round, white to off-white, film-coated tablets debossed with \n",
      "\"BMS 6060\" around the periphery of the tablet on one side and \"500\" debossed across the face of \n",
      "the other side.\n",
      "üî¢ Embedding (first 5 values): [-0.05471966 -0.02933148 -0.07809498 -0.04350906 -0.06809095]\n",
      "----------------------------------------\n",
      "üß© Chunk 312:\n",
      "the other side. \n",
      "GLUCOPHAGE 850 mg tablets are round, white to off-white, film-coated tablets debossed with \n",
      "\"BMS 6070\" around the periphery of the tablet on one side and \"850\" debossed across the face of \n",
      "the other side. \n",
      "GLUCOPHAGE 1000 mg tablets are white, oval, biconvex, film-coated tablets with \"BMS \n",
      "6071\" debossed on one side and \"1000\" debossed on the opposite side and with a bisect line on \n",
      "both sides. \n",
      "GLUCOPHAGE¬Æ XR (metformin hydrochloride) Extended-Release Tablets \n",
      "500 mg\n",
      "üî¢ Embedding (first 5 values): [-0.01728275 -0.05579798 -0.055039   -0.09257279 -0.06272505]\n",
      "----------------------------------------\n",
      "üß© Chunk 313:\n",
      "both sides. \n",
      "GLUCOPHAGE¬Æ XR (metformin hydrochloride) Extended-Release Tablets \n",
      "500 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6063-13 \n",
      "750 mg \n",
      "Bottles of 100 \n",
      "NDC 0087-6064-13 \n",
      "GLUCOPHAGE XR 500 mg tablets are white to off-white, capsule shaped, biconvex tablets, \n",
      "with \"BMS 6063\" debossed on one side and \"500\" debossed across the face of the other side. \n",
      "GLUCOPHAGE XR 750 mg tablets are capsule shaped, biconvex tablets, with \"BMS 6064\"\n",
      "üî¢ Embedding (first 5 values): [-0.02881264 -0.07092474 -0.07389444 -0.0954463  -0.05791159]\n",
      "----------------------------------------\n",
      "üß© Chunk 314:\n",
      "GLUCOPHAGE XR 750 mg tablets are capsule shaped, biconvex tablets, with \"BMS 6064\" \n",
      "debossed on one side and \"750\" debossed on the other side. The tablets are pale red and may \n",
      "have a mottled appearance. \n",
      "Storage \n",
      "Store at 20¬∞‚Äì25¬∞ C (68¬∞‚Äì77¬∞ F); excursions permitted to 15¬∞‚Äì30¬∞ C (59¬∞‚Äì86¬∞ F). [See USP \n",
      "Controlled Room Temperature.] \n",
      "Dispense in light-resistant containers. \n",
      "GLUCOPHAGE¬Æ is a registered trademark of Merck Sant√© S.A.S., an associate of Merck KGaA of \n",
      "29 \n",
      "Reference ID: 4079189\n",
      "üî¢ Embedding (first 5 values): [-0.01383215 -0.03771889 -0.10147881 -0.04363373 -0.02340134]\n",
      "----------------------------------------\n",
      "üß© Chunk 315:\n",
      "29 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.00333857 -0.08134235 -0.10806052 -0.03469538  0.00284927]\n",
      "----------------------------------------\n",
      "üß© Chunk 316:\n",
      "Darmstadt, Germany. Licensed to Bristol-Myers Squibb Company. \n",
      "Distributed by: \n",
      "Bristol-Myers Squibb Company \n",
      "Princeton, NJ 08543 USA \n",
      "[print code] \n",
      "Rev April 2017 \n",
      "30 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.01774417 -0.08201567 -0.07033808  0.01294485 -0.01911281]\n",
      "----------------------------------------\n",
      "üß© Chunk 317:\n",
      "Patient Information \n",
      "GLUCOPHAGE¬Æ \n",
      "(metformin hydrochloride) Tablets \n",
      "and \n",
      "GLUCOPHAGE¬Æ XR \n",
      "(metformin hydrochloride) Extended-Release Tablets \n",
      "Read this information carefully before you start taking this medicine and each time you refill \n",
      "your prescription. There may be new information. This information does not take the place of \n",
      "your doctor‚Äôs advice. Ask your doctor or pharmacist if you do not understand some of this \n",
      "information or if you want to know more about this medicine.\n",
      "üî¢ Embedding (first 5 values): [-0.02599681 -0.07022177 -0.03837924 -0.06611985 -0.02255506]\n",
      "----------------------------------------\n",
      "üß© Chunk 318:\n",
      "information or if you want to know more about this medicine. \n",
      "What are GLUCOPHAGE and GLUCOPHAGE XR? \n",
      "GLUCOPHAGE and GLUCOPHAGE XR are used to treat type 2 diabetes. This is also known \n",
      "as non-insulin-dependent diabetes mellitus. People with type 2 diabetes are not able to make \n",
      "enough insulin or respond normally to the insulin their bodies make. When this happens, sugar \n",
      "(glucose) builds up in the blood. This can lead to serious medical problems including kidney\n",
      "üî¢ Embedding (first 5 values): [-0.02616855 -0.04846527 -0.03710578 -0.03677725 -0.09820811]\n",
      "----------------------------------------\n",
      "üß© Chunk 319:\n",
      "(glucose) builds up in the blood. This can lead to serious medical problems including kidney \n",
      "damage, amputations, and blindness. Diabetes is also closely linked to heart disease. The main \n",
      "goal of treating diabetes is to lower your blood sugar to a normal level. \n",
      "High blood sugar can be lowered by diet and exercise, by a number of medicines taken by \n",
      "mouth, and by insulin shots. Before you take GLUCOPHAGE or GLUCOPHAGE XR, try to\n",
      "üî¢ Embedding (first 5 values): [-0.033726    0.07172125  0.00887543  0.04184739 -0.08681739]\n",
      "----------------------------------------\n",
      "üß© Chunk 320:\n",
      "mouth, and by insulin shots. Before you take GLUCOPHAGE or GLUCOPHAGE XR, try to \n",
      "control your diabetes by exercise and weight loss. While you take your diabetes medicine, \n",
      "continue to exercise and follow the diet advised for your diabetes. No matter what your \n",
      "recommended diabetes management plan is, studies have shown that maintaining good blood \n",
      "sugar control can prevent or delay complications of diabetes, such as blindness.\n",
      "üî¢ Embedding (first 5 values): [-0.01705988 -0.00901285 -0.03450781 -0.00063077 -0.1052962 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 321:\n",
      "sugar control can prevent or delay complications of diabetes, such as blindness. \n",
      "GLUCOPHAGE and GLUCOPHAGE XR have the same active ingredient. However, \n",
      "GLUCOPHAGE XR works longer in your body. Both of these medicines help control your \n",
      "blood sugar in a number of ways. These include helping your body respond better to the insulin it \n",
      "makes naturally, decreasing the amount of sugar your liver makes, and decreasing the amount of\n",
      "üî¢ Embedding (first 5 values): [-0.04602548 -0.05285032 -0.02910057 -0.00865412 -0.04834639]\n",
      "----------------------------------------\n",
      "üß© Chunk 322:\n",
      "makes naturally, decreasing the amount of sugar your liver makes, and decreasing the amount of \n",
      "sugar your intestines absorb. GLUCOPHAGE and GLUCOPHAGE XR do not cause your body \n",
      "to make more insulin. Because of this, when taken alone, they rarely cause hypoglycemia (low \n",
      "blood sugar), and usually do not cause weight gain. However, when they are taken with a \n",
      "sulfonylurea or with insulin, hypoglycemia is more likely to occur, as is weight gain. \n",
      "31 \n",
      "Reference ID: 4079189\n",
      "üî¢ Embedding (first 5 values): [ 0.01297682 -0.05500188 -0.06473711  0.04198729 -0.01870877]\n",
      "----------------------------------------\n",
      "üß© Chunk 323:\n",
      "31 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.00691419 -0.0901761  -0.100624   -0.04745576  0.00068777]\n",
      "----------------------------------------\n",
      "üß© Chunk 324:\n",
      "Tell your doctor if you are pregnant or plan to become pregnant. GLUCOPHAGE and \n",
      "GLUCOPHAGE XR may not be right for you. Talk with your doctor about your choices. You \n",
      "should also discuss your choices with your doctor if you are nursing a child. \n",
      "Can GLUCOPHAGE or GLUCOPHAGE XR be used in children? \n",
      "GLUCOPHAGE has been shown to effectively lower glucose levels in children (ages 10-16 \n",
      "years) with type 2 diabetes. GLUCOPHAGE has not been studied in children younger than 10\n",
      "üî¢ Embedding (first 5 values): [-0.02171373 -0.0132319  -0.02081763 -0.04040712 -0.05699124]\n",
      "----------------------------------------\n",
      "üß© Chunk 325:\n",
      "years) with type 2 diabetes. GLUCOPHAGE has not been studied in children younger than 10 \n",
      "years old. GLUCOPHAGE has not been studied in combination with other oral glucose-control \n",
      "medicines or insulin in children. If you have any questions about the use of GLUCOPHAGE in \n",
      "children, talk with your doctor or other healthcare provider. \n",
      "GLUCOPHAGE XR has not been studied in children. \n",
      "How should I take GLUCOPHAGE or GLUCOPHAGE XR?\n",
      "üî¢ Embedding (first 5 values): [ 0.03528487  0.00355556 -0.01325147 -0.01771017 -0.08228134]\n",
      "----------------------------------------\n",
      "üß© Chunk 326:\n",
      "GLUCOPHAGE XR has not been studied in children. \n",
      "How should I take GLUCOPHAGE or GLUCOPHAGE XR? \n",
      "Your doctor will tell you how much medicine to take and when to take it. You will probably start \n",
      "out with a low dose of the medicine. Your doctor may slowly increase your dose until your blood \n",
      "sugar is better controlled. You should take GLUCOPHAGE or GLUCOPHAGE XR with meals. \n",
      "Your doctor may have you take other medicines along with GLUCOPHAGE or GLUCOPHAGE\n",
      "üî¢ Embedding (first 5 values): [ 0.04764782 -0.02458643  0.01389685 -0.04685855 -0.09952107]\n",
      "----------------------------------------\n",
      "üß© Chunk 327:\n",
      "Your doctor may have you take other medicines along with GLUCOPHAGE or GLUCOPHAGE \n",
      "XR to control your blood sugar. These medicines may include insulin shots. Taking \n",
      "GLUCOPHAGE or GLUCOPHAGE XR with insulin may help you better control your blood \n",
      "sugar while reducing the insulin dose. \n",
      "Continue your exercise and diet program and test your blood sugar regularly while taking \n",
      "GLUCOPHAGE or GLUCOPHAGE XR. Your doctor will monitor your diabetes and may\n",
      "üî¢ Embedding (first 5 values): [-0.01024055  0.0513648  -0.01063215 -0.00458636 -0.07005104]\n",
      "----------------------------------------\n",
      "üß© Chunk 328:\n",
      "GLUCOPHAGE or GLUCOPHAGE XR. Your doctor will monitor your diabetes and may \n",
      "perform blood tests on you from time to time to make sure your kidneys and your liver are \n",
      "functioning normally. There is no evidence that GLUCOPHAGE or GLUCOPHAGE XR causes \n",
      "harm to the liver or kidneys. \n",
      "Tell your doctor if you: \n",
      "‚Ä¢  have an illness that causes severe vomiting, diarrhea or fever, or if you drink a much \n",
      "lower amount of liquid than normal. These conditions can lead to severe dehydration\n",
      "üî¢ Embedding (first 5 values): [ 0.01436844 -0.05181379  0.01885773 -0.03938456 -0.01284788]\n",
      "----------------------------------------\n",
      "üß© Chunk 329:\n",
      "lower amount of liquid than normal. These conditions can lead to severe dehydration \n",
      "(loss of water in your body). You may need to stop taking GLUCOPHAGE or \n",
      "GLUCOPHAGE XR for a short time. \n",
      "‚Ä¢  plan to have surgery or an x-ray procedure with injection of dye (contrast agent). You \n",
      "may need to stop taking GLUCOPHAGE or GLUCOPHAGE XR for a short time. \n",
      "32 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "üî¢ Embedding (first 5 values): [ 0.05545647 -0.07153305  0.04006244 -0.0127733   0.02136693]\n",
      "----------------------------------------\n",
      "üß© Chunk 330:\n",
      "32 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.02208034 -0.08363742 -0.102249   -0.04658747 -0.00547153]\n",
      "----------------------------------------\n",
      "üß© Chunk 331:\n",
      "‚Ä¢  start to take other medicines or change how you take a medicine. GLUCOPHAGE and \n",
      "GLUCOPHAGE XR can affect how well other drugs work, and some drugs can affect \n",
      "how well GLUCOPHAGE and GLUCOPHAGE XR work. Some medicines may cause \n",
      "high blood sugar. \n",
      "GLUCOPHAGE XR must be swallowed whole and never crushed or chewed. Occasionally, \n",
      "the inactive ingredients of GLUCOPHAGE XR may be eliminated as a soft mass in your stool\n",
      "üî¢ Embedding (first 5 values): [-0.01464025 -0.07439332  0.03043821 -0.030022   -0.05848818]\n",
      "----------------------------------------\n",
      "üß© Chunk 332:\n",
      "the inactive ingredients of GLUCOPHAGE XR may be eliminated as a soft mass in your stool \n",
      "that may look like the original tablet; this is not harmful and will not affect the way \n",
      "GLUCOPHAGE XR works to control your diabetes. \n",
      "What should I avoid while taking GLUCOPHAGE or GLUCOPHAGE \n",
      "XR? \n",
      "Do not drink a lot of alcoholic drinks while taking GLUCOPHAGE or GLUCOPHAGE XR. \n",
      "This means you should not binge drink for short periods, and you should not drink a lot of\n",
      "üî¢ Embedding (first 5 values): [ 0.03612337 -0.06279863 -0.00708777 -0.01756061 -0.03071213]\n",
      "----------------------------------------\n",
      "üß© Chunk 333:\n",
      "This means you should not binge drink for short periods, and you should not drink a lot of \n",
      "alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis. \n",
      "What are the side effects of GLUCOPHAGE and GLUCOPHAGE XR? \n",
      "‚Ä¢  Lactic \n",
      "acidosis. \n",
      "Metformin, \n",
      "the \n",
      "active \n",
      "ingredient \n",
      "in \n",
      "GLUCOPHAGE \n",
      "and \n",
      "GLUCOPHAGE XR, can cause a rare but serious condition called lactic acidosis (a \n",
      "buildup of an acid in the blood) that can cause death. Lactic acidosis is a medical\n",
      "üî¢ Embedding (first 5 values): [ 0.09227272 -0.08777823  0.01605861 -0.02314846 -0.00130233]\n",
      "----------------------------------------\n",
      "üß© Chunk 334:\n",
      "buildup of an acid in the blood) that can cause death. Lactic acidosis is a medical \n",
      "emergency and must be treated in the hospital. \n",
      "Call your doctor right away if you have any of the following symptoms, which could be signs of \n",
      "lactic acidosis: \n",
      "‚Ä¢  you feel cold in your hands or feet \n",
      "‚Ä¢  you feel dizzy or lightheaded \n",
      "‚Ä¢  you have a slow or irregular heartbeat \n",
      "‚Ä¢  you feel very weak or tired \n",
      "‚Ä¢  you have unusual (not normal) muscle pain \n",
      "‚Ä¢  you have trouble breathing\n",
      "üî¢ Embedding (first 5 values): [ 0.07652649 -0.10653078  0.00669607  0.04056636  0.05949597]\n",
      "----------------------------------------\n",
      "üß© Chunk 335:\n",
      "‚Ä¢  you have unusual (not normal) muscle pain \n",
      "‚Ä¢  you have trouble breathing \n",
      "‚Ä¢  you feel sleepy or drowsy \n",
      "‚Ä¢  you have stomach pains, nausea or vomiting \n",
      "Most people who have had lactic acidosis with metformin have other things that, combined with \n",
      "the metformin, led to the lactic acidosis. Tell your doctor if you have any of the following, \n",
      "33 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.\n",
      "üî¢ Embedding (first 5 values): [ 0.04882826 -0.14826986  0.02508179  0.09526972 -0.0168324 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 336:\n",
      "33 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.01129165 -0.09752664 -0.10904579 -0.05820581  0.0018242 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 337:\n",
      "because you have a higher chance for getting lactic acidosis with GLUCOPHAGE or \n",
      "GLUCOPHAGE XR if you: \n",
      "‚Ä¢  have severe kidney problems, or your kidneys are affected by certain x-ray tests that use \n",
      "injectable dye \n",
      "‚Ä¢  have liver problems \n",
      "‚Ä¢  drink alcohol very often, or drink a lot of alcohol in short-term \"binge\" drinking \n",
      "‚Ä¢  get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a\n",
      "üî¢ Embedding (first 5 values): [ 0.0575058  -0.12805551  0.04466908  0.02652655  0.03382372]\n",
      "----------------------------------------\n",
      "üß© Chunk 338:\n",
      "‚Ä¢  get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a \n",
      "fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with activity \n",
      "or exercise and do not drink enough fluids \n",
      "‚Ä¢  have surgery \n",
      "‚Ä¢  have a heart attack, severe infection, or stroke \n",
      "The best way to keep from having a problem with lactic acidosis from metformin is to tell your \n",
      "doctor if you have any of the problems in the list above. Your doctor may decide to stop your\n",
      "üî¢ Embedding (first 5 values): [ 0.0441231  -0.10477892  0.06967758  0.08296722  0.05481556]\n",
      "----------------------------------------\n",
      "üß© Chunk 339:\n",
      "doctor if you have any of the problems in the list above. Your doctor may decide to stop your \n",
      "GLUCOPHAGE or GLUCOPHAGE XR for a while if you have any of these things. \n",
      "Other Side Effects. Common side effects of GLUCOPHAGE and GLUCOPHAGE XR include \n",
      "diarrhea, nausea, and upset stomach. These side effects generally go away after you take the \n",
      "medicine for a while. Taking your medicine with meals can help reduce these side effects. Tell\n",
      "üî¢ Embedding (first 5 values): [ 0.04482388 -0.07082009  0.03640056 -0.03637886 -0.02018515]\n",
      "----------------------------------------\n",
      "üß© Chunk 340:\n",
      "medicine for a while. Taking your medicine with meals can help reduce these side effects. Tell \n",
      "your doctor if the side effects bother you a lot, last for more than a few weeks, come back after \n",
      "they‚Äôve gone away, or start later in therapy. You may need a lower dose or need to stop taking \n",
      "the medicine for a short period or for good. \n",
      "About 3 out of every 100 people who take GLUCOPHAGE or GLUCOPHAGE XR have an\n",
      "üî¢ Embedding (first 5 values): [ 0.04292458 -0.03680142  0.04233667 -0.01725853 -0.05047865]\n",
      "----------------------------------------\n",
      "üß© Chunk 341:\n",
      "About 3 out of every 100 people who take GLUCOPHAGE or GLUCOPHAGE XR have an \n",
      "unpleasant metallic taste when they start taking the medicine. It lasts for a short time. \n",
      "GLUCOPHAGE and GLUCOPHAGE XR rarely cause hypoglycemia (low blood sugar) by \n",
      "themselves. However, hypoglycemia can happen if you do not eat enough, if you drink alcohol, \n",
      "or if you take other medicines to lower blood sugar. \n",
      "General advice about prescription medicines\n",
      "üî¢ Embedding (first 5 values): [ 0.03786438 -0.04657652 -0.01247031 -0.00383856 -0.0512403 ]\n",
      "----------------------------------------\n",
      "üß© Chunk 342:\n",
      "or if you take other medicines to lower blood sugar. \n",
      "General advice about prescription medicines \n",
      "If you have questions or problems, talk with your doctor or other healthcare provider. You can \n",
      "ask your doctor or pharmacist for the information about GLUCOPHAGE and GLUCOPHAGE \n",
      "XR that is written for healthcare professionals. Medicines are sometimes prescribed for purposes \n",
      "other than those listed in a patient information leaflet. Do not use GLUCOPHAGE or\n",
      "üî¢ Embedding (first 5 values): [ 0.01660112  0.01352731  0.00593537 -0.03253993 -0.10362596]\n",
      "----------------------------------------\n",
      "üß© Chunk 343:\n",
      "other than those listed in a patient information leaflet. Do not use GLUCOPHAGE or \n",
      "GLUCOPHAGE XR for a condition for which it was not prescribed. Do not share your medicine \n",
      "with other people. \n",
      "34 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [ 0.00175208 -0.05419521 -0.08689814 -0.07392053 -0.00096814]\n",
      "----------------------------------------\n",
      "üß© Chunk 344:\n",
      "GLUCOPHAGE¬Æ is a registered trademark of Merck Sant√© S.A.S., an associate of Merck KGaA \n",
      "of Darmstadt, Germany. Licensed to Bristol-Myers Squibb Company. \n",
      "Other brands listed are the trademarks of their respective owners. \n",
      "Distributed by: \n",
      "Bristol-Myers Squibb Company \n",
      "Princeton, NJ 08543 USA \n",
      "[print code] \n",
      "Rev April 2017 \n",
      "35 \n",
      "Reference ID: 4079189 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      "üî¢ Embedding (first 5 values): [-0.01620409 -0.05990272 -0.08508383 -0.02250977 -0.02583025]\n",
      "----------------------------------------\n"
     ]
    }
   ],
   "source": [
    "view_all_chunks(\"pdf_chunks\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fde383ba-b032-42d7-a0b3-c1b4b693b98d",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
